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ABSTRACT
VERSICAN/COLLAGEN INTERACTIONS IN TISSUE STRUCTURE AND MECHANICSDongning Chen
Rebecca G. Wells Type I collagen is the most abundant structural protein in the extracellular matrix (ECM),
forming a dynamic 3D fibrous network that is highly regulated by other ECM components including
proteoglycans (PGs) and glycosaminoglycans (GAGs). Matrix PGs, especially the small leucine rich PG
(SLRP) subgroup, have been well studied as collagen binding proteins and regulators of fibrillogenesis.
However, the impact of the hyalectan subgroup of PGs, particularly versican, on collagen behaviors is not
well understood. There is a particular need for understanding the role of versican in the collagen network
because of its universal distribution in tissues and its altered expression during collagen-related fibrotic
disorders. My aim was to study collagen/versican interactions and to investigate the role of versican in
modulating collagen structural and mechanical behaviors. I used solid phase binding assays and the
Collagen Toolkit to identify binding sites, and I carried out in vitro turbidity assays combined with
fibroblast-derived matrices (FDM) to study fibrillogenesis. Collagen fiber organization was visualized
using scanning electron microscopy (SEM), and cell-mediated collagen realignments and contractions
were assessed by collagen plug and engineered microtissue assays. Shear rheometry was carried out on
collagen gels and liver tissues to evaluate the impact of versican on tissue mechanics. I determined that
versican and its V3 isoform bind collagen via the versican G3 domain and collagen R-G-Hydrophobic-O
motif, independent of versican GAG residues. Compared to SLRPs and the structurally similar hyalectan
aggrecan, versican shows unique effects on multiple collagen behaviors: 1) versican upregulates collagen
gelation and promotes the deposition of collagen-rich matrix with aligned fibers; 2) the presence of
versican improves fibril fusion into large bundles and forms a looser network; 3) versican improves cellmediated collagen compaction, alignment and microtissue contraction; 4) versican contributes to
collagen gel mechanics by decreasing stiffness and attenuating strain stiffening. In tissues, versican and
its GAGs also play a role by downregulating compression stiffening. Thus, versican is a unique regulator
of various collagen behaviors and therefore has potential therapeutic value in collagen-related
fibroproliferative diseases such as inflammation, fibrosis and cancer.
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ABSTRACT
VERSICAN/COLLAGEN INTERACTIONS IN TISSUE STRUCTURE AND MECHANICS
Dongning Chen
Rebecca G. Wells
Type I collagen is the most abundant structural protein in the extracellular matrix (ECM), forming
a dynamic 3D fibrous network that is highly regulated by other ECM components including
proteoglycans (PGs) and glycosaminoglycans (GAGs). Matrix PGs, especially the small leucine
rich PG (SLRP) subgroup, have been well studied as collagen binding proteins and regulators of
fibrillogenesis. However, the impact of the hyalectan subgroup of PGs, particularly versican, on
collagen behaviors is not well understood. There is a particular need for understanding the role of
versican in the collagen network because of its universal distribution in tissues and its altered
expression during collagen-related fibrotic disorders. My aim was to study collagen/versican
interactions and to investigate the role of versican in modulating collagen structural and
mechanical behaviors. I used solid phase binding assays and the Collagen Toolkit to identify
binding sites, and I carried out in vitro turbidity assays combined with fibroblast-derived matrices
(FDM) to study fibrillogenesis. Collagen fiber organization was visualized using scanning electron
microscopy (SEM), and cell-mediated collagen realignments and contractions were assessed by
collagen plug and engineered microtissue assays. Shear rheometry was carried out on collagen
gels and liver tissues to evaluate the impact of versican on tissue mechanics. I determined that
versican and its V3 isoform bind collagen via the versican G3 domain and collagen R-GHydrophobic-O motif, independent of versican GAG residues. Compared to SLRPs and the
structurally similar hyalectan aggrecan, versican shows unique effects on multiple collagen
behaviors: 1) versican upregulates collagen gelation and promotes the deposition of collagen-rich
matrix with aligned fibers; 2) the presence of versican improves fibril fusion into large bundles and
forms a looser network; 3) versican improves cell-mediated collagen compaction, alignment and
microtissue contraction; 4) versican contributes to collagen gel mechanics by decreasing stiffness

iii

and attenuating strain stiffening. In tissues, versican and its GAGs also play a role by
downregulating compression stiffening. Thus, versican is a unique regulator of various collagen
behaviors and therefore has potential therapeutic value in collagen-related fibroproliferative
diseases such as inflammation, fibrosis and cancer.
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CHAPTER 1 INTRODUCTION

The compositional, structural, and mechanical complexity of the extracellular matrix (ECM) is
important for maintaining appropriate cell and tissue functions. ECM consists of a threedimensional (3D) fibrous network in the form of crosslinked fibers primarily type I and other
fibrillar collagens. There are other important ECM components, including glycoproteins,
proteoglycans (PGs) and glycosaminoglycans (GAGs), which play key roles in controlling and
modulating ECM structural and mechanical properties as well as biological functions. The
heterogeneity of ECM composition and fibrous network organization contributes to tissue
specificity, and abnormal ECM deposition, organization and mechanics have been observed in
various pathological disorders.

Type I collagen, which is the most abundant member of the collagen superfamily, is a triple
helical ECM structural protein with two α1 and one α2 chains. Each α chain is composed of
repeating glycine-X-Y peptides, where X and Y are proline (28%) and hydroxyproline (38%)
(Gordon and Hahn 2010). The organization of collagen, which forms a fibrous network, is
essential for regulating ECM properties, especially structure and mechanics. Basically, there are
4 levels of collagen organization that have been defined: (1) triple helix collagen monomer
(length=280 nm and diameter=1.5 nm (Bozec and Horton 2005)); (2) collagen fibril (diameter=25400 nm, length=1 µm (Gelse, Pöschl, and Aigner 2003)(Buehler 2006)); (3) collagen fiber
(diameter=200-500 nm, up to a micron (Shen et al. 2008), but the difference between fibers and
bundles is not clearly defined) and (4) networks, bundles or sheets, which are very important for
maintaining appropriate cell and tissue behaviors during development and homeostasis but are
poorly defined. All four levels of collagen structures are precisely controlled by numerous factiors
including cells and collagen binding proteins and are crucial for stabilizing physiological tissue
properties and functions. Reorganization of collagen structure and the collagen fibrous network
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has been found during embryonic development and tissue remodeling, and remarkedly abnormal
alterations have been observed in pathological process especially the collagen-related fibrotic
disorders such as fibrosis, inflammation and cancer metastasis.

1.1 COLLAGEN FIBRILLOGENESIS
Type I collagen is a heterotrimer of two α1 and one α2 chain. COL1A1 and COL1A2, the α chain
genes for type I collagen (type I collagen will be referred to as collagen without additional labels in
this thesis), are transcribed into their corresponding mRNAs which are then translated into
procollagen α1 and α2 chains and synthesized on ribosomes along the rough endoplasmic
reticulum. The pro-α1 and α2 chains are folded from C-propeptide to N-propeptide to form lefthanded helical polypeptides and then these α chains join together to form the right-handed triple
helix (procollagen monomer) (Yamauchi and Sricholpech 2012)(Doege and Fessler 1986).
Procollagen peptide chain biosynthesis can be regulated at the translational level. For example,
published work indicates that two cis-acting sequences (5’ stem-loop and C-rich region in the 3’
untranslated region) are involved in α1(I) mRNA stabilization and translation which can lead to
increased collagen deposition from hepatic stellate cells (HSCs) (Stefanovic 2005).
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Figure 1.1 Collagen biosynthesis and fibrillogenesis (designed by M. Yamauchi and M.
Sricholpech (Yamauchi and Sricholpech 2012) and reprinted with permission)

For fibrillar collagen (type I is mainly discussed here), the N- and C-propeptides are cleaved by
ECM enzymes such as a disintegrin and metalloproteinase with thrombospondin motifs
(ADAMTS), bone morphogenetic protein 1 (BMP1) and tolloid-like protein 1 (TLL-1) (Humphries
et al. 2008) to expose N- and C-telopeptides, which trigger spontaneous collagen fibril formation
(Figure 1.1). In addition, the post-translational modifications of collagen are crucial for stabilizing
collagen fibril assembly. Lysine modifications, happening both intra and extracellularly, are
examples of collagen modifications for which lysine residues are hydroxylated into hydroxylysine
selectively inside cells and lysine and hydroxylysine residues in the telopeptides are oxidated by
lysyl oxidase (LOX) in the ECM to form aldehydes for collagen crosslinking (Yamauchi and
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Sricholpech 2012). The crosslinks between telopeptidyl aldehydes and lysine or hydroxylysine in
the helical region are responsible for spontaneous self-assembly into fibrils (Prockop et al.
1979)(Kadler et al. 1996). However, there are two models (the Kadler and Birk models) of the in
vivo process of collagen fibrillogenesis. The Kadler model suggests that the cleavage of the
propeptide happens intracellularly and that fibril assembly can happen both intra and
extracellularly (Canty and Kadler 2005), while the Birk model postulates that the cleavage of
propeptides occurs extracellularly and is based on data that the N- and C-proteinase are found in
the culture medium (Birk and Trelstad 1986). Although these proteinases are found in media, they
may be functional for cleaving collagen propeptides inside cells and may be secreted from cells
along with collagen. Thus, it is important to further understand the synthesis and secretion of
these proteinases in detail, focusing especially on whether they are activated intra or
extracellularly, which will shed light on the actual fibrillogenesis process in vivo. During
fibrillogenesis (mainly studied in vitro), there is a lag phase during which tropocollagen monomers
nucleate (into trimers) and then a rapid growth phase during which lateral growth occurs by the
addition of monomers longitudinally with fibrils fusion into larger fibers (Farber et al.
1986)(Dewavrin et al. 2014). The highly ordered fibrillar collagen structure shows a 67 nm Dperiodicity when imaged via atomic force microscopy (AFM) or electron microscopy (EM) (Baselt,
Revel, and Baldeschwieler 1993)(Hulmes et al. 1981). Compared to higher levels of collagen
organization, the mechanism of fibril formation has been well studied, with a particular focus on
factors such as temperature, pH and other ECM components that regulate collagen fibrillogenesis
both in vitro and in vivo. The effects of physical factors, such as pH and ionic strength, on in vitro
fibrillogenesis have been investigated using a turbidity assay, illustrating that both the rate and
fibril formation plateau increase with increasing pH in the range of 6-9 (Y. Li et al. 2009) and
decrease with increasing ionic strength (Yan et al. 2012). For in vivo fibrillogenesis, the most
crucial factors appear to be the presence of collagen binding partners such as collagen V (Birk
2001), fibronectin (Dzamba et al. 1993), GAGs (Stuart and Panitch 2008) and PGs (S. Chen et al.
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2014); their temporal and spatial expression during embryonic development can alter fibril
formation (as well as fibrous network organization) in different ways .

Collagen V can facilitate collagen I fibrillogenesis, but it is not required (Kadler, Hill, and CantyLaird 2008). The helical region of collagen V can co-assemble with collagen I to form heterotypic
fibrils, and the N-terminal domains (consisting of highly charged sulfate groups) of collagen V,
which are located in the gap region between highly-ordered collagen I monomers and exposed
horizontally to the fibril surface; a large number of the N-terminal domains at the surface can limit
the lateral growth (adding fibrils is not favored) (Birk 2001). In vivo, the corneal stroma in collagen
V-conditional null mice shows an increased collagen fibril diameter, abnormal fibril assembly,
disrupted lamellar structure and decreased corneal transparency (Sun et al. 2011). Fibronectin, a
ECM glycoprotein that forms focal adhesions with integrins at the cell membrane, accelerates in
vitro collagen fibrillogenesis (Speranza, Valentini, and Calligaro 1987). It can directly interact with
collagen (Balian, Click, and Bornstein 1980)(Owens and Baralle 1986), form a collagenfibronectin fibrillar structures and has a specific regulation during collagen deposition(McDonald,
Kelley, and Broekelmann 1982). Both collagen I and fibronectin can bind integrins (for example,
α5β1 for fibronectin and α2β1 for collagen I), but the role of the combined-presence and
interactions between collagen-fibronectin-integrin complexes in mediating collagen fibrillogenesis
are still under investigation. Fibronectin polymerization and collagen fibril assembly have shown
to have the same mechanistic elements in that integrins and the cytoskeleton are required (S. Li
et al. 2003). Other ECM proteins also play key roles in regulating collagen fibrillogenesis
especially PGs, and the PG/collagen interaction and its functional relevance in multiple collagen
behaviors, including fibrillogenesis, reorganization/realignment and mechanics, will be discussed
in detail in this work.
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1.2 FIBRILLOGENESIS ASSAYS
Beginning in the 1950s, researchers started using transmission electron microscopy (TEM) to
study the morphology of collagen fibrils and investigate regulators of fibril formation. For example,
P. Vanamee and K. R. Porter first used TEM to investigate the effect of salt and pH on fibril
morphology and the characteristic banding structure (Vanamee and Porter 1951). TEM mainly
focuses on visualizing the morphology of mature fibrils but the entire process of fibrillogenesis
cannot be investigated. Starting in 1960, G. C. Wood and M. K. Keech published a series of
papers reporting the use of an in vitro turbidity assay (also known as a spectrophotometric assay
and an in vitro fibrillogenesis assay) for studying the kinetics of collagen fibrillogenesis in vitro
(Wood and Keech 1960)(Keech 1961). G. C. Wood also used this assay to investigate the effects
of chondroitin sulfate (CS) and polyanions on fibrillogenesis (Wood 1960). The kinetic curves of
the turbidity assay generated by tracking the absorbance changes during collagen gelation using
a plate reader are typically sigmoidal with a lag phase representing collagen nucleation and a
growth phase representing the lateral growth of fibrils (Figure 1.2). This technique has been
widely used in a large number of studies focusing on various types of factors and regulators of
collagen fibrillogenesis, such as temperature (Achilli and Mantovani 2010), collagen concentration
(Raspanti et al. 2007), GAGs (Stuart and Panitch 2008), PGs (Vynios et al. 2001)(Reese,
Underwood, and Weiss 2013), cartilage oligomeric matrix protein (COMP) (Halász et al. 2007)
and fibronectin (Speranza, Valentini, and Calligaro 1987). Although the findings from these
publications highlighted some of the diverse and distinct roles of modulators of collagen
fibrillogenesis, there is a limitation that this technique cannot overcome. The absorbance readout
only indicates the turbidity changes of the collagen solution, but it cannot provide detailed
information about the actual morphological and structural features of collagen fibrils such as fibril
diameter and length as well as fibril quantities. Turbidity is mainly determined by the molecular
weight and light scattering factors of different aggregates (fibrils) (Silver and Birk 1983). Thus, a
combination of TEM and the turbidity assay has been commonly used for fibrillogenesis studies,
providing information about both kinetic and morphological changes during fibril formation. In the
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last twenty years, the development of time-lapse confocal reflection microscopy (CRM) has made
it possible to research the changes in fibril morphology and the kinetics of fibril growth during
almost the entire fibrillogenesis process (Brightman et al. 2000). Numerous biopolymers including
collagen have a special intrinsic optical feature that they can reflect light and this reflection can be
detected by a confocal microscope for imaging and quantitative analysis. The kinetic curves
tracking the pixel intensity of CRM during gelation share similar patterns as the absorbance
curves generated by the traditional turbidity assay and CRM-based findings on fibril morphology
strongly support that there is a lag phase for nucleation and a growth phase for fibril lateral
growth (Brightman et al. 2000)(Zhu and Kaufman 2014). CRM, however, cannot capture collagen
monomers or even early formed small aggregates during nucleation; thus, confocal fluorescence
microscopy (CFM) of fluorescently-labeled collagen has often been used to investigate the early
stages of gelation although it also has limitations in that labeling itself has a negative effect on
fibril formation (Y. Yang, Leone, and Kaufman 2009). Rheology has been used as a
complementary assay to evaluate both the mechanics and kinetics of fibrillogenesis. It has been
combined with CRM to study the effect of hyaluronic acid (HA) on collagen fibrillogenesis,
especially the structural and mechanical alterations of the collagen network during gelation (Y.
Yang and Kaufman 2009). AFM has also been used to investigate collagen assembly. For
example, the orientation and structural patterning of collagen assembly can be guided by
mechanical force applied using AFM tips and the collagen fibers deposited on a surface can be
imaged using AFM scanning (Jiang et al. 2004). The impact of small leucine rich proteoglycans
(SLRPs, such as decorin and lumican) on fibrillogenesis has been quantitatively investigated by
using AFM to scan surfaces coated with collagen/SLRPs mixtures (at different ratios) showing
that the increasing addition of decorin and lumican downregulates fibril diameter and increase
interfibrillar space (Stamov et al. 2013).
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Figure 1.2 The kinetic curves generated by the in vitro turbidity assay (collagen gelation in two
successive, identical experiments) published by G. Wood and M. Keech (Wood and Keech 1960)
and reprinted with permission.

1.3 COLLAGEN FIBROUS NETWORK ORGANIZATION
Collagen fibrous networks are networks formed by highly ordered and packed semiflexible
collagen fibers which are organized by covalent crosslinking of fibers as well as non-covalent
weak electrostatic interactions among charged or glycosylated residues. Fibrous networks are
essential 3D scaffolds for strengthening the ECM and are highly controlled and dynamically
mediated, supporting normal biological, structural and mechanical properties of tissues. The
regulatory mechanisms of collagen fiber formation, network formation, and in particular higherlevel organization of networks are not well understood and require further investigation. Generally,
nearby fibrils can entangle and twist into large fibers after collagen self-assembly into fibrils (Zhu
and Kaufman 2014). The organization of collagen fibrous networks is a crucial mediator of the
mechanics of collagenous matrices. In vitro gelation of collagen at different temperatures results
in different collagen networks with different size fibers and pores and these networks show
distinct mechanical properties including stiffness and strain stiffening behaviors (Jansen et al.
2018). It has also been shown that the shear storage modulus (G’) of a collagen gel can be
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predicted from its structural parameters such as fiber diameter and pore size, which are mediated
by network connections via covalent crosslinks and non-covalent weak interactions between
fibers (Y. Yang, Leone, and Kaufman 2009). For example, the addition of CS to collagen gels,
which causes increased fiber bundling and pore size, leads to decreased G’, while the addition of
HA, which decreases the pore size, leads to increased stiffness (Y. Yang et al. 2011). In addition,
the crosslinks within a collagen fibrous network also determine its mechanics. Glutaraldehydemediated crosslinking increases collagen gel stiffness via reorganizing and condensing fibrous
networks (Raub et al. 2007). In vivo, the formation of fibers and the lateral fusion of fibers into
higher order structures of bundles, sheets and networks are tissue specific. The appropriate
collagen organization at the third and fourth levels is extremely important for biological and
physiological functions (Figure 1.3), especially in tissues such as tendon and cornea with highly
ordered collagen organization. The well-oriented and highly-organized collagen fibrils in corneal
stroma are fundamental for its transparency. A typical lamellar structure has been observed in
corneal stroma (Jester et al. 2010) and the different orientation and arrangement of collagen
fibers in anterior and mid/posterior stroma are responsible for bearing stress from osmotic
pressure in the eyeball (Meek and Boote 2004). Tendon, which bears large tensile loads, has
highly oriented and packed collagen fibers and bundles arranging along the tensile direction
(Maria De Souza et al. 2006).
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Figure 1.3 The four levels of collagen organization (designed by J. Llewellyn)

Native tissues consist of ECM networks formed by collagen fibrous scaffolds and cells embedded
within these networks. Cells can modulate the organization of collagen fibrous networks in
multiple ways including applying contractile forces via mechanotransduction and secreting
collagen-related regulators (or binding proteins). Reciprocal cell-ECM crosstalk plays an
important role in mediating tissue development, homeostasis and remodeling and irregular cellECM interactions have been observed in pathological states. On the one hand, cells can
recognize mechanical signals from the ECM and convert them into downstream signaling
pathways via mechanosensing through cell-membrane proteins (such as integrins for focal
adhesion) which have specific effects on cell functions including migration and differentiation (Y.
Chen et al. 2017). On the other hand, contractile cells can apply force to collagen fibrous
networks and alter their organization by stretching, contracting and re-aligning collagen fibers
(Abhilash et al. 2014). Long-range force transmission, as a phenomena representing cell-ECM
crosstalk, is generated by contractile cells and the distance it acts over ranges from 250-1000 µm
(Wang et al. 2015). This cell-mediated collagen reorganization results in highly compacted and
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aligned collagen fibers and increased stiffness in the aligned area. Importantly, a fibrous network
with cross-linked collagen fibers is required for these long range cell-cell interactions (Ma et al.
2013). Externally applied mechanical forces and cell contractile forces also play similar roles in
collagen reorganization by stretching and aligning fibers (Vader et al. 2009). In native tissues,
dramatic alterations in collagen fibrous network organization can trigger and lead to the
progression of fibrogenesis and fibroproliferative diseases (Herrera, Henke, and Bitterman 2018).
Taking hepatic fibrosis as an example, bridging (septal) fibrosis, which shows a remarkable
reorganization of collagen fibrous networks and is mediated by activated fibroblasts, consists of
highly condensed and aligned thick fibers and has been regarded as a precursor of tissue
stiffening and severe chronic fibrosis such as cirrhosis (Maria De Souza et al. 2006). Interestingly
and similarly, early tissue stiffening during pulmonary fibrosis is mainly due to altered organization
of collagen fibrous networks via upregulated LOX-mediated crosslinking instead of the
accumulation of ECM (increased collagen content), which further highlights the importance of
understanding the mechanism of collagen network organization (Jones et al. 2018).

1.4 MATRIX PROTEOGLYCAN SUBFAMILIES AND THEIR FUNCTIONS AS
COLLAGEN REGULATORS
PGs are highly glycosylated matrix proteins of covalently-bound GAG side chains attached to a
core protein. Because of the highly negatively charged GAGs, PGs can attract water, cause
swelling, occupy large volume and enable tissues to resist compression (Yanagishita 1993).
There are two main subgroups of matrix (interstitial) PGs, SLPGs and the hyalectan family of
large chondroitin sulfate proteoglycans (CSPGs), which both have important regulatory functions
for various collagen behaviors. SLRPs, including decorin, lumican, fibromodulin, biglycan and
others, have core proteins of about 50-60 kDa with 1-4 GAG chains (Figure 1.4). They have been
studied for decades as collagen regulators mainly due to their significant effects on fibrillogenesis
both in vivo and in vitro. The mechanism of collagen/SLRPs interactions and their relevance to
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collagen behaviors in vivo, particularly fibrillogenesis during development, have been well studied.
The temporal and spatial expression of SLRPs is precisely controlled during development and is
important to support the regular physiological properties of specific tissues that require highly
organized collagen fibrous networks for their biological functions. For example, biglycan and
lumican participate in the formation of the lamellar collagen structure in cornea which is crucial for
corneal transparency (S. Chen et al. 2014), and decorin, fibromodulin and lumican play a role in
tendon development, modulating fiber morphology, diameter and arrangement as well as
interfibrillar space (Ezura et al. 2000)(G. Zhang et al. 2006). In vitro fibrillogenesis (turbidity)
assays suggest that decorin, lumican and biglycan downregulate collagen gelation with a
decreased fibril formation plateau and that their core proteins play distinct roles compared to
intact SLRPs (with GAG side chains) (Rada, Cornuet, and Hassell 1993)(Reese, Underwood, and
Weiss 2013). By using AFM to scan a mica disc coated with collagen/SLRP mixtures,
researchers have found that the addition of decorin and lumican to collagen leads to collagen
networks with enlarged interfibrillar spaces and decreased fibril diameters (Stamov et al. 2013).
Importantly, the binding sites between collagen and SLRPs have been identified through a
combination of 3D crystal structures and solid phase binding assays. SLRPs have typical leucinerich protein domains that form a horseshoe shaped structure (Orgel et al. 2009) and interact with
collagen via these leucine rich repeats (LRRs). Decorin, for example, interacts with charged
residues in the d band of the collagen α1 chain via the charged residues on its concave (inner)
surface, which allows decorin to function as a structural spacer between collagen monomers
during fibrillogenesis (Weber, Harrison, and Iozzo 1996). In more detail, researchers confirmed
that fibromodulin and lumican compete for binding collagen as they interact with collagen at
similar sequences on LRRs (Svensson, Närlid, and Oldberg 2000)(Kalamajski and Oldberg 2009),
while another research showed that fibromodulin and decorin bind to collagen at different
sequences on LLRs (Hedbom and Heinegard 1993). Both findings provide strong support for
concluding that lumican and decorin interact with collagen differently. In addition, the core
proteins of different SLRPs have different quantities of LRRs and the horseshoe structures have
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different concave diameters (Scott 1996), which can further affect their roles in regulating
collagen fibrillogenesis and arrangement structurally. Different SLRPs also have different
numbers, types and locations of GAG side chains: decorin has one CS or dermatan sulfate (DS)
side chain located close to its N-terminus, biglycan has two CS or DS located close to its Nterminus, while lumican has 4 keratan sulfate (KS) chains on its leucine-rich domain (Y. Zhang et
al. 2013)(Appunni et al. 2019). The variations in their GAG side chains can induce distinct
alterations on collagen fibrillogenesis (Stuart and Panitch 2008). Thus, different SLRPs including
decorin and lumican, although belonging to the same subfamily and sharing similar core protein
structures, differentially regulate multiple collagen behaviors.

Figure 1.4 The structure of decorin, biglycan and lumican (published by S. Appunni, et al.
(Appunni et al. 2019) and reprinted with permission)
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The hyalectan family, named for the HA binding abilities of its members, consists of versican,
aggrecan, neurocan and brevican (Iozzo and Schaefer 2015). Compared with SLRPs, these large
CSPGs have a significantly larger mass of negatively charged GAG side chains with total
molecular weights of 1-2.5 MDa. They can bind HA to form larger bio-complex aggregates that
retain water, increase osmotic pressure and occupy large spaces in the ECM (Wight 2002)(Kiani
et al. 2002). Aggrecan is predominantly found in cartilage and neurocan and brevican are mainly
expressed in the central nervous system. However, versican is universally distributed and
demonstrates versatile biological functions. It demonstrates altered expression and turnover in
ECM-related disorders such as fibrosis and metastasis. Unlike SLRPs, which have been deeply
investigated as collagen binding proteins and regulators of fibrillogenesis, the mechanisms of
collagen/CSPGs interactions and the roles of large CSPGs in modulating fibrillogenesis remain
unclear. Taking aggrecan as an example, a microplate solid-phase binding assay has indicated
that aggrecan interacts with collagen through its KS binding domain (Hedlund et al. 1999) and the
turbidity assay has found that aggrecan has no impact on in vitro collagen gelation (Vynios et al.
2001). On the other hand, although a solid-phase binding assay was reported to show a direct
interaction between versican and rat type I collagen (Yamagata et al. 1986), the physical nature
and mechanism of the interaction between versican and collagen have not been well defined and
the binding sites have not been identified. Additionally, the CS side chains, numbering up to 23
for the largest versican V0 isoform while over 100 for aggrecan, have complicated and
controversial effects on regulating collagen fibrillogenesis. Work by Bierbaum et al. (Bierbaum et
al. 2006) and Öbrink et al. (Öbrink 1973) has shown that the addition of CS accelerates in vitro
collagen gelation while Mathews et al. (Mathews and Decker 1968) have reported opposing
findings. Overall, there is a particular need to clarify the role of versican in regulating collagen
behaviors given its widespread distribution, unknown collagen-binding mechanism and precisely
regulated expression during collagen-related fibroproliferative disorders.
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1.5 VERSICAN AND ITS BIOLOGICAL FUNCTIONS
Versican, as a hyalectan family member, has a typical N-terminal G1 domain that can bind HA (in
combination with link protein) to form large aggregates in the ECM and also has a C-terminal G3
domain that can interact with integrin, tenascin and fibronectin (Wight, Kang, and Merrilees 2014).
Unlike aggrecan which has a KS binding domain adjacent to the G1 domain that functions as a
collagen binding site, versican only has CS GAG side chains. Thus, the interaction between
collagen and versican cannot be predicted from its structural similarity to aggrecan. There are 5
different versican isoforms. V0-V3 are commonly found in tissues and their structures are shown
in Figure 1.5: V0 has both α- and β-GAG domains (17-23 CS chains), V1 has the β-GAG domain
(12-15 CS chains), V2 has the α-GAG domain (5-8 CS chains), V3 has no GAG domain (Wight
2002) and newly-found V4 from breast cancer has part of the β-GAG domain (Kischel et al. 2010).
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Figure 1.5 The structure of different versican isoforms and aggrecan (created with
BioRender.com)

Most researches on versican are focused on its versatile roles in regulating cell behaviors such
as adhesion, proliferation and migration (Wight 2002) and on its altered gene expression and
ECM deposition during pathological states. Versican, especially its different isoforms and
domains, has also been widely studied for its diverse and controversial biological regulation of
cell responses and tissue functions. Conflicting findings have shown that versican can mediate
adhesion: the G1 domain inhibits 3T3 fibroblast adhesion (B. L. Yang et al. 1999) while the G3
domain interacts with β-integrin to promote astrocytoma cell adhesion (Y. Wu et al. 2002).
Another published work studying the V1 isoform (containing G1, G3 and β-GAG domain) has
found that V1 increases fibroblast adhesion and decreases migration (J. M. Carthy et al. 2015). In
addition, versican shows an inhibitory effect on neural cell migration and axonal growth in the
peripheral nervous system (Landolt et al. 1995) with both G1 and the versican GAG side chains
playing important regulatory roles. Different versican isoforms also have distinct effects in
modulating cell proliferation and apoptosis: V1 can upregulate fibroblast proliferation and inhibit
cell death while V2 shows opposing effects (Sheng et al. 2005). However, the distinct
mechanisms of these versican-related isoform- and domain-specific regulations of cell behaviors
have not been well explained. In collagen-related fibroproliferative diseases such as cancer,
inflammation and fibrosis, versican generally shows increased deposition and participates in
disease progression. For example, versican promotes tumorigenesis, increases cancer cell
proliferation, upregulates angiogenesis and induces tumor invasion and metastasis (Du, Yang,
and Yee 2013)(Ricciardelli et al. 2009). Versican has also been confirmed as an early regulator
during pulmonary and hepatic fibrosis; it remains increased during the entire fibrogenesis and
shows decreased expression during recovery (Venkatesan et al. 2000)(Bukong et al. 2016).
Versican also plays a role in embryonic development with a precisely modulated pattern of
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expression. In a mouse model, versican expression reaches a peak at E13.5 and then decreases
during development and remains at a low level in the adult. When comparing the expression of
different isoforms during development, V0 and V1 are predominantly expressed while the
deposition of V2 and V3 remains low in embryonic head and lung (Snyder et al. 2015); isoform
distribution has not been well studied in other tissues. Although versican has shown a wellcontrolled expression during embryonic development and an abnormally altered expression
during various collagen-related fibroproliferative malignancies, the effects of versican on
regulating collagen behaviors including fibrillogenesis, fiber organization and tissue mechanics
have been understudied and significant knowledge gaps remain.
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CHAPTER 2 VERSICAN BINDS COLLAGEN VIA ITS G3 DOMAIN
AND COLOCALIZES WITH COLLAGEN FIBERS
J. Llewellyn contributed to the dissection of mouse bile ducts.
B. Zuo, from the Electron Microscopy Resource Laboratory (Department of Biochemistry &
Biophysics), helped with bile duct sample processing and staining and immune electron
microscopy imaging.
The Collagen Toolkit II and its sequence information were provided by R. W. Farndale at
Cambcol, Cambridge, UK.

2.1 INTRODUCTION
Collagen is the most important structural protein in the ECM, representing about 25-35% of total
proteins and is responsible for maintaining ECM structural and functional integrity (Ricard-Blum
2011). Among all types of collagens, type I collagen is the most abundant (more than 90%) and
most ubiquitous member. Collagen I have two α1 and one α2 chains containing repeats of the
specific amino acid sequence glycine-X-Y and is organized in left-handed helices. The three α
chains rotate into a right-handed triple helix stabilized by hydrogen bonds between interchain
glycine and by electrostatic interactions between adjacent α chains (Ramachandran and
Chandrasekharan 1968)(Persikov et al. 2005). After being secreted from cells and undergoing the
cleavage of N- and C-terminal propeptides, collagen (used to refer to collagen type I when not
otherwise specified in this thesis) monomers can self-assemble into fibrils and entangle into fibers
or large bundles. Because of its high content, wide distribution and fibrillar organization,
collagen’s interactions with various ECM components, cell membrane proteins/receptors and
growth factors have been well studied and the collagen-binding sites have been mapped for key
interactors such as integrins, fibronectin and SLRPs (Emsley et al. 2000)(Kalamajski and Oldberg
2010).
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Collagen binding partners, which participate in cell-ECM crosstalk, have been investigated in
depth. Cell-ECM interactions are achieved by the binding between collagen and cell-membrane
receptor integrins such as α1β1 and α2β1 (Jokinen et al. 2004). Integrins serve as linkers
between cells and the matrix in this reciprocal cell-collagen (ECM) communication: cells can
sense the mechanical cues from collagen fibrous networks via integrins and collagen fibrous
networks can be re-organized and aligned by cellular contractile force applied via integrins. By
using collagen mimetic peptides in a solid phase binding assay, researchers have found that
α1β1 and α2β1 integrins interact competitively with GER and GER-like motifs and have mapped
the typical binding sequences on collagen for integrins to be GFOGER (central binding region)
and GLOGER (N-terminal binding region) (Knight et al. 2000)(Xu et al. 2000). Additionally,
fibronectin, an ECM glycoprotein, can function as a ‘link’ protein that binds both collagen and
integrin to stabilize and facilitate cell-collagen interactions. Through the use of proteolyticallycleaved collagen peptides, the fibronectin binding site was found to be located at residues 757791 of α1(I), which overlap with the collagenase cleavage site between residues 775 and 776
(Kleinman et al. 1978). Similar techniques have been applied to study the binding mechanism
between collagen and other ECM proteins including SLRPs.

Matrix PGs, also known as interstitial PGs, which are highly glycosylated with negatively-charged
GAG side chains, are important ECM proteins that can interact with collagen and regulate
collagen fibrillogenesis. There are two main subfamilies of matrix PGs: SLRPs (less than 100 kDa)
and large CSPGs (the hyalectan family, over 1 MDa). SLRPs, including decorin, lumican,
fibromodulin and others, have been appreciated for decades as important collagen-binding
proteins and crucial regulators of structural and functional collagen network maturation during
development (Kalamajski and Oldberg 2010). Importantly, the structural interactions and binding
sites between collagen and SLRPs have been well studied compared to large CSPGs. SLRPs
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interact with collagen via their LRRs and have specific impacts on fibrillogenesis because of their
horseshoe-like structures (Scott 1996). For example, by mapping the charged residues on the
concave surface of decorin and the d band of collagen α1(I), a space-filling representation of a
decorin/collagen binding model was generated showing that the collagen monomer fits into the
inner cavity formed by horseshoe structure of decorin LRRs (Weber, Harrison, and Iozzo 1996).
However, another structural binding model (the fibril surface model) proposes that decorin
interacts with adjacent collagen monomers via its N- and C-terminal arms, instead of LRRs, to
alter the arrangement of collagen monomers (Scott 1996)(Orgel et al. 2009). Importantly, different
SLRPs have different numbers of LRRs that make the size of the horseshoe structure variable:
decorin has 10 LRRs which are a combined size of about 5-6 nm, while lumican has 11 LRRs
and fibromodulin has 12 LRRs (more than 6 nm) (Scott 1996). Different SLRPs have distinct roles
in arranging collagen fiber organization. By using radiolabeled SLRPs in a collagen binding assay,
SLRPs binding sites on collagen were further assessed and it was found that fibromodulin and
lumican bind to the same sites on collagen but that these are distinct from the decorin binding site
(Hedbom and Heinegard 1993)(Svensson, Närlid, and Oldberg 2000). This assay using
radiolabeled SLRPs to bind fibrillar collagen uses other non-labeled SLRPs as potential inhibitors
to study competitive collagen binding among various SLRPs. To further understand the
homologous collagen binding site of fibromodulin and lumican, fragments containing different
LRRs from each SLRP were expressed by bacteria; the solid phase binding assay using the LRR
fragments of opposing SLRPs as inhibitors confirmed that fibromodulin and lumican interact
collagen via the same LRR 5-7 (Kalamajski and Oldberg 2009). A controversial result using this
method suggested that fibromodulin LRR 11 has a higher binding affinity than LRR 5-7 and that
mutating Glu-353 and Lys-355 destroys its collagen binding ability (Kalamajski and Oldberg 2007).
The recent development of the Collagen II and III Toolkit libraries (containing 56 and 57 triple
helical synthetic collagen mimetic peptides, respectively) by the University of Cambridge
(Cambcol) has made it possible and convenient to identify collagen binding sites for numerous
proteins including integrins, fibromodulin and matrix metalloproteinases (MMP) (Farndale 2019).
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With this tool, fibromodulin has been found to interact with Toolkit peptides II/III-44, III-5 and III-53;
II/III-44 are known as the MMP cleavage sites and III-5/53 with a similar KGHR sequence are
involved with helical crosslinking (Kalamajski et al. 2016). In addition to the in vitro binding assays,
immune electron microscopy (IEM) has also been used to study the colocalization of collagen
fibers and their binding partners in vivo and it has been shown that decorin colocalizes with
collagen fibers in fetal human dermis and aggrecan colocalizes partially with collagen II fibers in
cartilage (Fleischmajer et al. 1991)(Hedlund et al. 1999).

With the solution of SLRP crystal structures, synthesis of SLRP fragments and the development
of the Collagen Toolkit library, the interactions between collagen and SLRPs have been well
studied and the binding sites have been mapped. However, the interactions between collagen
and large CSPGs (the hyalectan family) have been neglected in these studies. The hyalectan
family is a group of large matrix PGs with CS side chains which can interact with HA (thus, the
derivation of the name hyalectan) to form large bottlebrush like bio-aggregates. Both of the
hyalectans versican and aggrecan play key roles in modulating ECM structural, mechanical and
functional features via their various interacting partners including HA, tenascin and fibulin (Y. J.
Wu et al. 2005)(Aspberg 2012). Many more studies have been carried out for aggrecan/collagen
interactions given its important biological and mechanical functions in cartilage, while less is
known about versican/collagen interactions in spite of versican’s universal distribution throughout
various tissues. For aggrecan, a solid phase binding assay has shown that aggrecan interacts
with both type I and II collagen via its KS domain and that it colocalizes with type II collagen fibers
in vivo (Hedlund et al. 1999). For versican, there is one report in the literature of solid-phase
binding data indicating its binding to rat type I collagen (Yamagata et al. 1986). Given that
versican participates in various collagen-related fibroproliferative diseases (Theocharis 2008), it is
important to identify the actual interaction between versican and collagen and map their binding
sites.
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In this chapter, I investigate the localization of versican in collagenous tissues using IEM, which
can show both versican localization and collagen fibers. To study the mechanism of collagenversican interactions in vitro, a solid phase binding assay is carried out using native versican as
well as the recombinant V3 isoform and G1 and G3 domains. To identify the versican binding
sites on collagen, the Collagen Toolkit, a library of synthetic collagen memetic peptides, is used.

2.2 METHODS
2.2.1 Reagents and antibodies
Rat tail type I collagen (with intact telopeptides) was from Corning (Corning, NY, USA). Versican
was isolated from bovine liver (Plaas and Sandy 1993). Cesium chloride, aggrecan (A1960),
decorin (D8428), hyaluronan biotin sodium salt, chondroitinase ABC (ChABC) from Proteus
vulgaris, bovine serum albumin, casein blocking buffer and Tween-20 were from Sigma (St. Louis,
MO, USA). Sodium hyaluronate (200 kDa) was from Lifecore (Chaska, MN, USA). Versican
extraction buffer contained guanidine hydrochloride (Sigma), sodium acetate (Sigma) and
protease complete tablets (Roche, Basel, Switzerland). Recombinant human lumican and
versican isoform V3 proteins were from R&D Systems (Minneapolis, MN, USA). Recombinant
human versican G1 and G3 domains (ab152303 and ab236178) were from Abcam (Cambridge,
UK). Biotinylated versican G1 domain was from Echelon Biosciences (Salt Lake City, UT, USA).
High sensitivity streptavidin-HRP and 1-step Ultra TMB-ELISA were from Thermo Fisher
Scientific (Waltham, MA, USA). The Collagen Toolkit II was from Cambcol Laboratories (Ely, UK).

Anti-versican antibody 12C5 was from DSHB (Development Studies Hybridoma Bank, Iowa city,
IA, USA), anti-aggrecan BC-3, anti-collagen I antibody (biotin, ab24821) and HRP anti-6X His
antibody (MA1-21315-HRP) were from Thermo Fisher Scientific, and anti-versican (β-GAG
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domain, Ab1033), anti-decorin antibody ab175404 and anti-versican antibody (β-GAG domain,
Ab1033) were from Sigma. Donkey Anti-Rabbit IgG H&L (12nm Gold) preadsorbed (ab105295)
was from Abcam.

2.2.2 Immune electron microscopy
Neonatal day 3 and adult mouse bile ducts were fixed with 4% paraformaldehyde/0.1%
glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) overnight at 4°C. Fixed samples were
submitted to the Electron Microscopy Resource Laboratory (Department of Biochemistry &
Biophysics, University of Pennsylvania, Philadelphia, PA, USA) for processing and staining. After
subsequent rinsing in buffer and diH2O, samples were dehydrated with a graded ethanol series
and then infiltrated and embedded in LRWhite. After cutting, thin sections were stained with antiversican antibody (β-GAG domain, ab1033) at 1:10 dilution overnight at 4°C. After rinsing 3 times,
sections were incubated with secondary anti-rabbit antibody (12 nm gold particles (ab105295)) at
1:50 overnight at 4°C. After rinsing, sections were stained with phosphotungstic acid (PTA) and
uranyl acetate (UA). Sections were imaged with a JEOL 1010 electron microscope fitted with a
Hamamatsu digital camera and AMT Advantage NanoSprint500 software, and IEM images were
taken randomly on each sample. Collagen fibers with gold particles attached were captured at
75,000× and the number of gold particles per fiber area was quantified (all 55 IEM images from
one neonatal sample and 38 images from one adult sample were analyzed).

To confirm that there was no non-specific binding of antibodies, a control experiment was carried
out using IEM to study plain collagen and collagen-versican matrices. Rat tail type I collagen was
diluted to a final concentration of 1.5 mg/mL (in PBS) using 10× PBS and diH2O and the pH was
adjusted to 7.4 using 1 N NaOH. For some collagen gels, versican was added to a final
concentration 0.1 mg/mL. 200 µL gel solution was added to a 1.5 mL tube and was incubated at
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37°C for gelation. The gels were gently detached from the tube by pipetting and were washed
with PBS 3 times. After fixing with 10% formalin for 10 min, the gels were rinsed and permeated
with 0.1% Triton-X. After rinsing, the gels were incubated with antibodies as described previously
for bile duct samples. After rinsing, sections were stained with PTA and UA. Sections were
imaged with a JEOL 1010 electron microscope fitted with a Hamamatsu digital camera and AMT
Advantage NanoSprint500 software, and IEM images were taken randomly on each sample.

2.2.3 Versican isolation
Native versican was extracted from bovine liver using a modification of a published protocol
(Plaas and Sandy 1993). Briefly, bovine liver tissue was mechanically disrupted and digested with
extraction buffer (pH=7.2) containing 4 M guanidine hydrochloride, 100 mM sodium acetate and
protease Complete tablets at 4°C for 72h. The supernatant of the extraction buffer was obtained
by spinning down tissue residues at 16,000×g for 1h. Cesium chloride was added to the
supernatant solution until the density reached 1.59 g/mL and it was then centrifuged at
100,000×g for 24h. 1 mL fractions were pipetted carefully from the top surface to the bottom and
the density of each fraction was measured. Fractions with a density above 1.54 g/mL were
dialyzed against 1 M sodium chloride for 24h and against diH2O for 24h. Samples were
reconcentrated using a 100 kDa centrifugal filter (Millipore Sigma, Burlington, MA, USA). The
compositions of extracted samples were analyzed by dot blotting using anti-versican, -aggrecan
and -decorin antibodies.

2.2.4 Solid phase binding assay
The solid phase binding assay was designed based on Enzyme-linked immunosorbent assay
(ELISA) methods. To study the interaction between collagen and versican, a 96-well plate was
coated with isolated versican or recombinant V3 isoform at 0.25 µg/ml. The plate was then
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blocked with 3% BSA in TTBS (TBS supplemented with 0.05% Tween-20) or casein blocking
buffer at room temperature (RT) for 3h. After it was rinsed 3 times, type I collagen was diluted to
0.1, 0.5, 1.0, 2.5 and 5 µg/ml (in 1% BSA/PBS binding buffer) and added to the plate for overnight
incubation at RT. After 3 rinses, biotinylated anti-collagen antibody was added to each well at
1:1000 (with 1% BSA/TBS) and incubated at 37°C for 1h. After 3 rinses, Streptavidin-HRP was
added at 1:4000 and incubated at RT for 30 min. After 5-7 rinses, TMB was added until color
became apparent (about 10 min) and 2 N sulfuric acid was added to stop the reaction. The
absorbance was read at 450 nm. To assess the interactions of the versican core protein, isolated
versican was digested with 250 mU ChABC (per mg substrate in 50mM sodium acetate pH=8) at
37°C overnight and then dialyzed with diH2O to remove CS. To study the binding site on V3,
recombinant G1 and G3 domains were compared using the solid phase assay described above.
The interaction between collagen and G1 was also studied using biotinylated G1: the 96-well
plate was coated with collagen at 10 and 100 µg/mL and biotinylated G1 was added at 0.1, 0.5, 1,
5 and 10 µg/mL for binding. A competition experiment was designed to study the role of HA in
collagen/versican interactions and the role of collagen in HA/versican interactions. A plate was
coated with 0.25 µg/mL V3 and bound with 1 µg/mL collagen mixed with increasing content of HA
(0.1, 0.5, 1, 5, 10 ng/mL) or the plate was coated with 0.25 µg/mL V3 and bound with 10 ng/ml
biotin-HA with increasing content of collagen (0.1, 0.5, 1.0, 2.5 and 5 µg/mL). To study the effect
of pH on the interaction between collagen and versican, the pH of 1% BSA/TBS buffer was
adjusted to 6, 7.4 and 8. To study the effect of ionic strength on the interaction between collagen
and versican, sodium chloride was added to 1% BSA/TBS buffer to reach a concentration of 0.05,
0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55 and 0.6M (Hedlund et al. 1999).

2.2.5 Collagen Toolkit binding assay
The Collagen Toolkit II, a library of synthetic collagen mimetic peptides, was synthesized by
Cambcol and was coated and lyophilized on a 96-well plate. Additional empty wells on the plate
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were coated with full-length collagen (rat tail type I). The plate was blocked with casein blocking
buffer at RT for 3h and recombinant V3 isoform or G3 domain was added at 10 µg/mL and
incubated at 4°C overnight. After rinsing, the bound V3 or G3 was detected using anti-His
antibody (HRP conjugated, diluted at 1:1000). After rinsing, TMB was added until color appeared
(about 10 min) and 2 N sulfuric acid was added to stop the reaction. The absorbance was read at
450 nm.

2.3 RESULTS
2.3.1 Versican colocalizes with collagen fibers both in vivo and in vitro
As published previously by our group using immunostaining, the expression of versican
decreases during bile duct development (Khandekar et al. 2020), I compared the localization and
deposition of versican in neonatal and adult bile duct using IEM. The extra-hepatic bile duct is a
tube-like structure formed by cholangiocytes and surrounded by a collagen-, PG- and HA-rich
matrix. The nano gold particles (the black dots on IEM figures, seen Figure 2.1A, B) illustrated the
localization of versican via primary versican β-GAG antibody and 12 nm gold conjugated
secondary antibody staining. Collagen fibers in the adult bile duct were more mature with a highly
organized and aligned pattern and large fiber bundles. Unlike in the adult bile duct, collagen fibers
in the neonatal bile duct were sparse, wavy and thin. Versican colocalized with collagen fibers in
both neonatal and adult bile ducts and its deposition decreased during development (Figure 2.1C).
IEM was also applied to plain collagen (as a control) and collagen-versican co-gels. Collagen
fibers in collagen gels visualized by IEM were not as well-organized as native fibers in vivo, but
versican was still found to colocalize with collagen fibers. As there are no black dots in Figure
2.1E, I confirmed that the antibodies I used did not have non-specific binding to collagen itself.
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Figure 2.1 Versican colocalizes with collagen fibers in the extrahepatic bile duct and in vitro, as
shown by immune-gold labeling. (A, B) Representative IEM figures showing the colocalization of
versican on collagen fibers in mouse bile duct samples: (A) neonatal day 3, (B) adult. (C)
Quantification of versican colocalized with collagen fibers was calculated by the number of gold
particles per total fiber area (all 55 IEM images from one neonatal sample and 38 images from
one adult sample were analyzed). (D, E) Representative IEM figures showing that there is the
colocalization of versican and collagen fibers in collagen-versican gel but not in pure collagen gel
(as a control). One experiment was done for each condition with three technical repeats for bile
duct samples and two technical repeats for gel samples. Red arrows point at gold dots binding to
versican and blue arrows point at collagen fibers. Scale bar = 200 nm, direct magnification =
75,000×. Data represent mean ± SD, ****P<0.0001.
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2.3.2 Versican isolation and analysis
Native versican was isolated from bovine liver and purified with ultracentrifugation. After
assessing its purity by dot blotting, I found that isolated versican samples were contaminated with
aggrecan and decorin (Figure 2.2). In this case, the following approaches described in this thesis
had both aggrecan and decorin as negative controls and had pure recombinant V3 isoform as a
positive control.

Figure 2.2 The purity of isolated versican from bovine liver. (A) Dot blotting of representative
density fractions stained with anti versican G1 (12C5) and anti veriscan βGAG (Ab1033)
antibodies confirmed the presence of versican (mostly V0 and V1 isoforms). (B, C) Dot blotting
with aggrecan and decorin antibodies also demonstrated minor contamination of the versican
sample with aggrecan (B) and decorin (approximately 0.37 mg/mL decorin in 4.68 mg/ml
extracted sample) (C).
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2.3.3 Versican and its V3 isoform bind to collagen
To investigate the interaction between collagen and versican, a solid phase binding assay was
used. A 96-well plate was coated with isolated versican and recombinant V3 isoforms (contains
G1 and G3 domain lacking GAG-binding domains). The amount of collagen bound to versicancoated wells increased with increasing addition of collagen and showed saturable binding (Figure
2.3A). When the plate was coated with increasing concentrations of versican, I also observed an
increased binding of collagen (Figure 2.3A). The same trend was found for V3-coated plates, as
shown in Figure 2.3B, although the plateau was higher compared to versican coating. To validate
this solid phase binding assay, versican, V3, decorin, lumican and aggrecan were compared and
similar saturable binding patterns were observed (Figure 2.3C). The binding of collagen to V3,
decorin and lumican was higher compared to its binding to versican and aggrecan (Figure 2.3C).
After digesting isolated versican with chondroitinase ABC to remove GAG residues (no GAG was
detected using the Blyscan assay after digestion and data were not shown here), I found that it
was mainly the versican core protein that participated in its collagen interactions (Figure 2.3D). To
analysis binding affinity, I analyzed the data using the Scatchard equation: ΔA/C = ΔAmax/Kd ΔA/Kd (ΔA is measured value of absorbance and C is collagen concentration). By plotting ΔA/C
versus C, the dissociation constant (Kd) and maximum absorbance (Amax) were calculated from
the slope and X-intercept of the linear fitting of the Scatchard plot and R2 showed the quality of
linear fitting (Figure 2.3E-G). The interaction between collagen and V3 was stronger with a lower
Kd (without significant difference, Figure 2.3H) compared to isolated versican and its core protein,
and the maximum amount of collagen binding to V3 and the versican core protein were
significantly higher than binding to intact versican (Figure 2.3I).
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Figure 2.3 Versican and its V3 isoform bind collagen. (A, B) A 96-well plate was coated with
isolated versican (Ver) or recombinant V3 isoform (V3) at 0.05, 0.1, 0.25, 0.5 and 1 µg/mL and
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collagen (Col) was added at 0.1, 0.5, 1, 2.5 and 5 µg/mL for binding. (C) A 96-well plate was
coated with different matrix PGs including Ver, V3, decorin (Dec), lumican (Lum) and aggrecan
(Agg) at 0.25 µg/mL and Col was added at 0.1, 0.5, 1, 2.5 and 5 µg/mL for binding. (D) A 96-well
plate was coated with Ver, V3 and versican core protein (Ver-ChABC, generated by ChABC
digestion) at 0.25 µg/mL and Col was added at 0.1, 0.5, 1, 2.5 and 5 µg/mL for binding. In binding
curves, error bars represent SD. (E-G) The Scatchard analysis of (D) by plotting ΔA/C versus C
with R2 (mean of three individual experiments) indicating linear fitting quality. (H) Kd was
calculated from the slope of the linear fitting of the Scatchard plot. (I) Amax was the X-intercept of
the linear fitting of the Scatchard plot. Three independent experiments were carried out for each
condition with one technical repeat in each experiment. Data represent mean ± SD, *P<0.05,
**P<0.01, ***P<0.001 and ****P<0.0001.

2.3.4 Versican core protein interacts with collagen via its G3 domain
To narrow down the collagen binding sites on V3, I studied the interaction between collagen and
the versican G1 and G3 domains (which are the two parts of V3) using a solid phase binding
assay in which a plate was coated with collagen and G1 or G3 added with comparison of their
binding capacity. I observed that there was an interaction between collagen and the G3 domain
but not between collagen and the G1 domain (Figure 2.4A). To confirm this finding, I also used a
solid phase binding assay in which a plate was coated with collagen and bound with biotinylated
G1 domain and I found that there was significantly less biotinylated G1 bound to collagen (Figure
2.4B).

Because versican binds HA via its G1 domain (S. Shi et al. 2004), a competition binding assay
was designed to confirm that versican binds collagen and HA at different locations (G3 versus
G1). Versican was used to coat 96-well plates and then exposed to collagen mixed with

31

increasing amounts of HA. The collagen-versican binding was not affected by additional HA
(Figure 2.4C). In a reverse design in which versican was used to coat the plates and HA mixed
with increasing collagen was added, HA-versican binding was also unchanged by additional
collagen (Figure 2.4D). The competition binding assay thus supported the conclusion that
versican binds to collagen via G3 and does so independently of the G1 domain binding HA.
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Figure 2.4 Versican binds collagen via its G3 domain in contrast to its G1 domain binding HA. (A)
A plate was coated with recombinant G1 and G3 domains at 0.25 µg/mL and Col was added at
0.1, 0.5, 1, 2.5 and 5 µg/mL for binding. (B) A 96-well plate was coated with Col at 10 and 100
µg/mL and biotinylated G1 was added at 0.1, 0.5, 1, 5 and 10 µg/mL. (C) A plate was coated with
V3 and bound with collagen mixed with increasing amounts of HA. (D) A plate was coated with
V3 and bound with HA mixed with increasing amounts of collagen. (E) A diagram shows the
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proposed collagen/versican and HA/versican interaction (created with BioRender.com). Three
independent experiments were carried out for each condition with one technical repeat in each
experiment. Data represent mean ± SD.

2.3.5 The collagen/versican interaction is sensitive to pH and ionic strength
To further characterize the interaction between collagen and versican, the impact of pH and ionic
strength was examined. With increasing pH, the interaction between collagen and versican was
attenuated (Figure 2.5A), suggesting an important role for negatively-charged GAG side chains
as well as other charged amino acids on the core protein. The same trend was also observed for
the interaction between collagen and V3 (Figure 2.5B), which was also consistent with the
charged residues of the versican core protein having a regulatory role, altering the
versican/collagen interaction capacity regardless of versican’s GAG side chains. Both
collagen/versican and collagen/V3 interactions were found to be downregulated with increasing
ionic strength (Figure 2.5C), which further supported that charged residues modulated their
binding. The amount of collagen binding was gradually decreased when NaCl was increased from
0 to 0.15 M and was not affected when NaCl was higher than 0.2 M. As the physiological ionic
strength is 10-20 mM, my data supported the conclusion that the collagen/V3 interaction was
sensitive to ionic strength changes in the physiological range while the collagen/versican
interaction remained constant.
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Figure 2.5 pH and ionic strength modulate collagen/versican and collagen/V3 interactions. (A, B)
Solid phase binding assay using binding buffer at different pH values (pH 6, pH 7.4 as
physiological condition and pH 8) indicated that increased pH downregulated collagen/versican
and collagen/V3 binding. (C) Solid phase binding assay using binding buffer with increasing ionic
strength (modified by adding NaCl at 0.05-0.6 M). Three independent experiments were carried
out for each condition with one technical repeat in each experiment. Data represent mean ± SD.

2.3.6 Potential versican binding sites on collagen are identified using the
Collagen Toolkit
The Collagen Toolkit II is a library of synthetic type II collagen peptides which covers the whole
triple helical region (aa. 201 – aa. 1214). Each Toolkit peptide has 27 amino acids (9 G-X-Y
repeats) with overlap of 3 G-X-Y repeats between sequential peptides (Table 2.1). Because the
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sequence of collagen II is similar to collagen I, it can be used for identifying the protein binding
sites on collagen I.

Table 2.1 The amino acid sequence of 56 Collagen Toolkit II (O represents hydroxyproline).
Peptide

Sequence

MW

TK-II-1

GPC-(GPP)5-GPMGPMGPRGPOGPAGAOGPQGFQGNO-(GPP)5-GPC-

5558

NH2
TK-II-2

GPC-(GPP)5-GPQGFQGNOGEOGEOGVSGPMGPRGPO-(GPP)5-GPC-

5648

NH2
TK-II-3

GPC-(GPP)5-GPMGPRGPOGPOGKOGDDGEAGKOGKA-(GPP)5-GPC-

5572

NH2
TK-II-4

GPC-(GPP)5-GEAGKOGKAGERGPOGPQGARGFOGTO-(GPP)5-GPC-NH2

5621

TK-II-5

GPC-(GPP)5-GARGFOGTOGLOGVKGHRGYOGLDGAK-(GPP)5-GPC-NH2

5710

TK-II-6

GPC-(GPP)5-GYOGLDGAKGEAGAOGVKGESGSOGEN-(GPP)5-GPC-NH2

5533

TK-II-7

GPC-(GPP)5-GESGSOGENGSOGPMGPRGLOGERGRT-(GPP)5-GPC-NH2

5668

TK-II-8

GPC-(GPP)5-GLOGERGRTGPAGAAGARGNDGQOGPA-(GPP)5-GPC-NH2

5503

TK-II-9

GPC-(GPP)5-GNDGQOGPAGPOGPVGPAGGOGFOGAO-(GPP)5-GPC-

5385

NH2
TK-II-10

GPC-(GPP)5-GGOGFOGAOGAKGEAGPTGARGPEGAQ-(GPP)5-GPC-NH2

5423

TK-II-11

GPC-(GPP)5-GARGPEGAQGPRGEOGTOGSOGPAGAS-(GPP)5-GPC-NH2

5447

TK-II-12

GPC-(GPP)5-GSOGPAGASGNOGTDGIOGAKGSAGAO-(GPP)5-GPC-NH2

5295

TK-II-13

GPC-(GPP)5-GAKGSAGAOGIAGAOGFOGPRGPOGPQ-(GPP)5-GPC-NH2

5417

TK-II-14

GPC-(GPP)5-GPRGPOGPQGATGPLGPKGQTGEOGIA-(GPP)5-GPC-NH2

5510

TK-II-15

GPC-(GPP)5-GQTGEOGIAGFKGEQGPKGEOGPAGPQ-(GPP)5-GPC-NH2

5607

TK-II-16

GPC-(GPP)5-GEOGPAGPQGAOGPAGEEGKRGARGEO-(GPP)5-GPC-NH2

5558
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TK-II-17

GPC-(GPP)5-GKRGARGEOGGVGPIGPOGERGAOGNR-(GPP)5-GPC-NH2

5628

TK-II-18

GPC-(GPP)5-GERGAOGNRGFOGQDGLAGPKGAOGER-(GPP)5-GPC-NH2

5680

TK-II-19

GPC-(GPP)5-GPKGAOGERGPSGLAGPKGANGDOGRO-(GPP)5-GPC-NH2

5529

TK-II-20

GPC-(GPP)5-GANGDOGROGEOGLOGARGLTGROGDA-(GPP)5-GPC-NH2

5606

TK-II-21

GPC-(GPP)5-GLTGROGDAGPQGKVGPSGAOGEDGRO-(GPP)5-GPC-NH2

5562

TK-II-22

GPC-(GPP)5-GAOGEDGROGPOGPQGARGQOGVMGFO-(GPP)5-GPC-

5650

NH2
TK-II-23

GPC-(GPP)5-GQOGVMGFOGPKGANGEOGKAGEKGLO-(GPP)5-GPC-NH2

5625

TK-II-24

GPC-(GPP)5-GKAGEKGLOGAOGLRGLOGKDGETGAA-(GPP)5-GPC-NH2

5536

TK-II-25

GPC-(GPP)5-GKDGETGAAGPOGPAGPAGERGEQGAO-(GPP)5-GPC-NH2

5447

TK-II-26

GPC-(GPP)5-GERGEQGAOGPSGFQGLOGPOGPOGEG-(GPP)5-GPC-NH2

5577

TK-II-27

GPC-(GPP)5-GPOGPOGEGGKOGDQGVOGEAGAOGLV-(GPP)5-GPC-NH2

5458

TK-II-28

GPC-(GPP)5-GEAGAOGLVGPRGERGFOGERGSOGAQ-(GPP)5-GPC-NH2

5638

TK-II-29

GPC-(GPP)5-GERGSOGAQGLQGPRGLOGTOGTDGPK-(GPP)5-GPC-NH2

5917

TK-II-30

GPC-(GPP)5-GTOGTDGPKGASGPAGPOGAQGPOGLQ-(GPP)5-GPC-NH2

5401

TK-II-31

GPC-(GPP)5-GAQGPOGLQGMOGERGAAGIAGPKGDR-(GPP)5-GPC-NH2

5561

TK-II-32

GPC-(GPP)5-GIAGPKGDRGDVGEKGPEGAOGKDGGR-(GPP)5-GPC-NH2

5525

TK-II-33

GPC-(GPP)5-GAOGKDGGRGLTGPIGPOGPAGANGEK-(GPP)5-GPC-NH2

5444

TK-II-34

GPC-(GPP)5-GPAGANGEKGEVGPOGPAGSAGARGAO-(GPP)5-GPC-NH2

5344

TK-II-35

GPC-(GPP)5-GSAGARGAOGERGETGPOGPAGFAGPO-(GPP)5-GPC-NH2

5450

TK-II-36

GPC-(GPP)5-GPAGFAGPOGADGQOGAKGEQGEAGQK-(GPP)5-GPC-NH2

5495

TK-II-37

GPC-(GPP)5-GEQGEAGQKGDAGAOGPQGPSGAOGPQ-(GPP)5-GPC-NH2

5475

TK-II-38

GPC-(GPP)5-GPSGAOGPQGPTGVTGPKGARGAQGPO-(GPP)5-GPC-NH2

5412

TK-II-39

GPC-(GPP)5-GARGAQGPOGATGFOGAAGRVGPOGSN-(GPP)5-GPC-NH2

5436

TK-II-40

GPC-(GPP)5-GRVGPOGSNGNOGPOGPOGPSGKDGPK-(GPP)5-GPC-NH2

5525

TK-II-41

GPC-(GPP)5-GPSGKDGPKGARGDSGPOGRAGEOGLQ-(GPP)5-GPC-NH2

5561
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TK-II-42

GPC-(GPP)5-GRAGEOGLQGPAGPOGEKGEOGDDGPS-(GPP)5-GPC-NH2

5561

TK-II-43

GPC-(GPP)5-GEOGDDGPSGAEGPOGPQGLAGQRGIV-(GPP)5-GPC-NH2

5531

TK-II-44

GPC-(GPP)5-GLAGQRGIVGLOGQRGERGFOGLOGPS-(GPP)5-GPC-NH2

5705

TK-II-45

GPC-(GPP)5-GFOGLOGPSGEOGKQGAOGASGDRGPO-(GPP)5-GPC-NH2

5551

TK-II-46

GPC-(GPP)5-GASGDRGPOGPVGPOGLTGPAGEOGRE-(GPP)5-GPC-NH2

5514

TK-II-47

GPC-(GPP)5-GPAGEOGREGSOGADGPOGRDGAAGVK-(GPP)5-GPC-NH2

5491

TK-II-48

GPC-(GPP)5-GRDGAAGVKGDRGETGAVGAOGAOGPO-(GPP)5-GPC-NH2

5449

TK-II-49

GPC-(GPP)5-GAOGAOGPOGSOGPAGPTGKQGDRGEA-(GPP)5-GPC-NH2

5431

TK-II-50

GPC-(GPP)5-GKQGDRGEAGAQGPMGPSGPAGARGIQ-(GPP)5-GPC-NH2

5534

TK-II-51

GPC-(GPP)5-GPAGARGIQGPQGPRGDKGEAGEOGER-(GPP)5-GPC-NH2

5644

TK-II-52

GPC-(GPP)5-GEAGEOGERGLKGHRGFTGLQGLOGPO-(GPP)5-GPC-NH2

5746

TK-II-53

GPC-(GPP)5-GLQGLOGPOGPSGDQGASGPAGPSGPR-(GPP)5-GPC-NH2

5427

TK-II-54

GPC-(GPP)5-GPAGPSGPRGPOGPVGPSGKDGANGIO-(GPP)5-GPC-NH2

5409

TK-II-55

GPC-(GPP)5-GKDGANGIOGPIGPOGPRGRSGETGPA-(GPP)5-GPC-NH2

5528

TK-II-56

GPC-(GPP)5-GPRGRSGETGPAGPOGNOGPOGPOGPO-(GPP)5-GPC-NH2

5521

To identify the versican binding sites on collagen, I compared the versican binding capacity of
these Toolkit peptides to the versican binding of full-length collagen. V3 showed a relatively high
binding when interacting with Toolkit peptides 4, 8, 11, 15 and 18 (Figure 2.6A). Toolkit peptides
4, 8, 11 and 18 also showed up as positive binding candidates for G3 (Figure 2.6B). In addition,
Toolkit 5 and 44 were identified as potential binding sites for the G3 domain (Figure 2.6B).

38

Figure 2.6 Potential V3 isoform and its G3 domain binding sites on collagen were identified using
the Collagen Toolkit. Toolkit peptide-coated 96-well plates were tested with the addition of
recombinant V3 or G3 (both have His tags), and bound V3 or G3 was detected using an HRP
conjugated anti-His antibody. Empty wells in the plate provided by Camcol were coated with fulllength collagen as a positive control. Two independent experiments were done with V3 with one
representative graph shown. One experiment was done with G3.

2.4 DISCUSSION
Matrix PGs, especially SLRPs, have been well studied and reported to be important collagen
binding ECM proteins and key regulators for collagen fibrillogenesis during development. I report
here that versican, a universally distributed hyalectan PGs, can interact with collagen both in vitro
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and in vivo, and may modulate collagen fiber formation maturation and organization during
development. IEM successfully confirms the colocalization of versican and collagen fibers in the
extrahepatic bile duct, with decreased versican deposition during development. A solid phase
assay identified G3 domain as the collagen binding site on versican, and the Collagen Toolkit
assay identified Toolkit peptides 4, 8, 11, 15 and 18 as potential V3 binding peptides, with the
study on G3 adding Toolkit peptides 5 and 44 to the candidate list.

SLRPs, the small matrix PG subfamily, have been heavily studied as regulators of the size,
morphology and organization of collagen networks during development and appear to be
especially important for tissues such as cornea (S. Chen et al. 2014) and tendon (G. Zhang et al.
2006) that require well-organized fibrous networks for their physiological functions. For example,
lumican and biglycan deficiency cause an impaired lamellar organization of collagen fibers and
damage the transparency of cornea (S. Chen et al. 2014); the loss of lumican and fibromodulin
leads to abnormal fiber structure and irregular interfibrillar spaces in tendon (Ezura et al. 2000).
Unlike SLRPs, large hyalectan PGs including versican have not been well investigated as
mediators of collagen maturation during development. Our lab has published that versican
expression decreases during extrahepatic bile duct development, as determined by
immunostaining neonatal and adult bile duct samples (Khandekar et al. 2020) and I further
validated this observation by using IEM, which shows the colocalization of versican with collagen
fibers and a decrease in versican deposition in the region of collagen fibers during development.
IEM has also been used to study the interaction between collagen and other matrix PGs: in fetal
dermis, a large amount of decorin has been observed that colocalizes with collagen fibers and
forms a spiral like decoration along individual fibers (Fleischmajer et al. 1991); in cartilage, a
small number of aggrecan KS domains colocalize with collagen (type II) fibers while others mainly
stay in the interfibrillar space (forming large HA-aggrecan aggregates) (Hedlund et al. 1999). To
further validate this versican/collagen colocalization, IEM was carried out on a collagen-versican
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co-gel which illustrates that there is a direct interaction between collagen and versican in vitro.
However, the mechanism of the collagen/versican interaction and its regulation of collagen
fibrillogenesis and organization remains unclear.

To understand the collagen binding sites on versican, solid phase binding assays were used. It is
important to clarify that isolated versican from bovine liver is contaminated with aggrecan and
decorin. Although isolated versican, isolated versican core protein (generated by ChABC
digestion), and recombinant V3 isoforms all demonstrate a collagen binding capacity,
recombinant V3, as a pure core protein, has a particularly high binding affinity and capacity.
Given the fact that isolated versican was contaminated with aggrecan and decorin, the direct
binding between collagen and pure recombinant V3 confirm the actual binding between collagen
and versican core protein. As V3 only contains N-terminal G1 and C-terminal G3 domain (lacking
GAG domain), my further investigation in comparing the collagen binding capacity of G1 versus
G3 further demonstrates that it is versican core protein G3 domain that directly bind collagen. As
further validated by competition experiments, the collagen-binding site and the HA-binding site on
versican are distinct: collagen binds to the C-terminal G3 domain of versican while HA binds to
the N-terminal G1 domain, without evidence of interactions between the binding sites. Although
aggrecan is thought to be structurally similar to versican, it has distinct interactions with collagen
compared to versican given that the collagen binding site on aggrecan is in the KS domain (the
core protein of this domain), a domain that versican lacks (Hedlund et al. 1999). Compared to
isolated versican (Kd=1.29 nM) and its core protein (Kd=2.23 nM), recombinant V3 shows a higher
binding affinity (Kd=0.69 nM) suggesting that the GAG residues, which are highly negatively
charged, might play a negative role in interactions between collagen and versican. The Kd for
collagen/fibromodulin and collagen/decorin interactions are 9.9 nM (Hedbom and Heinegard 1993)
and 14 nM (Vynios et al. 2001), while the Kd is 1.1 µM for collagen/aggrecan binding (Hedlund et
al. 1999). This indicates that there is a strong interaction between collagen and V3 compared to
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the weak electrostatic interaction between collagen and aggrecan. Importantly, both
collagen/versican and collagen/V3 interaction are pH and ionic strength sensitive indicating that
charged residues play an important role in these interactions. Given that G3 domain is the
collagen binding sites, I have analyzed the charged tracts on its amino acid sequence (Figure 2.7)
and found that positive tracts including 3182-KYFAHRR-3188, 3306-KTFGKMKPR-3324, 3360RTYSMKYFK-3368 and 3386-RWSRR-3390 and negative tracts including 3122-DQCELDFDE3130 and 3163-EQDTETCD-3170 are potential binding residues which require further
investigation using a solid phase binding assay with recombinant binding residues to identify the
actual collagen binding motifs of versican.

Figure 2.7 The highly charged tracts on the amino acid sequence of G3 core protein. Blue –
positive charged; red – negative charged; grey highlights – highly charged tracts. (This analysis
was done by R. W. Farndale.)
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Based on the data from the solid phase assay and collagen/HA/V3 competition experiments, I
have confirmed that the V3 isoform binds collagen via its G3 domain, but I have not studied the
core protein of the α and β-GAG domains. There are some limitations to these studies: (1)
purification of versican from native tissue is difficult and we have been unable to isolate pure
protein; (2) there is not any normal tissue that has a large accumulation of versican; (3) versican
has over 3000 amino acids which makes it hard to synthesize fragments covering the entire core
protein for screening binding sites. In future experiments, using recombinant versican α and βGAG domains in a solid phase assay will shed light on potential binding sites in these two large
domains of versican core protein.

To identify the versican binding sites on collagen, the Collagen Toolkit solid phase assay has
been used to detect potential binding peptides. After comparing the binding capacity of 56
synthetic collagen memetic peptides (Toolkits) to that of native collagen, Toolkit peptides 4, 8, 11,
15 and 18 show high binding to V3 and Toolkit peptides 4, 5, 8, 11, 18 and 44 show high binding
to G3. This is a strong evidence that V3 and G3 share the same binding sequence as they all
bind to Toolkit 4, 8, 11 and 18, which are not published as common binding peptides (except
Toolkit 8, known as an integrin binding site) (Farndale 2019). Importantly, G3 adds Toolkit 5 and
44 to the candidate list. 5 and 44 both have important biological functions, having been reported
as crosslinking and collagenase sites, respectively, which suggests a potential regulatory role of
versican in collagen crosslinking and degradation. Why G3 binds to these peptides and V3 does
not is unclear. There might be conformational changes in V3 compared to G3 alone (potentially
with the G1 and G3 domains in V3 binding to each other, or dimerizing) which effectively
sequester the binding sites of Toolkit 5 and 44. In this case, different versican isoforms may have
different conformations and 3D crystal structures, which have not been studied. The structural
variances of versican isoforms may lead to distinct binding capabilities and binding partners and
might explain the diverse and opposing biological functions of these isoforms (Ricciardelli et al.
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2009). After assessing the alignment of these Toolkit candidates, the R-G-Hydrophobic-O motif is
highly aligned among all these candidates (Figure 2.8). R can be substituted by K in Toolkit 15,
and the aliphatic stems of E, R and P provide hydrophobic interactions. Another possible motif is
the GPA triplets that has also been found in some Toolkits which the small sidechain of alanine
might avoid steric hindrance but not contribute to binding directly. In addition, GPP might also
function similarly as GPA given that the ring of proline does not protrude too far from the axis of
the helix. In the future, the binding between versican and R-G-Hydrophobic-O motif will be
validated by using corresponding collagen mimetic peptides in a solid phase binding assay and
studying versican binding with Toolkit III (synthetic collagen peptides of type III collagen) will
explore additional versican/collagen binding sites. In addition, understanding the 3D
conformational structure of V3 and G3 as well as the binding motif (R-G-Hydrophobic-O in the
helix) will shed light on building the 3D binding model of collagen/versican interaction.

Figure 2.8 The binding motifs analyzed by the alignment of versican-binding Toolkits. The
alignment analysis was done by R. W. Farndale.
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In addition, collagen fibers form a 3D dynamic fibrous network via strong covalent interactions
including LOX mediate crosslinks (Robins 2007) and weak interactions including electrostatic
interactions between charged residues (Wallace 1990). Thus, the presence of versican in
collagen matrices can regulate the organization of collagen fibers through binding between
collagen and the G3 domain. This is particularly important given the evidence that G3 interacts
with collagen crosslink sites. A future investigation into the 3D structural collagen/versican binding
model will help understand the mechanisms of versican/collagen interactions in modulating
collagen fibrous networks, specifically the promotion of fiber fusion into bundles and increased
fiber alignment (shown in Chapters 3 and 4). The pH sensitivity of the versican/collagen
interaction has a potentially crucial physiological relevance in vivo, considering the acidic tumor
microenvironment as an example (Justus, Dong, and Yang 2013). The pH of the tumor
microenvironment can be as low as 5.6 (Griffiths 1991) and acidic pH (pH=6) is preferred for
versican/collagen interactions (Figure 2.5A, B). Thus, increased deposition of versican in cancer
(Ricciardelli et al. 2009) could modulate the collagen fibrous network via upregulating
versican/collagen interactions that facilitate the accumulation of a collagen rich matrix with highly
aligned fibers (Figure 4.2, 4.4), which could enhance metastasis (Han et al. 2016).

In sum, versican colocalizes with collagen fibers both in vitro and in vivo, supporting the presence
of a direct interaction between collagen and versican. There is decreased versican expression
during bile duct development, suggesting a regulatory role in collagen fibrillogenesis and fibrous
network maturation. Versican directly interacts with collagen via its C-terminal G3 domain, in
contrast to its N-terminal G1 domain which binds HA. Highly charged residues on the binding
sites, four positively charged tracts and two negatively charged tracts as potential binding motifs
on G3, are important for collagen/versican interaction given its pH and ionic strength sensitivity.
The Toolkit results further confirm the direct interaction between collagen and versican, indicate
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the importance of R-G-Hydrophobic-O motifs in collagen/versican binding and identify a potential
role for G3 in collagen crosslinking and degradation.

46

CHAPTER 3 VERSICAN REGULATES COLLAGEN
FIBRILLOGENESIS AND ORGANIZATION DIFFERENTLY
COMPARED TO OTHER MATRIX PROTEOGLYCANS
This chapter is adapted from the publication: D. Chen, L.R. Smith, G. Khandekar, P. Patel, C.K.
Yu, K. Zhang, C.S. Chen, L. Han, R.G. Wells, Distinct effects of different matrix proteoglycans on
collagen fibrillogenesis and cell-mediated collagen reorganization, Sci. Rep. 10 (2020) 1–13.
doi:10.1038/s41598-020-76107-0.
L.R. Smith and P. Patel helped with versican isolation from bovine liver.

3.1 INTRODUCTION
Type I collagen is the most abundant structural protein in the ECM. It is synthesized and folded
into a triple helix in the endoplasmic reticulum, post-translationally modified and transferred via
the Golgi apparatus and then secreted into the ECM (Canty and Kadler 2005). After the cleavage
of N- and C-propeptides, collagen monomers can form internal and external crosslinks and selfassemble into collagen fibrils which show a typical 67 nm D-periodicity as part of a well-organized
banding pattern (Yamauchi and Sricholpech 2012). Fibrils can further form large fibers (although
the distinction between fibril and fiber remains unclear) and they can undergo lateral fusion into
larger bundles, form a complex fibrous network and build up higher tissue-level organization.
Collagen fibrillogenesis is precisely controlled and dynamically regulated during tissue
development and abnormal fibrillogenesis has been observed during collagen-related disorders.
Collagen also has a crucial role in maintaining appropriate structural and mechanical complexity
of the ECM in specific tissues (Banos, Thomas, and Kuo 2008). Importantly, the structure and
organization of collagen fibrous networks is highly regulated by interacting with other ECM
components including PGs and GAGs (Kalamajski and Oldberg 2010). PGs are highly
glycosylated proteins attached to negatively-charged GAG side chains; the negative charges on
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GAGs enable them to attract water, increase swelling and resist compression (Yanagishita 1993).
PGs as well as GAGs have been widely studied as regulators for collagen fibrillogenesis and
therapeutic targets for ECM-related diseases including inflammation, fibrosis and cancer
(Theocharis 2008).

Matrix (interstitial) PGs are divided into two subgroups: SLRPs and hyalectans (large CSPGs).
SLRPs have 50-60 kDa core proteins with only 1-4 GAG side chains (DS, CS or KS) and the
family includes decorin, lumican, and fibromodulin. As important collagen binding partners,
SLRPs have been well studied as key regulators of fibrillogenesis both in vitro and in vivo. An in
vitro spectrophotometric (turbidity) assay has been widely applied to study various factors, such
as pH, ionic strength and polyanions, that regulate fibril formation and fibrous network
organization (Yan et al. 2012)(Wood 1960). As demonstrated using the turbidity assay, decorin
and lumican have negative effects on fibrillogenesis such that they decrease both the rate and
plateau of fibril formation (Rada, Cornuet, and Hassell 1993). During development, SLRPs are
required for maintaining normal fiber formation and organization, especially for tissues like cornea
and tendon, which need highly organized collagen networks for their regular functions. Lumicanand biglycan-deficient mice have disrupted lamellar fiber structures in the cornea that affect
corneal transparency (S. Chen et al. 2014), and decorin-, fibromodulin- and lumican-deficient
mice show abnormal fiber morphology, altered fiber size distributions and atypically non-uniform
interfibrillar space in tendon (Ezura et al. 2000)(G. Zhang et al. 2006). However, the roles of large
CSPGs, the other matrix PG subfamily, in regulating collagen fibrillogenesis and fibrous network
organization are still unclear. The large hyalectan PG family includes versican (which contains a
360 kDa core protein with up to 23 CS side chains for the largest V0 isoform), aggrecan (which
contains a 250 kDa core protein with over 100 GAG side chains, including both CS and KS) and
others that are defined based on their ability to bind HA (Dours-Zimmermann and Zimmermann
1994)(Kiani et al. 2002). Compared with SLRPs, these large PGs have a significantly longer core
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protein with a larger mass of negatively charged GAGs. The molecular weight of full-length large
CSPGs can reach up to 1-2.5 MDa and when bound to long HA chains they can form larger
space-filling bottlebrush-like aggregates. Their GAG side chains have been shown previously to
have distinct impacts on collagen fibrillogenesis (Stuart and Panitch 2008), and small
compositional changes in GAGs, such as addition of different types of hexuronic acids and
altered sulfation levels, can also affect collagen fibrillogenesis. For example, dermatan sulfate
(DS) epimerase 1-null mice have decreased iduronic acid in their GAGs, including on versican,
and demonstrated abnormal collagen fibril formation and irregular collagen structure in skin
(Maccarana et al. 2009). Unlike aggrecan, which is predominantly expressed in cartilage,
versican is more universally distributed throughout the human body and shows increased
deposition and turnover during numerous fibroproliferative process (Theocharis 2008)(BodeLesniewska et al. 1996). Although aggrecan and versican interact with collagen differently, the
effects of large PGs on regulating fibrillogenesis are not well understood. There is a particular
need to clarify the role of versican in regulating collagen fibrillogenesis and the organization of the
collagen fibrous network given its widespread distribution and altered expression in collagenrelated disorders.

In this chapter, distinct effects of different matrix PGs, even within a particular subfamily, on
regulating in vitro collagen gelation (in part representing fibrillogenesis) are investigated using an
in vitro turbidity assay. The impacts of isolated versican, its core protein, GAG side chains and
the small V3 isoform on collagen behaviors in the turbidity assay are studied. The effects of
different matrix PGs on the organization of collagen fibrous networks are visualized and analyzed
by scanning electron microscopy (SEM). Both assays highlight the unique role of versican, even
compared to the large PG aggrecan, in mediating fibrillogenesis and collagen network
organization.
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3.2 METHODS
3.2.1 Reagents
Bovine type I atelo-collagen (lacking N- and C-terminal telopeptide regions) was from Advanced
Biomatrix (San Diego, CA, USA) and rat tail type I telo-collagen (with intact telopeptide regions)
was from Corning (Corning, NY, USA). Versican was isolated from bovine liver. Aggrecan
isolated from bovine cartilage was a gift of Lin Han (Drexel University) (Lee et al. 2013) and was
also purchased from Sigma (A1960) (St. Louis, MO, USA). Decorin (D8428), CS sodium salt
isolated from bovine cartilage and ChABC from Proteus vulgaris were from Sigma. Recombinant
human lumican protein (lacking GAG chains) was from R&D Systems (Minneapolis, MN, USA).

3.2.2 In vitro spectrophotometric (turbidity) assay
Type I bovine atelo-collagen was diluted to a final concentration of 1.5 mg/mL. All solutions were
kept on ice before gelation. Briefly, 187.5 µL collagen solution (3.2 mg/mL) was gently mixed with
40 µL 10× PBS, 4 µL 1N NaOH, and 168.5 µL diH2O. All collagen solutions were kept on ice
before testing. In some cases, type I rat tail telo-collagen was used and prepared similarly. For
testing different wavelengths of spectrophotometry, the absorbances of both atelo- and telocollagen solution were read under 313, 400, 500, 600, 700 and 800 nm. For some experiments,
versican, aggrecan and decorin were added to the collagen solution to a final concentration of 0.1
mg/mL; lumican was added to 0.01 and 0.05 mg/mL (which were used at physiological relevant
collagen:PG ratio according the 1.6:1 Col:GAG ratio in native liver (unpublished data quantified
by L. Chin)). CS were tested by adding to final concentrations of 0.01, 0.04, 0.07 and 0.1 mg/mL.
The versican core protein was obtained by treating the intact protein with 250 mU ChABC (per
mg substrate) in 50 mM sodium acetate (pH=8.0) overnight at 37°C, followed by dialysis with
diH2O. The pH of the collagen solution was carefully adjusted to 7.4 and the solution was always
incubated on ice for 1 h before pipetting into a 96-well plate. The absorbance of the solution was
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read at 37°C by a plate reader (Infinite 200 Pro, Tecan Life Sciences) at 400 nm until gelation
was complete (when the absorbance curve reached the plateau) (Vogel and Trotter 1987).

3.2.3 Scanning electron microscopy
Rat tail type I collagen was diluted to a final concentration of 1.5 mg/ml and supplemented with
different PGs as descried above for the turbidity assay. It was polymerized at 37°C on 8 mm
coverslips in a 6-well plate for 25 min (the plate was covered with wet Kimwipes and sealed with
paraffin). The collagen gels were fixed with 2.5% glutaraldehyde in cacodylate buffer overnight at
4°C. The samples were further processed by the Cell and Developmental Biology Microscopy
Core (University of Pennsylvania, Philadelphia, PA, USA). Briefly, samples were dehydrated with
a graded series of ethanol washes (50, 75, 90, 95, 100%) and incubated with 50%
hexamethyldisilazane (HDMS) for 30 min. Samples were then incubated with 100% HDMS for 3
times and air dried before mounting on stubs. Samples were imaged on a FEI Quanta 250 FEG
scanning electron microscope (Thermo Scientific). Bovine collagen (atelo-collagen) was prepared
and studied in the same manner. 5 figures were taken per each gel at 5 random locations at
10,000×. 5 randomly cropped figures (384×256 pixels) from each SEM figure were analyzed
using DiameterJ, an image J plugin, which was used to quantify fiber diameter and length,
porosity, pore size and connections.

3.2.4 Statistical analysis
All results were analyzed by GraphPad Prism 7 (San Diego, CA, USA) using an unpaired t test or
one-way ANOVA. P values were determined by Tukey’s multiple comparison test, in which
*P<0.05 was considered to be statistically significant.
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3.3 RESULTS
3.3.1 The spectrophotometric (turbidity) assay is a valid in vitro method for
studying collagen gelation (fibrillogenesis)
The in vitro turbidity assay, which tracks the turbidity changes during collagen gelation using a
spectrophotometer, has been used for decades to study the potential regulators of collagen
gelation (partially representing fibrillogenesis) in vitro (Wood and Keech 1960). It generates a
sigmoidal curve with a lag phase (representing nucleation), followed by a growth phase
(representing lateral growth) and finally a final plateau representing complete gelation. During the
growth phase, the formation of large aggregates (fibrils) contributes to the quick increase in
turbidity due to an increased molecular weight and altered light scattering. While this assay does
not directly measure fibrillogenesis, the increments in turbidity partially represent collagen fibril
formation and alterations in collagen organization. This assay has been widely used to test
various fibrillogenesis regulators and most researchers have used two different wavelengths, 313
and 400 nm, in this spectrophotometric assay (Wood and Keech 1960)(Harris, Soliakov, and
Lewis 2013). In this case, I tested the effects of different wavelengths (including 313 and 400 nm)
on the turbidity assay using both telo- and atelo-collagen. All of the different wavelength
measurements resulted in typical sigmoidal kinetic curves representing gelation (Figure 3.1). The
kinetic curves from 313 nm and 400 nm both showed significant changes in absorbance during
gelation compared to other wavelengths. I chose to use the 400 nm wavelength to study the roles
of different matrix PGs in regulating collagen gelation in vitro because 400 nm was used in
previously published work for comparing the effects of small tendon PGs and large cartilage PGs
on fibrillogenesis (Vogel and Trotter 1987).
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Figure 3.1 Results from in vitro turbidity assays carried out at different wavelengths. (A) 1.5
mg/mL telo-collagen, (B) 1.5 mg/mL atelo-collagen. The lines represent mean curves, and the
dotted lines represent SD for the technical replicates. This experiment was performed once with
three technical replicates.

3.3.2 Versican regulates collagen fibrillogenesis differently compared to other
matrix PGs
I tested both rat tail telo-collagen and bovine atelo-collagen gelation and studied the effect of
versican on gelation in both cases. I found that telo- and atelo-collagen showed different kinetic
curves; it took a longer time for atelocollagen to reach full gelation (Figure 3.2A). Telo-collagen is
acid-extracted and includes intact telopeptides while atelo-collagen is pepsin-extracted and lacks
telopeptides. Telopeptides function as docking sites for collagen crosslinking, which guides the
alignment of collagen monomers and promotes lateral growth. Thus the diffusion time of the
monomer addition during fibril formation is impacted for atelocollagen compared to telocollagen
(Shayegan et al. 2016). In both cases, the addition of isolated full-length versican, which consists
mainly of βGAG-attached large V0 and V1 isoforms (shown in Figure 2.2 that there is positive
staining of βGAG in isolated versican sample), accelerated collagen gelation and increased the
final fibril formation plateau regardless of the two different collagens (Figure 3.2A, purple and blue
curves). Because of the rapidity of telo-collagen gelation and the goal of studying different
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modulators of gelation, I used atelo-collagen for all following turbidity experiments; this made it
easier to compare the distinct roles of different matrix PGs in modulating collagen fibrillogenesis.
To compare the effect of large CSPGs, versican and aggrecan, on collagen fibrillogenesis, I
mixed either of the two large PGs with atelo-collagen before initiating the turbidity assay. When
collagen was mixed with versican, the increase in absorbance was more rapid and the gelation
plateau was higher compared with collagen alone (Figure 3.2B, purple and black curves); as a
control, versican alone tested under identical conditions showed no change in absorbance
(Figure 3.2C), suggesting that the dramatic change in the gelation curve with versican added to
collagen was due to the interaction between the two proteins. Interestingly, the addition of
aggrecan, which is structurally similar to versican, slowed the rate of fibrillogenesis without
changing the gelation plateau (Figure 3.2B, blue curve). Because my isolated bovine versican
was contaminated with decorin, which has been reported to be an inhibitor of collagen
fibrillogenesis in vitro (Reese, Underwood, and Weiss 2013), I also tested the effect of decorin
(intact structure with GAGs, from bovine articular cartilage) and lumican (recombinant core
protein only, without GAGs) on collagen gelation, as controls. I found that the addition of either
decorin or lumican led to a decreased rate of collagen fibrillogenesis. Decorin had particularly
marked effects on both the rate and plateau (Figure 3.2D, green curve) while lumican
downregulated collagen gelation in a dose-dependent manner (Figure 3.2D). Thus, the presence
of decorin in my isolated native versican is unlikely to account for the effects observed in the
turbidity assay given that decorin alone had the opposite effect as the isolated versican and the
recombinant V3 isoform of versican core protein (Figure 3.3C) has similar effects as the form I
isolated.
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Figure 3.2 Different matrix proteoglycans have distinct effects on collagen gelation in the in vitro
turbidity assay. (A) Versican (Ver; 0.1mg/mL) was added to rat tail telo-collagen (Col; 1.5 mg/mL)
and bovine atelocollagen (1.5 mg/mL). (B) Versican (Ver; purple curve) or aggrecan (Agg; blue
curve), both at 0.1 mg/mL, were added to atelocollagen (Col; 1.5mg/mL, black curve). Versican
accelerated gelation dramatically while aggrecan slightly right-shifted the turbidity curve. (C)
Versican alone (0.1 mg/mL) failed to gel and showed no change in turbidity over time under the
assay conditions. (D) The SLRPs lumican (Lum; 0.01, 0.05 and 0.1 mg/mL) and decorin (Dec, 0.1
mg/mL) were added to atelocollagen (Col; 1.5 mg/mL). Decorin had a larger impact on
decreasing fibrillogenesis than lumican. For all turbidity assays under all testing conditions, the
pH and gelation temperature were the same. For all panels except C, three independent
experiments were carried out for each condition, each with three technical replicates. Because
there can be day-to-day differences in the absolute absorbance values for the assay, a
representative figure from one experiment with mean curves is shown for each condition;
however, all assays in a panel were carried out in parallel, and relative values among the different
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conditions were consistent in each individual experiment. C was performed once with three
technical replicates. The lines represent mean curves, and the dotted lines represent SD.

3.3.3 Versican core protein, with a minor contribution from the CS side chains,
regulates collagen gelation
Because of the specific bottlebrush-like structure (a core protein attached with GAG side chains)
of versican, I tested whether the versican core protein or the GAG side chains were the primary
contributors to the effect of versican on collagen fibrillogenesis. Firstly, I studied the effect of CS,
part of the GAG side chains of both versican and aggrecan, on collagen gelation in vitro. The
addition of CS left-shifted the absorbance curve in a dose-dependent manner but less markedly
than observed for intact versican at a comparable concentration (Figure 3.3A), suggesting that
the interaction between collagen and versican was mainly via the core protein, not the GAG side
chains. This is consistent with the finding reported in Chapter 2, from a solid phase assay, that
versican binds collagen via its G3 domain. Secondly, I studied the role of the versican core
protein in the turbidity assay. To obtain versican core protein, isolated intact versican was
digested with ChABC to detach CS side chains, was dialyzed against diH2O to remove digested
CS, and then added to atelo-collagen for the turbidity assay. I observed that the impact of the
versican core protein on the rate and plateau was slightly less than for the intact versican (Figure
3.3B, purple and pink curves). For experiments regarding enzyme-treated material, I confirmed
that the heat-inactivated enzyme had minimal effects on fibrillogenesis (Figure 3.3B, blue curve).
Additionally, I studied the effect of the recombinant V3 isoform, which only contains the G1 and
G3 domains of versican without GAG modification, on collagen fibrillogenesis for both collagen
types. I observed the same pattern as with intact full length versican, which showed an increase
of both the rate and plateau for both telo- and atelo-collagen (Figure 3.3C, blue and purple
curves). Thus, the versican core protein, with at best a minor contribution from its CS side chains,
modulated collagen fibrillogenesis in vitro.
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Figure 3.3 The versican core protein plays a major role in regulating collagen gelation. (A)
Chondroitin sulfate (CS; 0.01, 0.04, 0.07 and 0.1 mg/mL; green, yellow, orange and red curves)
was added to collagen (Col; 1.5 mg/mL; black curve). (B) After digestion of the versican CS side
chains with ChABC, the remaining versican core protein was added at 0.1 mg/mL (pink curve) to
atelo-collagen (1.5 mg/mL) and caused a similar although slightly blunted right shift to the curves.
Heat-inactivated ChABC had minimal effect on collagen gelation (blue curve). (C) Recombinant
V3 isoform (V3, 0.1 mg/mL) was added to rat rail telo-collagen (1.5 mg/mL) and bovine atelocollagen (1.5 mg/mL). Three independent experiments were carried out for each condition, each
with three technical replicates. Because there can be day-to-day differences in the absolute
absorbance values for the assay, a representative figure from one experiment with mean curves
is shown for each condition; however, all assays in a panel were carried out in parallel, and
relative values among the different conditions were consistent in each individual experiment. The
lines represent mean curves, and the dotted lines represent SD.
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3.3.4 Versican alters the organization of collagen fibrous networks differently
than other matrix PGs
To investigate the role of PGs in regulating the organization of collagen fibers, I used SEM to
visualize individual fibers in collagen networks modified with different matrix PGs. Firstly, I
compared the structure of both telo- and atelo-collagen networks (Figure 3.4A, B) and found that
atelo-collagen formed a looser network with thicker fibers, decreased total fiber length and
increased pore size (Figure 3.4C-G). The telo-collagen network had significantly fewer
connections (crosslinks) than the telo-collagen network, consistent with the fact that atelocollagen lacks the telo-peptides that are the most common sites of covalent crosslinking.
Because the gelation time of atelo-collagen was three times longer than of telo-collagen (Figure
3.2A) and concerns that dehydration might occur during the gelation of atelo-collagen, telocollagen was used in the SEM assay to evaluate the effect of PGs on the collagen fibrous
network.
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Figure 3.4 Matrices made from telo- and atelo-collagen show different structural features, as
visualized by SEM. (A, B) Representative SEM imaging of collagen matrices: (A) 1.5 mg/mL telocollagen; (B) 1.5 mg/mL atelo-collagen. (C-G) Fiber diameter (µm), total fiber length (µm),
number of intersections, mean pore size (µm2) and porosity (%) were quantified using the ImageJ
plugin, DiameterJ. Three independent experiments were carried out for each condition and one
gel was generated for each condition in each experiment. 5 SEM images were taken for each gel
at random locations. When analyzing images using DiameterJ, 5 figures were cropped from each
SEM image and a measurement was taken on each cropped figure. Each data point represents a
single measurement. Scale bar = 1 µm. Data represent mean ± SD. ****P<0.0001.

The SEM imaging of collagen matrices manipulated with different matrix PGs showed distinct
fiber and structural features of the collagen networks (Figure 3.5A-D). The addition of versican to
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collagen matrices resulted in a looser network with fewer fiber connections, significantly enlarged
fiber diameter, decreased total fiber length and decreased pore size (Figure 3.5E-I). Importantly,
an increased number of fibers fused into large bundles was also observed when versican was
present in the collagen network (Figure 3.5A, J). Because of the formation of large collagen
bundles, the number of intersections (network connections/crosslinks) in the collagen-versican
network was significantly lower (Figure 3.5G). The addition of aggrecan, another large CS
proteoglycan that is structurally similar to versican, had no significant impact on fiber diameter,
total fiber length or mean pore size but showed a slight decrease in connections (Figure 3.5E-I).
For SLRPs, the addition of decorin to collagen resulted in a denser network, decreased fiber
diameter and pore size, and increased total fiber length (Figure 3.5E-I). However, the addition of
another SLRP, lumican, had a different impact on the structure of the collagen network. It had no
impact on fiber diameter and porosity, but resulted in significantly increased mean pore size and
decreased total fiber length and intersections (Figure 3.5E-I). Importantly, collagen gel samples,
which naturally contained certain amount of water (like a hydrogel), were dehydrated during the
sample fixation and preparation for SEM, causing the network to lose its native hydrated structure.
The volume occupied by PGs and the water attracted by negatively charged GAGs were also
affected during the sample preparation process. The relative collagen fiber morphology, diameter,
and connections as well as the pore area of the fibrous network, however, were likely to persist
and were comparable among different collagen/PG networks.
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Figure 3.5 Matrix PGs have different effects on the structure of collagen networks. (A-D)
Representative SEM images of telo-collagen matrices manipulated with different PGs. Telocollagen (Col; 1.5 mg/mL) with 0.1 mg/mL versican (Ver) (A); 0.1 mg/mL aggrecan (Agg) (B); 0.05
mg/mL lumican (Lum) (C) and 0.1 mg/mlL decorin (Dec) (D). (E-I) Fiber diameter (µm), total fiber
length (µm), number of intersections, mean pore size (µm2) and porosity (%) were quantified
using DiameterJ. (J) Numbers of fibrils in bundles were counted manually for each cropped figure.
Three independent experiments were carried out and one gel was generated for each condition in
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each experiment. 5 SEM images were taken for each gel at random locations. When analyzed
using DiameterJ, 5 sections were cropped from each SEM image and a measurement was taken
on each cropped figure. Each data point represents a single measurement. Scale bar = 1 µm.
Data represent mean ± SD. **P<0.01, ***P<0.001 and ****P<0.0001.

3.4 DISCUSSION
Matrix PGs are important regulators of collagen fibrillogenesis and regulate the organization of
collagen fibrous networks. I report here that different matrix PGs, regardless of their structural
similarity, demonstrate distinct roles in modulating collagen gelation (fibrillogenesis) and alter
fibrous network organization differently in vitro. Versican, a widely distributed hyalectan PG, has
particularly specific effects on collagen behaviors in contrast to other matrix PGs, including the
structurally similar hyalectan aggrecan.

The in vitro spectrophotometric (turbidity) assay has been used since the 1960s for studying the
kinetics of collagen gelation (Wood and Keech 1960). The sigmoidal curves generated by
recording the dynamic turbidity changes during the entire gelation process represent, in part,
information about the kinetics of collagen fibrillogenesis. It can show the early nucleation (the lag
phase) and lateral growth (the rapid growth phase) clearly. The weakness of this assay is that the
absorbance readout only represents the molecular weight of aggregates (fibrils) and the different
light scattering factors of these aggregates (fibrils) (Silver and Birk 1983), which does not provide
details about the number and size of individual fibrils. This assay also only reports the properties
of collagen gelation in vitro and cannot mimic the complex environment in vivo, including cellmediated collagen expression and deposition. Thus, caution needs to be taken with any
application of the conclusions from this assay to in vivo situations. This assay has also been used
to investigate the role of matrix PGs, as important collagen binding proteins, in fibrillogenesis.
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Previously published in vitro turbidity data has shown that decorin, lumican and biglycan (intact
full length proteins as well as their core proteins) inhibit collagen gelation by decreasing the
gelation rate and the fibril formation plateau (Rada, Cornuet, and Hassell 1993)(G. Zhang et al.
2009). Similarly, we observed here the same negative effect of decorin and lumican on collagen
gelation using the turbidity assay, with the alterations in the kinetic curves for collagen/decorin
gelation are more pronounced (much flatter with a lower plateau) than for collagen/lumican. One
explanation for this difference between decorin and lumican is that the decorin core protein has
12 leucine rich repeats (LRRs) while lumican has 10 LRRs (Appunni et al. 2019). In this case, the
similar horseshoe shaped structures of SLRPs turn out to have different geometries, especially
the concave distance between N- and C-terminus. Importantly, the collagen binding sites on
SLRPs are located on LRRs suggesting that different numbers of LRRs may have significant
effects on modulating collagen lateral growth and organization during fibrillogenesis (Kalamajski
and Oldberg 2009). There is also evidence indicating that decorin and lumican interact with
collagen at different sites (Svensson, Närlid, and Oldberg 2000)(Hedbom and Heinegard 1993),
which might lead to differential regulation of collagen fibril formation. Another reasonable
explanation relates to the source of the SLRPs I used. The decorin, which has one GAG (CS or
DS) side chain, was a native intact PG isolated from bovine cartilage, while lumican was the
recombinant core protein, which lacks GAG side chains (there are 4 KS side chains on native
lumican) (Appunni et al. 2019). As different GAGs have distinct effects on fibrillogenesis, the
types, numbers and locations of GAG side chains may dramatically alter the role of SLRPs in
regulating collagen fibrillogenesis.

In contrast to SLRPs, large hyalectan PGs including versican and aggrecan have not been well
studied as regulators of collagen fibrillogenesis. Unlike aggrecan, which is more widely studied as
an abundant structural and functional ECM protein in cartilage, the role of versican in regulating
collagen behaviors has been neglected despite its universal distribution in various human tissues
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and altered expression in collagen-related diseases. As assessed using the in vitro turbidity
assay, versican has a particularly notable ability to upregulate the rate and plateau of collagen
gelation, while aggrecan has a modest negative effect. My finding with aggrecan is consistent
with previously reported in vitro turbidity results that aggrecan does not have a significant
influence on gelation (Vynios et al. 2001). One explanation for the different effects of versican and
aggrecan on regulating collagen gelation is that the binding sites – the versican G3 domain
versus the aggrecan KS domain – interact with collagen differently. Another explanation is the
distinct numbers and types of GAG side chains for versican and aggrecan. A typical intact
aggrecan has over 100 GAG (both CS and KS) side chains and the physical repulsion caused by
these highly negatively-charged GAGs may affect the lateral fibril growth by limiting fibril fusion
and crosslinks between adjacent collagens. Versican, depending on its isoforms, has up to 23
GAG side chains (only CS), suggesting that the physical repulsion caused by its GAGs is
significantly lower. Additionally, CS has been shown to have complicated and controversial
effects on fibrillogenesis: some published literature (Öbrink 1973) has found that CS accelerates
fibrillogenesis while others (Mathews and Decker 1968) have reported the opposite observation.
Importantly, my data illustrate that CS slightly upregulates the rate of gelation in a dosedependent manner, suggesting that minor changes in CS concentration can play its role which
has also been shown previously by using a rheometer to study fibrillogenesis in vitro (Y. Yang et
al. 2011). Other factors including the molecular weight and sulfation level of GAGs can also affect
their regulation of collagen fibrillogenesis.

Given that different matrix PGs show distinct alterations during in vitro collagen gelation, I used
SEM imaging of collagen matrices to compare the contribution of matrix PGs in altering collagen
fibrous network organization. SEM provides detailed visualization into the fibrous network and
helps to generate quantitative data, but a limitation of the technique is that the matrix is in a
dehydrated state that may not represent the actual fiber morphology and pore size. The relative
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structural features, however, are likely to persist. My SEM data indicate that versican and
aggrecan, both large hyalectan PGs, regulate collagen networks differently. The results, showing
that versican leads to the formation of a looser network with larger fiber bundles and smaller
pores compared to a modest effect only for aggrecan on network connections, emphasize the
unique role of versican amongst the PGs tested. Previously published work has shown that the
presence of large cartilage PGs (mainly aggrecan) or small tendon PGs (mainly decorin)
decreases fiber size using the in vitro turbidity assay (Vogel and Trotter 1987). Evidence
addressing the influence of SLRPs on the structure of the collagen fibrous network is
contradictory. Reese et al. have found that the inclusion of decorin into collagen gels (at 1:40
weight ratio) led to a denser network with thinner fibers (Reese, Underwood, and Weiss 2013).
However, Raspanti et al. have reported that the addition of decorin to collagen (at 1:5 weight ratio)
induced the fusion of collagen fibrils, resulting in fibrils with increased diameter (Raspanti et al.
2007). However, my data indicate that the presence of decorin in collagen matrices (1:15 weight
ratio) results with a looser network with thinner fibers. Combining these data, there might be a
dose-dependent regulation by decorin of the collagen network. For lumican, Rada et al. have
shown that its inclusion into the collagen network in vitro decreases fibril diameter, as visualized
by transmission electron microscopy (Rada, Cornuet, and Hassell 1993), and Chakravarti et al.
have found that the size of fibrils in vivo in the corneal stroma is increased in lumican-deficient
mice (Chakravarti et al. 2006). My data indicate that lumican leads to the formation of a loose
network with no influence on fiber size. There are no published SEM data for comparison.

In sum, I observe distinct roles of matrix PGs, even within the same subfamilies, on regulation of
collagen gelation (fibrillogenesis) and in modulating the organization of collagen fibrous networks.
This suggests that the precisely-controlled deposition and the relative amounts of different PGs
expressed in normal and diseased tissues, including in development and collagen-related
disorders such as fibrosis and cancer metastasis, may have important impacts on collagen
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behavior. Temporally and spatially dynamic collagen organization in native ECM is poorly
understood but investigating the expression of different PGs quantitatively and comparing their
distinct roles in fibrillogenesis might improve understanding of collagen fibrous network
maturation and reorganization during development and collagen-related pathology. Given the
evidence that versican has unique regulations in fibrillogenesis and collagen network organization
compared to other matrix PGs, it is particularly important to investigate versican, which is a
universally distributed large PG that is upregulated in disease, as a potential therapeutic target for
collagen-related fibrotic disorders. I speculate that the progression of fibrogenesis could be
potentially controlled and reversed by modulating versican expression, deposition and
degradation so as to mediate collagen fibrillogenesis and organization.
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CHAPTER 4 VERSICAN REGULATES CELL-MEDIATED
COLLAGEN ORGANIZATION, ALIGNMENT AND CONTRACTION
This chapter is adapted from the publication: D. Chen, L.R. Smith, G. Khandekar, P. Patel, C.K.
Yu, K. Zhang, C.S. Chen, L. Han, R.G. Wells, Distinct effects of different matrix proteoglycans on
collagen fibrillogenesis and cell-mediated collagen reorganization, Sci. Rep. 10 (2020) 1–13.
doi:10.1038/s41598-020-76107-0.
Parts of the collagen plug assay data involving versican are adapted from my master thesis,
Effect of versican on collagen fibrous networks and long-range force transmission by contractile
cells (2016).
G. Khandekar contributed to the engineered microtissue assay (focusing on lumican).
J. Llewellyn contributed to the isolation of portal fibroblasts.

4.1 INTRODUCTION
In native ECM, the collagen fibrous network is highly organized and dynamically mediated by not
only ECM proteins, but also various types of cells (especially contractile cells) embedded in the
network. There is a reciprocal interaction between contractile cells and collagen networks in the
ECM. On the one hand, cells can sense structural and mechanical stimuli from the ECM and
convert them into biochemical signals via mechano-transduction through various cell membrane
receptors; these can further modulate cell behaviors such as adhesion, proliferation, migration
and differentiation (Y. Chen et al. 2017). On the other hand, the organization of collagen fibrous
networks can be regulated by forces generated by contractile cells that can stretch and align
collagen fibers via focal adhesions (Abhilash et al. 2014). This cell-ECM reciprocal crosstalk is
crucial for regulating cell function and tissue morphogenesis and is also important in maintaining
normal development and homeostasis. To better understanding the role of versican in regulating
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various collagen behaviors in native ECM, the impact of versican on cell behaviors needs to be
investigated, including the impact of versican on cell-mediated regulations of collagen
fibrillogenesis (deposition), organization and contraction.

Versican, a universally distributed large hyalectan, has an atypical effect on in vitro collagen
fibrillogenesis (shown to upregulate fibrillogenesis, as studied by an in vitro turbidity assay) and
on the organization of collagen network (as visualized by SEM). However, the role of versican in
cell-mediated collagen deposition and organization is still unclear. In native tissues, fibroblasts
are the most common cell type participating in the production of ECM components like collagen
and PGs. Thus, a fibroblast-derived matrix (FDM) assay can be used as an in vitro model to study
the effect of versican on fibroblast-mediated collagen deposition and organization. Abnormal
organization of collagen fibrous networks (such as caused by collagen fiber realignment and
compaction), accumulation of ECM proteins, and activation of fibroblasts into myofibroblasts have
been observed for multiple ECM (collagen)-related disorders. Taken hepatic fibrosis as an
example, the deposition of collagen (type I) increases up to 10-fold (Kershenobich Stalnikowitz
and Weissbrod 2003) and the accumulation of versican is also upregulated about 4 fold (Bukong
et al. 2016). Importantly, one typical tissue pattern observed during advanced hepatic fibrosis is
bridging fibrosis, where highly compacted and aligned collagen regions develop between groups
of activated fibroblasts, likely mediated via long range force transmission (Wang et al. 2015). The
presence of cross-linked collagen networks and collagen fiber re-organization are thought to be
required for this long distance mechanotransduction (Ma et al. 2013). Matrix PGs, as important
collagen binding proteins, could play a key role in this cell-mediated collagen realignment. The
collagen plug assay, in which fibroblast spheroids are seeded on collagen gels, is a reasonable in
vitro model of bridging fibrosis that has been used to study collagen re-organization via long
range force transmission. This is particularly important for understanding the role of versican, as a
unique regulator (among those tested) in fibrillogenesis, in regulating fiber rearrangement and
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condensation during fibrogenesis. Higher level tissue contraction, which is regulated by collagen
organization and cellular contractility, is a crucial function of native tissue during morphogenesis
and wound healing (wound closure) (Desmoulière, Chaponnier, and Gabbiani 2005). Given that
matrix PGs are important collagen regulators, they can modulate tissue contraction via
rearranging collagen fibers. Microfabricated tissue gauges (also known as engineered
microtissues), a recently developed technique to investigate biochemical, mechanical and other
cues that mediate microtissue formation, can be used to compare the effects of different matrix
PGs on microtissue contraction.

In this chapter, I report an investigation into the effects of versican (and other matrix PGs) on
multiple cell-mediated collagen network behaviors. FDMs are used to mimic in vivo collagen
deposition and to study the role of versican and its V3 isoform in cell-mediated collagen synthesis,
deposition and arrangement. Due to the different interactions between PGs and collagen
(Chapter 2, 3), I also compare the distinct effects of various PGs on mediating collagen
realignment via long-range force transmission and on higher level tissue contraction.

4.2 METHODS
4.2.1 Reagents, antibodies, and cells
Rat tail type I collagen (with intact telopeptide regions) was from Corning (Corning, NY, USA).
Versican was isolated from bovine liver. Aggrecan isolated from bovine cartilage was a gift of Lin
Han (Drexel University) (Lee et al. 2013) and also purchased from Sigma (A1960). Decorin
(D8428) was from Sigma (St. Louis, MO, USA) and human recombinant lumican and the versican
V3 isoform protein were from R&D Systems (Minneapolis, MN, USA). Gelatin from porcine skin
and ethanolamine were purchased from Sigma. Glutaraldehyde soludion (50%) was purchased
from Fisher Scientific (Hampton, NH, USA). Dulbecco’s phosphate buffered saline with calcium
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chloride and magnesium chloride (DPBS+ (10×)) and Dulbecco’s phosphate buffered saline
without calcium chloride and magnesium chloride (DBPS- (1×)) were purchased from Life
Technologies (Carlsbad, CA, USA). Vitronectin (recombinant human protein) was purchased from
Fisher Scientific. Sylgard 184 polydimethylsiloxane (PDMS) and its curing agent were from Dow
Corning (Midland, MI, USA). Trichloro silane, isopropanol, pluronic F127 and Medium 199 were
purchased from Sigma; sodium bicarbonate from Corning; and CellPURE™ HEPES from Fisher
Scientific. 40% acrylamide and 2% bisacrylamide stock solutions were purchased from Bio-Rad
(Bio-Rad Laboratories, Hercules, CA, USA). Tetramethylethylene diamine (TEMED), ammonium
persulfate (APS) and 0.2 µm fluorescent beads in solution were from Fisher Scientific. Coverslip
activation reagents were aminopropyltrimethoxysilane (Sigma) and glutaraldehyde (Sigma). PAA
gel surface activation reagents were ethyl(dimethylaminopropyl) carbodiimide (EDC) and Nhydroxysuccinimide (NHS) solution (Fisher Scientific). Collagenase from Clostridium histolyticum
was purchased from Sigma. VECTASHIELD PLUS antifade mounting medium with 4′,6diamidino-2-phenylindole (DAPI) was from Vector Laboratories (Burlingame, CA, USA).

Anti α-smooth muscle actin antibody (A2547) was from Sigma. Anti-fibronectin antibody (ab2413)
was from Abcam. Cy™3 AffiniPure Donkey Anti-Mouse IgG (H+L) (715-165-151) and Cy™3
AffiniPure Donkey Anti-Rabbit IgG (H+L) (711-165-152) were from Jackson ImmunoResearch
(West Grove, PA, USA).

NIH 3T3 fibroblasts (CRL-1658) were obtained from the ATCC (Manassas, VA, USA) and portal
fibroblasts were isolated from rat liver as described (Wen et al. 2012). Both types of fibroblasts
were cultured in DMEM (Dulbecco’s Modification of Eagle’s Medium with 4.5 g/L glucose and Lglutamine without sodium pyruvate (Corning)) with 10% fetal bovine serum (Gemini Bio-Products,
West Sacramento, CA, USA) supplemented with 1% penicillin/streptomycin (Corning) and 0.5%
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fungizone (Life Technologies) at 37°C in a humidified atmosphere with 5% CO2/balance air. For
FDMs, DMEM was supplemented with 10% calf serum (Fisher Scientific) instead of fetal bovine
serum.

4.2.2 Fibroblast-derived matrices
FDMs were generated according to a published protocol (Franco-Barraza et al. 2016). MatTek
glass-bottomed dishes were rinsed with DPBS+ and incubated with 0.2% (w/v) gelatin solution
(diluted in DPBS+ at 37°C and sterilized through a 0.2 µm filter) for 1 h at 37°C. After rinsing with
DPBS+, dishes were incubated with 1% (v/v) glutaraldehyde (diluted in DPBS+ and sterilized
through a 0.2 µm filter) at RT for 30 min. After rinsing with DPBS+ 5 min for 3 times, dishes were
then incubated with 1 M ethanolamine (diluted in diH2O and sterilized through a 0.2 µm filter) at
RT for 30 min. After rinsing 3 times with DPBS+, DMEM culture media with 10% calf serum, 1%
penicillin/streptomycin and 0.5% fungizone was added for checking the pH. After aspirating media,
0.1 mg/mL versican, V3 or vitronectin (as a control) was used to coat glass-bottomed culture
dishes by incubating overnight at 37°C. After aspirating the coating solution, semi-confluent 3T3
fibroblasts were trypsinized and seeded at 2.5×105 cells/mL. After overnight culture, media were
replaced with media containing 100 µg/mL ascorbic acid; this was freshly changed every 48 h. At
the third media refresh, additional versican, V3 or vitronectin was added. After 7 days of culture,
FDMs were rinsed with DPBS-, fixed with 10% formalin and stored at 4°C. Second harmonic
generation (SHG) imaging was used to visualize collagen fibril organization; the orientation of
collagen fibrils was analyzed by ImageJ and its plugin OrientationJ. Each image was adjusted to
its average intensity using Z-stack and two channels (SHG signal and autofluorescence from
fibroblasts) were split using the Stack to Images option. The dominant angle of collagen fibrils
was calculated by using the Orientation Dominant Direction option of OrientationJ and was used
for angle normalization. The distribution of fibril orientation was quantified using the OrientationJ
Distribution option: the σ of pixels in the Gaussian window was set to 3; Gaussian Gradient was
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chosen for the provided options; the Min. Coherency and Energy was set to 0%; and the following
options were selected: Orientation in the Hue section, Coherency in the Saturation section and
Original-image in the Brightness section. After running the analysis, the list of orientations (in
degrees) and the distribution of orientations were normalized to the dominant angle, and the
normalized data was plotted using GraphPad and analyzed using two-way ANOVA.

4.2.3 Immunostaining
FDMs were stained with anti-fibronectin (1:100) and anti α-smooth muscle actin (α-SMA, 1:100)
antibody at 4°C overnight and then stained with Cy3 anti-rabbit secondary antibody (1:600) after
rinsing. FDM samples were mounted with coverslips, imaged with confocal microscopy, and
quantified using ImageJ.

4.2.4 Sirius red staining
Sirius red was used to stain collagen in fixed FDM samples. Briefly, FDMs were rinsed with PBS
for 5 min and incubated with Sirius red for 1 h at RT. After staining, FDMs were rinsed twice with
acidified water (5 mL acetic acid in 1 L water) and were dehydrated 3 times with 100% ethanol.
After dehydration, FDMs were cleared with xylene and mounted with coverslips. The area fraction,
which is the area with Sirius red staining over total area, was analyzed for each image using
ImageJ.

4.2.5 Collagen plug assay
Rat tail type I collagen was diluted to a final concentration of 1.5 mg/mL using 10× PBS, distilled
water and 1 N NaOH (for adjusting pH to 7.4) as described before. Isolated versican, aggrecan or
decorin were added to the collagen solution to a concentration of 0.1 mg/mL; lumican was added
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to 0.01 and 0.05 mg/mL. The pH of the collagen solution was adjusted to 7.4 and incubated on
ice for 1 h before it was pipetted into a microwell dish with a glass-bottomed cutout (14 mm
Microwell, MatTek, Ashland, MA). The dish was sealed with parafilm and kept in an incubator (5%
CO2/balance air) overnight at 37°C. Cells were trypsinized and suspended in DMEM at 25,000
cells/mL (for NIH 3T3 cells) and 200,000 cells/mL (for portal fibroblasts). Fibroblast spheroids
were formed by the hanging droplet method (Kelm et al. 2003). Briefly, 20 µL droplets of
suspension cell solution were placed on the underside of a petri dish lid. To avoid drying, 10 mL
DMEM were added to the dish. After inversion of the lid, the cell droplets were cultured for 5 days
(for NIH 3T3 cells) or 3 days (for portal fibroblasts). Cells proliferated and accumulated at the free
liquid-air interface and formed spheroids. At the time of seeding, 1 mL media was added on top of
each collagen gel. Spheroids were captured by a 20 µL pipette and carefully placed on the gel in
pairs approximately 500 µm apart with about 4 pairs per gel. This distance ensured long-range
force transmission happened between contractile cells and was suitable for SHG imaging in the
same microscope frame. The gel was incubated for 4 h for spheroid attachment and 2 mL DMEM
media were added. After culturing for another 20 h, gels were rinsed with PBS and fixed with 10%
formalin for 10 min, and the samples were sealed with parafilm and stored in PBS at 4°C. To test
the plasticity of collagen realignment in both plain collagen and collagen/versican plugs, plugs
with live 3T3 cells were first imaged with SHG and then treated with sodium azide for 5 min to
induce cell death, and plugs with dead cells were imaged again using SHG. To quantify plasticity,
the intensity and anisotropy visualized after cell death was normalized to the original intensity and
anisotropy in the presence of live cells.

4.2.6 Second harmonic generation imaging
SHG imaging requires a multiphoton microscope and is based on the hyperpolarizabilities of noncentro-symmetric molecular assemblies (Williams, Zipfel, and Webb 2005). Collagen networks
produce second-harmonic generation images with a fibril-like pattern (Suzuki et al. 2012). A Leica
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SP5 spectral imaging confocal/dual-photon microscope (Leica Microsystems, Inc., Mannheim,
Germany) was used to collect SHG signals from spheroid-seeded collagen gels. The coherent
Chameleon Ultra II Ti:Sapphire laser (Coherent Inc., Santa Clara, CA) was tuned to 800 nm in
wavelength, and images were captured on a non-descanned detector configured to wavelengths
smaller than 495 nm. The parameters were set up as following: Trans = 34%, Gain = 85%, Offset
= 47% and Smart Gain at 900 V. The lens (20×, 1.0 NA water immersion lens) was submerged in
PBS during imaging. SHG images of collagen gels were collected at a Z-stack height of 20 μm
(with 28 steps, 0.74 μm of each step) with a resolution of 1024×1024 at 200 Hz. The SHG image
of the background of each gel was captured from an area without nearby spheroids. Image J was
used to analyze the collagen alignment between two spheroids. The SHG images were adjusted
by applying average intensity in the Z-stack. The region of interest was determined by using the
polygon tool and the mean pixel intensity was measured. An ImageJ plug-in, FibrilTool
(Boudaoud et al. 2014), was used to analyze the anisotropy of alignment in the bridged region
between two spheroids and, as background, the anisotropy of matrices distant from spheroids.
The distance between two spheroids was measured with a line tool.

4.2.7 Engineered microtissue assay
Engineered microtissue gauges were fabricated using a published protocol (Ramade et al. 2014).
The mold was a gift from Dr. Chris Chen (Boston University). The molds (stamps) were rinsed
with isopropanol and sonicated for 10 min. After air drying, the molds were coated with plasma
using a plasma etcher. Then the molds were placed in a vacuum chamber and salinized
overnight. PDMS was mixed and stirred with its curing agent at a ratio of 10:1 for 5 min and was
degassed until no bubbles were present. Some PDMS was placed in 35 mm petri dishes to cover
the bottom and cured at 65°C for 30 min. Other PDMS was pipetted on top of the stamps and
degassed again. After degassing, the stamps were inverted and placed in the center of PDMS
covered dishes. The remaining dish areas were filled with PDMS and cured at 65°C overnight.
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Stamps were then removed and the resulting µTUG platforms were rinsed with ethanol and
isopropanol. 1.5 mg/mL collagen solution was prepared as described in Table 4.1. Isolated
versican, aggrecan or decorin was added to reach a final concentration of 0.1 mg/mL while
lumican was used at 0.01 and 0.05 mg/mL. The pH was adjusted to 7.4 and the collagen solution
was incubated on ice. The platforms were sterilized with UV light for 15 min, rinsed with 70%
ethanol following with 0.2% pluronic F127 and then centrifuged at 500×g until there were no
bubbles in the wells. After rinsing the platforms twice with PBS, 1 mL collagen/PG solution was
added to each dish and degassed for 3 min. The platforms were then centrifuged at 700×g for 2
min and stored at 4°C to avoid gelation. NIH 3T3 fibroblasts were harvested from culture plates
and 150,000 cells were mixed gently with 0.5 mL collagen solution, and then added to each
platform. The platforms were centrifuged at 206×g for 2 min and were turned 90 degrees for
centrifugation again. Extra solution was carefully aspirated, and the platforms were placed
inverted into a centrifuge and spun at 37×g for 15-20 s. 1 mL PBS was added to the lid and the
platforms were incubated at 37°C for 20 min until gelation. 1.5 mL culture media was added to
each platform and the platforms were cultured at 37°C for roughly 24 h, until microtissues had
formed. Images were taken using a light microscope (Leica DM IRM) before and after the
removal of microtissues by pipetting and rinsing wells with PBS. Cantilever displacements were
measured and used to determine the contraction of engineered microtissues.

Table 4.1 Components in collagen solutions for engineered microtissue assay
diH2O

1067 µL

M199 (10×)

200 µL

HEPES (250 mM)

80 µL

NaHCO3 (5% w/v)

14 µL

NaOH (1 M)

24 µL
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Collagen (4.88 mg/mL)

615 µL

4.2.8 Traction force microscopy
Traction force microscopy (TFM) was used to study the effect of matrix PGs on cell contractility.
The protocol was modified from previous publications (Yeung et al. 2005)(Chopra et al. 2011).
Quartz slides were salinized in a vacuum chamber overnight and cleaned with kimwipes before
using. Circular coverslips were activated by plasma for 30 s and incubated in 0.5% (v/v) APTES
in diH2O for 30 min on a shaker. After rinsing several times, they were incubated with 0.5% (v/v)
glutaraldehyde in diH2O for 1 h on a shaker and then air dried. 7.9 kPa polyacrylamide gels
(Table 4.2) were made by mixing 40% acrylamide and 2% bisacrylamide with TEMED and 1%
APS. This gel solution was mixed with 0.2 µm fluorescent beads in solution (diluted at 1:1000)
and placed on quartz slides, and then covered with a 25 mm glass coverslip pre-activated with
0.5% aminopropyltrimethoxysilane and 0.5% glutaraldehyde. After polymerization for 30 min in a
moisture environment, quartz slides (facing up) were warmed in the UVO chamber for 2 min. The
gels were submerged in water, then gently taken off from the quartz slides. The gel surface was
activated with EDC/NHS solution (17.5 mg/mL NHS and 10 mg/mL EDC in milliQ water) for 15
min and then coated with collagen (10 µg/mL, mixed with different matrix PGs (0.1mg/mL for
versican and aggrecan, and 0.05mg/mL for lumican) and either cellular or plasma fibronectin
(0.1mg/mL)). Fibroblasts were seeded at 20,000 cells per gel and incubated overnight. Live cell
imaging was applied using EVOS AUTO2 (Thermo Invitrogen) and single cell images were taken
before and after removing cells with 10% sodium dodecyl sulfate. The average traction force was
calculated by measuring the displacement of fluorescent beads (ImageJ plugin available at
https://sites.google.com/site/qingzongtseng/tfm) (Chopra et al. 2018).
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Table 4.2 The protocol for making 7.9 kPa polyacrylamide gel
Stiffness

40%

2%

10×PBS

diH2O

TEMED

1%

Total

(Pa)

acrylamide

bisacrylamide

(µL)

(µL)

(µL)

APS

volume (µL)

(µL)

(µL)

187.5

35

7900

(µL)
100

576.5

1

100

1000

4.2.9 Fibroblast proliferation in contractile collagen gels
To test the effect of matrix PGs on fibroblast proliferation, the same number of NIH 3T3
fibroblasts cultured in engineered microtissues were cultured in contractile collagen gels modified
with different PGs and the cell proliferation under various PG conditions was investigated.
Collagen solutions manipulated with PGs were prepared as previously described in the
engineered microtissue assay. 3T3 fibroblasts were mixed with the gel solution, added to 48 well
plate and incubated at 37°C for 20 min for gelation. Plain collagen gels and collagen/PG co-gels
were gently detached from each well and cultured for 24 h. The contractile gels were then
digested with 10 mg/mL collagenase for 15 min at 37°C and the cell numbers were counted and
compared among all conditions.

4.2.10 Statistical analysis
All results were analyzed by GraphPad Prism 7 (San Diego, CA, USA) using unpaired t test, oneway or two-way ANOVA. P values were determined by Tukey’s multiple comparison test, in which
*P<0.05 was considered to be statistically significant.
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4.3 RESULTS
4.3.1 Versican promotes the deposition of collagen-rich matrix from fibroblasts
I showed in previous chapters that versican binds collagen and regulates fibrillogenesis and fiber
organization in vitro, but it is also important to further investigate the role of versican in cellmediated collagen fibrillogenesis and deposition. I used the FDM assay, an in vitro model that
results in collagen deposition and organization mimicking the composition and structure of native
ECM, to study the effects of versican and the small V3 isoform on fibroblast-mediated ECM
deposition. For coating, 0.1 mg/mL versican or V3 was added to glass-bottomed culture dishes
and incubated overnight at 37°C. Vitronectin was used as a coating control because it had
minimal impact on fibroblasts in comparison to bovine serum albumin. To avoid fibroblast
activation, 3T3 cells were cultured with 10% calf serum and used at passage numbers less than
15. After seeding on the coated dishes, 3T3 fibroblasts were cultured for 7 days to generate
FDMs. Sirius red staining for collagen showed that all FDMs were collagen-rich matrices with
nicely formed fibrous networks (Figure 4.1A-C). There were subtle increases in collagen area
fraction for cells on dishes coated with versican and V3, although there is no significant difference
(Figure 4.1D). While Sirius red highlighted the area fraction with collagen, the images could not
show individual fibrils and the fibrous network organization clearly.
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Figure 4.1 Sirius red staining illustrates collagen-rich matrices in FDMs. Only one representative
FDM of each condition was stained with Sirius red because other samples were used for
immunostaining purpose. (A-C) Representative Sirius red staining of FDMs: (A) vitronectin
coating as a control, (B) versican coating, (C) V3 coating. (D) Area fraction with positive Sirius red
staining was quantified using Image J. One FDM for each coating condition was stained and nine
light microscopy images were taken. Scale bar = 100 µm. Data represent mean ± SD.

To better visualize the collagen fibrous network, SHG imaging was used. SHG detects collagen
fibrils without staining as a result of its non-centro-symmetric organization (Suzuki et al. 2012).
Using the multiphoton microscope, the intense excitation at 900 nm encounters the non-centro-
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symmetric structural protein and induces a secondary harmonic generation signal at half the
original wavelength. In this assay, SHG images showed a good resolution of collagen fibrils and
the SHG signal intensity partially represented collagen content (the correlation between SHG
intensity and collagen density is not linear, but can be used to identify differences between
matrices). As shown in Figure 4.2A-C, fibroblasts cultured on differently-coated coverslips
produced well-formed collagen fibrous networks with locally aligned fibers. Coating with versican
or the V3 isoform significantly increased the SHG signal intensity (Figure 4.2D) suggesting the
formation of collagen-rich matrices. Fibronectin, a cell-associated protein that interacts with
collagen, was also expressed in FDMs, mainly surrounding fibroblasts (Figure 4.2E-G). The
presence of versican and V3 isoform slightly increased fibronectin deposition (Figure 4.2H).

Figure 4.2 Versican and V3 isoform upregulate the formation of collagen rich matrices produced
by fibroblasts. (A-C) Representative SHG imaging of FDMs: (A) vitronectin coating as a control,
(B) versican coating, (C) V3 coating. (D) Quantification of the intensity of SHG signal. The data
from each individual experiment were normalized to its control group (dashed line). (E-G)

80

Representative confocal imaging of fibronectin staining (red - fibronectin, blue - DAPI): (E)
vitronectin coating as a control, (F) versican coating, (G) V3 coating. (H) Quantification of the
intensity of fibronectin staining. The data from each individual experiment were normalized to its
control group (dashed line). Four independent experiments were carried out with two technical
repeats for each coating condition in each experiment. Scale bar = 100 µm. Data represent mean
± SD, *P<0.05 and ****P<0.0001.

To improve the accuracy of the FDM assay, I included additional steps to standardize the
fibroblasts in a quiescent state. One step was to use calf serum instead of fetal bovine serum
when culturing fibroblasts. Another step was to use fibroblasts that were not passaged more than
15 times. To assess the activation state, I stained FDMs with anti-α-smooth muscle actin (α-SMA)
antibody, which is highly expressed in activated fibroblasts (myofibroblasts). As shown in Figure
4.3A-F, α-SMA staining was minimally positive in these fibroblasts and the stretched filament-like
structures were rarely observed. The intensity of α-SMA staining was similar for all conditions
(Figure 4.3G). Additionally, to control for the possibility that the increased SHG signal for the
versican or V3 isoform coating condition (Figure 4.2A-D) might be due to altered cell proliferation,
I also counted the cell number and found that the presence of versican or V3 isoform had no
impact on fibroblast proliferation (Figure 4.3H).
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Figure 4.3 The presence of versican or V3 isoform in addition to collagen had no impact on
fibroblast quiescence or proliferation. (A-F) Representative confocal imaging of α-SMA staining:
(A, B) vitronectin coating as a control, (C, D) versican coating, (E, F) V3 coating. (G)
Quantification of the intensity of α-SMA staining. (H) Quantification of cell number for each
condition, from four independent experiments. One FDM for each condition was stained for αSMA in each experiment. Scale bar = 100 µm. Data represent mean ± SD.

4.3.2 Versican improves fiber alignment in collagenous matrices deposited by
fibroblasts
To analyze the fiber orientation in FDMs, OrientationJ, an ImageJ plugin, was used to analyze
SHG images. Collagen fibers oriented at different angles were labeled with gradient colors
(Figure 4.4A-C). To plot and compare the distribution of fiber orientation (angles), the number of
fibers oriented at a certain angle was normalized to the dominant angle of each SHG image; after
normalization, the dominant angle was set at 0° for all analyzed image. As shown in Figure 4.4D,
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collagen fibers were highly aligned in the versican or V3 addition conditions compared to the
control group (statistical significance was analyzed using two-way ANOVA and is shown in Table
4.3).

Figure 4.4 Versican and V3 promote the deposition of highly aligned collagen fibers in FDMs. (AC) Representative SHG images (the same as in Figure 4.2A-C) analyzed by OrientationJ: (A)
vitronectin coating as a control, (B) versican coating, (C) V3 coating. (D) The distribution of fiber
orientation was quantified by OrientationJ and normalized to the dominant angle of each SHG
image, which was then set to 0°. Four independent experiments were carried out with two
technical repeats for each coating condition in each experiment. Scale bar = 100 µm. Data
represent mean ± SD, *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001.
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Table 4.3 Statistical significance of differences in fibril orientation between conditions. Data from
Figure 4.4D were analyzed using two-way ANOVA.
Data #1

Data #2

Angle range

Significance

Control

Ver

-40° to -30°

**

Control

Ver

-30° to -20°

****

Control

Ver

-20° to -10°

****

Control

Ver

-10° to 0°

****

Control

Ver

0° to 10°

****

Control

Ver

10° to 20°

***

Control

Ver

20° to 30°

***

Control

Ver

30° to 40°

**

Control

V3

-40° to -30°

*

Control

V3

-30° to -20°

*

Control

V3

-20° to -10°

*

Control

V3

20° to 30°

**

Control

V3

30° to 40°

**

Control

V3

40° to 50°

**

Control

V3

50° to 60°

*

Ver

V3

-30° to -20°

*

Ver

V3

-20° to -10°

***

Ver

V3

-10° to 0°

***

Ver

V3

0° to 10°

**
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4.3.3 Versican, unlike other matrix PGs tested, increases collagen compaction
mediated by fibroblast spheroids
To evaluate the effect of matrix PGs as modulators of cell-mediated collagen re-organization and
long-range cell-cell communication, the collagen plug assay (a pseudo-3D model) was used. In
this assay, pairs of fibroblast spheroids were seeded atop collagen gels and collagen
condensation and alignment between pairs were imaged and analyzed using SHG imaging. For
quantitative analysis, I calculated the SHG intensity and anisotropy using ImageJ and its plugin
FibrilTool. Anisotropy (normally a number from 0 to 0.2) reflects the alignment of fibrils: a higher
anisotropy number indicates an increase in parallel aligned fibrils, while 0 means randomly
distributed fibrils.

To compare the large hyalectan PGs, I mixed isolated versican or aggrecan with collagen and
allowed gelation to occur, then placed 3T3 fibroblast-generated spheroids atop gels and imaged
the collagen fibers after 24 h of culture, a sufficient time to enable cell-mediated collagen
rearrangements to occur. The collagen fibrils visualized by SHG in the controls were highly
compacted and aligned in the regions between pairs of spheroids (Figure 4.5A-C). The addition of
versican increased cell-mediated collagen condensation while aggrecan had no significant effect
on collagen compaction (Figure 4.5A-D). This was constant with the data shown in the in vitro
turbidity assay suggesting that versican and aggrecan had distinct effects on collagen
fibrillogenesis. Interestingly, cell-mediated compaction of collagen in the collagen-versican
mixture was highly sensitive to pH at values ranging from 7.20 to 7.40 (Figure 4.5G). Cellmediated compaction in a plain collagen plug, however, was not sensitive to pH in a similar range
(Figure 4.5F). There was no significant difference in anisotropy between any of the conditions,
indicating that fibers in all conditions were equally parallel in the aligned area (Figure 4.5E).

85

Figure 4.5 Large PGs have differential effects on cell-mediated collagen reorganization. (A-C)
Representative SHG images of aligned collagen fibrils between pairs of NIH 3T3 spheroids. Blue
represents the SHG signal from collagen; green is cell autofluorescence. (A) Plain collagen (Col;
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1.5 mg/mL), (B) collagen-versican (Ver; 0.1 mg/mL) and (C) collagen-aggrecan (Agg; 0.1 mg/mL)
plugs. (D & E) Quantification of intensity and anisotropy in the aligned collagen area for A-C. (F,
G) Collagen compaction in plain collagen plugs (F) was not pH sensitive, but the impact of
versican on collagen compaction was highly pH-dependent (G). Each data point in D-G
represents collagen compaction between one pair of spheroids. At least 3 independent
experiments were carried out for each condition, with at least 3 pairs of plugs examined for each
experiment. For the pH testing in F and G, 4-12 pairs of spheroids were analyzed for each pH
condition. Spheroids were seeded approximately 500 µm apart. Scale bars = 100 µm. Data
represent mean ± SD. *P<0.05, **P<0.01, ***P˂0.001 and ****P<0.0001.

I also used portal fibroblast-containing spheroids to assess the impact of SLRPs including decorin
and lumican on cell-mediated collagen remodeling. These two SLRPs were shown to be negative
regulators of collagen fibrillogenesis in the in vitro turbidity assay. Here I observed a consistent
pattern. There was a significant decrease in collagen condensation with the addition of either
SLRP (Figure 4.6A-E), although lumican did not show the dose-dependent effect that I observed
from the in vitro turbidity assay (potentially because intensity was already low using these cells).
Interestingly, the presence of decorin decreased the anisotropy significantly, although anisotropy
was similar under all other conditions (Figure 4.6F).
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Figure 4.6 SLRPs regulate cell-mediated collagen reorganization differently. (A-D)
Representative SHG images of collagen fibrils between portal fibroblast spheroids on (A) plain
collagen (1.5 mg/mL), (B) collagen-decorin (Dec; 0.1 mg/mL) and (C, D) collagen-lumican (Lum,
0.01 or 0.05 mg/mL) plugs. (E, F) Quantification of intensity and anisotropy in the aligned
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collagen area for A-D. Each data point in E and F represents collagen compaction between one
pair of spheroids. At least 3 independent experiments were carried out for each condition, with at
least 3 pairs of plugs in each experiment. Spheroids are seeded approximately 500 µm apart.
Scale bar = 100 µm. Data represent mean ± SD, **P<0.01 and ****P<0.0001.

4.3.4 Versican has no alteration on the plasticity of cell-mediated collagen
reorganization
To address the role of versican in the plasticity of cell-mediated collagen alignment (effectively,
irreversible collagen reorganization), I used the collagen plug assay and imaged aligned areas
using SHG before and after cell death. I compared the SHG signal intensity of plain collagen and
collagen/versican co-gels. The normalized intensity and anisotropy (such that data after cell death
were normalized to data before death) were approximately 1, which indicated that the intensity
and anisotropy did not change after removing the contractile forces generated by fibroblasts
(Figure 4.7A, B). It supported the conclusion that cell-mediated collagen alignment was a plastic
(permanent) deformation. The addition of versican did not alter the plasticity of collagen
reorganization.
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Figure 4.7 Cell-mediated collagen re-organization is plastic in both plain collagen and collagenversican plugs. The intensity (A) and anisotropy (B) were quantified by ImageJ and FibrilTool.
Data generated after cell death were normalized to data generated when cells were alive. Three
independent experiments were carried out for each condition with 26 technical repeats for Col
and 11 technical repeats for Col-Ver 0.1 in total. Data represent mean ± SD.

4.3.5 Matrix PGs have no impact on fibroblast contractility
As part of long-range force transmission, cells can generate forces that rearrange collage fibers.
This is mediated by cell contractility. To rule out changes in cell contractility on different
collagen/PG matrices as an explanation for the observed differences in collagen compaction,
traction force microscopy (TFM) was used to measure 2D contractility directly. Polyacrylamide
gels embedded with fluorescent beads were coated with collagen/matrix PG mixtures and 3T3
fibroblasts were cultured overnight; these contracted the gel, leading to bead displacement. The
calculated average traction from bead displacement reflected the contractility. I also coated PAA
gels with two types of fibronectins, cellular and plasma fibronectin, as positive controls. As shown
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in Figure 4.8, both types of fibronectin increased fibroblast contractility (and cellular fibronectin
showed a significant increase on contractility compared to plasma fibronectin). I also found that
matrix PGs, regardless of the different subfamilies, had no effect on fibroblast contractility in 2D
(Figure 4.8). This suggested that the role of PGs in regulating cell-mediated collagen organization
is mainly due to interactions with collagen and alteration on the structure of the fibrous network.

Figure 4.8 Matrix PGs have no impact on fibroblast contractility. 7.9 kPa polyacrylamide gels
were coated with 0.1 mg/mL collagen (Col) mixed with plasma fibronectin (pFn), cellular
fibronectin (cFn), versican (Ver), aggrecan (Agg) or lumican (Lum) at 0.1 mg/mL. The inclusion of
PGs did not alter cellular contractility. In contrast, there was a significant increase with both
variants of fibronectin, which were included for comparison. Three independent experiments were
carried out for Col-Agg and four independent experiments were carried out for all other conditions.
Each point represents a single cell and N=72 for Col, N=93 for Col-pFn, N=111 for Col-cFn, N=62
for Col-Ver, N=52 for Col-Agg and N=44 for Col-Lum. Data represent mean ± SD. **P<0.01 and
****P<0.0001.
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4.3.6 Versican, unlike other matrix PGs, increases fibroblast contractility in
engineered microtissues
At a higher level, tissue contraction can occur as a result of cell-mediated reorganization of the
collagen fibrous network. The TFM assay only evaluated the cellular level contractility in 2D while
here I used engineered microtissue gauges, which enable study of both ECM (collagenous
matrices) contraction and cell contractility, to determine the role of versican and other matrix PGs
in higher level 3D tissue contraction. Engineered microtissues were generated by gelling
collagen/fibroblast mixtures in PDMS microwells with pairs of PDMS cantilevers; cell contractility
and ECM re-organization resulted in the displacement of the cantilevers. Representative light
microscopic images of microtissues (plain collagen with 3T3 fibroblasts) showed the
displacement of the cantilevers in the presence and absence of microtissues (Figure 4.9A, B).
SHG imaging showed that the collagen fibrils in engineered microtissues were well organized and
highly aligned (Figure 4.9C). Quantification of the cantilever displacement from a large number of
engineered microtissues with and without PG addition showed that the addition of versican
significantly increased microtissue contraction while the addition of aggrecan had no effect
(Figure 4.9D, E). For the SLRPs, the addition of decorin (0.1 mg/mL) decreased the contraction
compared to plain collagen (Figure 4.9E), while the presence of lumican showed a dosedependent effect: 0.05 mg/mL lumican addition led to a decrease in the contraction while the
addition of lumican at a lower concentration (0.01 mg/mL) had no effect (Figure 4.9E). Because
tissue contraction is correlated with the number of cells embedded and cell contractility, I
quantified fibroblast proliferation in contractile collagen gels to rule out the effects of PGs on cell
proliferation. I counted the cell number in contractile collagen gels manipulated with different PGs
after 24 h of culture. The addition of different PGs did not alter fibroblast proliferation in contractile
collagen gels (Figure 4.9F). In addition, it was shown previously that matrix PGs had no impact
on fibroblast contractility in 2D as assessed by TFM (Figure 4.8). Thus, the distinct regulations of
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matrix PGs on microtissue contraction appeared mainly due to their different interactions with
collagen and diverse effects on collagen network organization.

Figure 4.9 Matrix PGs have different effects on the contraction of engineered collagenous
microtissues. (A, B) Representative light microscopic images of PDMS cantilever displacement in
engineered microtissues. (C) SHG imaging of a representative engineered microtissue formed by
NIH 3T3 fibroblasts cultured in plain collagen. (D) Quantification of increased displacement
observed with inclusion of 0.1 mg/mL versican (Ver) in 1.5 mg/mL collagen (Col) microtissue. (E)
Quantification of the displacement observed in collagen microtissues with or without aggrecan
(Agg; 0.1 mg/mL), decorin (Dec; 0.1 mg/mL), or lumican (Lum; 0.01 mg/mL or 0.05 mg/mL). N>30
microtissues per each platform, at least three independent experiments (platforms) per condition.
Points represent mean per platform. Scale bar = 200 µm. Data represent mean ± SD. *P<0.05
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and **P<0.01. (F) The number of fibroblasts counted in contractile collagen gels manipulated with
PGs after 24 h of culture. Three independent experiments were carried out for each condition and
three technical repeats for each experiment. Data represent mean ± SD.

4.4 DISCUSSION
Versican and other matrix PGs, as collagen-binding proteins and key regulators of collagen
fibrillogenesis and organization, have distinct impacts on modulating cell-related collagen
behaviors. The combination of FDM, collagen plugs and engineered microtissue assays
illustrates the importance of matrix PGs in mediating multiple cell-mediated collagen behaviors. It
also highlights again the unusual role of versican amongst the PGs in modulating cell-mediated
collagen behaviors, particularly in contrast to similar large PG aggrecan. SLRPs, another matrix
PG subfamily as discussed in previous chapters, consistently show effects on cell-mediated
collagen behaviors that are in contrast to versican.

I showed in Chapter 3 that versican upregulates collagen gelation (fibrillogenesis) and promotes
the formation of a looser network with thicker fibers. It is thus key to assess the potential effect of
versican on collagen deposition in native ECM where cells dynamically synthesize and organize
collagen fibers. By analyzing the SHG images of FDMs, the presence of versican or V3 isoform
has been found to upregulate the production of collagen-rich matrices and improve fiber
alignment locally, which is consistent with the turbidity data showing that versican increases the
rate and plateau of in vitro collagen fibrillogenesis. Additionally, these observations further
support the previously described IEM data showing that versican could play a key role in
mediating fibrillogenesis in vivo. Because of the formation of collagen-rich matrices with aligned
fibers, versican accumulation and versican/collagen interactions can play important roles in
fibrotic disorders (Taufalele et al. 2019). For example, versican expression and its cleavage via
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ADAMTS are upregulated during liver fibrosis and downregulated during recovery (Bukong et al.
2016). Additionally, aligned collagen fibers can direct the invasion of carcinoma cells (Ray et al.
2018)(Han et al. 2016), which indicates that a potential mechanism of metastasis is upregulated
by versican (due to the reorganization and alignment of collagen networks I observed). The
validity of my findings regarding the role of versican in FDM deposition, however, would be
improved by using versican-knockout fibroblasts in future experiments.

Cell-ECM reciprocal crosstalk, particularly cell-mediated collagen reorganization and long-range
cell-cell mechanosensing, has been investigated here using the collagen plug assay. This assay
is of particular interest because it may serve as a model of in vivo pathology such as bridging
fibrosis, which is typical of advanced hepatic fibrosis (Herrera, Henke, and Bitterman 2018).
Versican, but not the structurally similar large hyalectan PG aggrecan, increases collagen
compaction in the fibroblast-generated bridging area. Interestingly, the pH-dependent effects
observed for collagen/versican plugs suggest that the highly negatively-charged GAGs and
charged residues on versican/collagen binding sites may play a significant role in reorganizing the
collagen network. In this case, although versican and the V3 isoform (which lacks the GAG
binding domain) interact with collagen similarly. They may regulate the organization of fibrous
network differently due to the physical repulsion caused by negative charges. For SLRPs, decorin
and lumican both decrease collagen condensation in the aligned area which aligns well with
previously described results from the turbidity assay that SLRPs are negative regulators of
fibrillogenesis. Importantly, the TFM data indicating that matrix PGs do not affect fibroblast
contractility strongly support that the different observations from the collagen compaction and
alignment mediated by fibroblast spheroids are mainly caused by distinct collagen/PG
interactions and various structural alterations in the collagen/PG network. The horseshoe-like 3D
structure of decorin can occupy the space around collagen monomers to limit parallel fibril
assembly via interacting with collagen α1 chain on its concave surface (Orgel et al. 2009), which
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is a potential explanation for our observation that the addition of decorin blunted the increase in
anisotropy of collagen fibers in response to cell contractility in the plug assay. Decorin, as a
structural spacer, would make it harder for contractile forces to stretch fibers closer and align
them in a linear fashion. Lumican, however, which shares a similar horseshoe-like structure, has
no impact on anisotropy. One potential explanation for these differences is that lumican and
decorin bind collagen at different LRRs. Additionally, the geometry of their concave structures
may be distinct due to the number of LRRs (decorin has 12 while lumican only has 10). They also
have different types and numbers of GAG side chains that may affect their interactions with
collagen: decorin has 1 CS or DS close to the N-terminus; native lumican has 4 KS on LRRs
(Appunni et al. 2019), while the recombinant lumican core protein that was used here was not
GAG modified. In addition, this work indicated that collagen compaction and realignment
generated by contractile cells cause plastic deformation (permanent reorganization).

An engineered microtissue assay was used here to evaluate tissue contraction in 3D. This
technique has been widely used for screening drugs (West et al. 2013), for studying magnetic
force derived cell responses (Zhao et al. 2013) and for investigating mechanical and cellular
force-induced reorganization of collagen and fibronectin networks (van Spreeuwel et al. 2014).
This technique has advantages compared to traditional collagen gel contraction assays: (1)
quantification of tissue contraction by measuring cantilever displacement is straightforward and
accurate; (2) collagen fibers become highly aligned between cantilevers, which can mimic
fibrogenesis (as observed during fibrosis and metastasis); (3) it provides a large quantity of data
with a small amount of sample used. This latter was particularly important for my project as I only
have limited amounts of isolated full-length versican and the recombinant V3 isoform. By using
engineered microtissues, different matrix PGs showed distinct effects on tissue contraction.
Decorin has been reported previously as an inhibitor of collagen gel contraction when mixed with
collagen gel or added to culture media (Bittner et al. 1996)(Z. Zhang et al. 2009), which is

96

consistent with my findings in engineered microtissues. In contrast to decorin, lumican as
reported in the published literature, at a very low concentration (approximately 0.4 ng/mL),
increases fibroblast-mediated collagen gel contraction (Liu et al. 2013). In contrast, I have found
that 10 ng/mL (consistent with the lumican concentration in native tissues (Svensson, Närlid, and
Oldberg 2000)) has no effect on contraction, while the inclusion of lumican at 50 ng/mL
decreases microtissue contraction. Understanding the potentially dose-dependent effect of
lumican on multiple collagen behaviors will require further investigation. Importantly, versican
shows an unusual impact on collagen behaviors such that the addition of versican into
engineered microtissues increases contraction, which is consistent with data in a previous
publication indicating that versican upregulates fibroblast-mediated collagen gel contraction (J.
Carthy et al. 2008). However, aggrecan has no effect on microtissue contraction. As matrix PGs
have no effects on either cell contractility in 2D or cell proliferation culturing within contractile
collagen gels, I conclude that the distinct effects of PGs on altering tissue contraction are mainly
due to their different roles in binding collagen and regulating the organization of the collagen
fibrous network. Assessment of the impacts of PGs on cell contractility in 3D needs to be carried
out as a future experiment.

In sum, different matrix PGs, even within the same subfamilies, show distinct roles in regulating
multiple cell-mediated collagen behaviors. The observations from all three assays further support
that versican is a unique collagen regulator among the PGs tested. This suggests that the
precisely controlled expression of PGs during normal and collagen-related disease states may
have a significant influence on collagen network organization and on cell-ECM crosstalk. In liver
fibrosis for example, both versican and lumican are upregulated during fibrogenesis (Bukong et al.
2016)(Krishnan et al. 2012), but I report here that they have opposite effects on modulating cellmediated collagen condensation. Other work has also indicated that lumican and aggrecan have
distinct but time-dependent expression patterns during liver fibrosis (Krull and Gressner 1992).
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Thus, investigating the time-dependent deposition of different PGs quantitatively would be a way
to start testing my hypothesis that specific PGs are potential therapeutic targets; it may be
possible to control long range force transmission, cell-mediated collagen reorganization and
tissue contraction by altering the expression of specific PGs.
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CHAPTER 5 VERSICAN REGULATES THE MECHANICS OF
COLLAGEN IN THE ECM
Y. Du helped with the liver perfusion.

5.1 INTRODUCTION
The mechanics as well as the structure of collagen fibrous networks are highly regulated, and this
is necessary for maintaining normal cell and tissue functions. The mechanical properties of
collagen networks are regulated by various factors including fiber sizes, fiber
orientation/organization, number and types of crosslinks, the presence of collagen-binding
proteins and others. Although there is a correlation between the structure and the mechanics of
collagen networks, the relationship is neither fully understood nor defined. It has been reported
that in vitro collagen gelation under different temperatures changes fiber diameters and pore
sizes, leading to altered shear moduli (G) and strain stiffening behaviors: gelation at 26°C, for
example, causes an increased fiber diameter and an increased G’ (Jansen et al. 2018). In
addition to temperature, pH also alters the structure and mechanics of collagen networks. The
structural observations that collagen networks gelled at pH=6.9-8.0 form larger fibers (Y. Li et al.
2009) correlate well with the mechanical findings that collagen gels formed at pH=8 show
increased G’ (Diamantides et al. 2017). Increasing fibrous network crosslinks via chemical and
photo crosslinker additions during collagen gelation significantly increases the stiffness
(Diamantides et al. 2017)(Tian, Liu, and Li 2016). Given the compositional complexity of the ECM,
other ECM components, especially collagen binding partners, are likely to be important regulators
of the mechanics of collagen networks. GAGs are negatively charged polysaccharide chains
formed by disaccharide repeats which can interact with collagen and regulate collagen structure
and mechanics. The addition of HA into a collagen network decreases fiber diameter and pore
size resulting in an increased G’ (Y. Yang and Kaufman 2009). The addition of CS increases pore
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size and fiber diameter by promoting lateral fibril fusion, and the G’ of collagen/CS networks are
upregulated in a CS dose-dependent manner (Y. Yang et al. 2011). The importance of GAGs in
collagen network mechanics suggests that PGs, as core proteins for GAG attachment, may also
play a role in regulating the mechanics of in vitro collagen gels.

As the most fundamental structural protein, collagen is a key element in predicting and modeling
the mechanics of collagenous tissues. As the mechanics of in vitro collagen gels are highly
regulated by the fibrous network organization, tissue mechanics in vivo can also be modulated by
collagen/ECM fiber organization. In a number of pathological states, alterations in tissue
mechanics have been observed along with the accumulation of ECM proteins including collagen
and matrix PGs. Alterations in collagen arrangement may enhance the progression of these
disorders including fibrosis and cancer (Piersma, Hayward, and Weaver 2020). Meanwhile, a
significant increase in stiffness has been found preceding increased collagen deposition
(Georges et al. 2007) suggesting that potential early alterations such as collagen crosslinking and
fiber reorganization/realignment may play a role in initiating tissue stiffening and thereby
fibrogenesis. In this case, matrix PGs, as important modulators of collagen fibrous networks, are
candidate regulators of tissue mechanics. Aggrecan, which is primarily expressed in articular
cartilage, modulates cartilage mechanics via the osmotic pressure derived from its fixed
negatively-charged GAGs and via the bulk mass of large HA-aggrecan aggregates (Lu et al.
2004). The nano-mechanics of aggrecan, which are mainly represented by solid-fluid interactions
and electrostatic interactions between GAGs, have been used as primary cues for predicting the
macro-mechanics of cartilaginous tissues (Tavakoli Nia et al. 2015). The loss of aggrecan
expression in cartilage results in ECM stiffening, osteoarthritis, and damage to skeletal growth
(Alberton et al. 2019). Upregulated versican deposition has been found in both liver and
pulmonary fibrosis (Bukong et al. 2016)(Bensadoun et al. 1996), in which there is a 30-fold
increase in stiffness in fibrotic tissues (Wells 2008)(Hinz 2012). Less is known, however, about
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the role of versican in tissue mechanics, in contrast to the structurally-similar large hyalectan PG
aggrecan. Interestingly, externally applied mechanical force can alter the expression of certain
matrix PGs. For example, external mechanical ventilation of the rat lung causes significantly
increased deposition of versican and biglycan, and it also upregulates tissue resistance and
elasticity as measuring by complex impedance using volume oscillation (Al-Jamal and Ludwig
2001). Additionally, asymmetric compressive loading of the intervertebral disc increases the
degradation of aggrecan, upregulates the expression of ADAMTS-4 and induces stiffening
(Walter et al. 2011). Thus, there may be a reciprocal interaction between PG deposition and
mechanics: PGs can regulate tissue mechanics via their distinct functional interactions with
collagen and different effects on the organization of fibrous networks; mechanical changes can
also alter the deposition of different PGs differentially.

In this chapter, I investigate the specific role of versican in regulating the mechanics of
collagenous matrices and tissues. Shear rheology is used to assess the viscoelasticity and nonlinear behaviors of collagen matrices and tissues. The effects of different matrix PGs on in vitro
collagen gel mechanics are compared. To study the functional interaction between collagen and
versican in vivo, liver tissues were perfused with ADAMTS-5 or ChABC and evaluated by shear
rheometry to identify the role of versican in native tissue mechanics, particularly compression
stiffening and plasticity.

5.2 METHODS
5.2.1 Reagents and Antibodies
Type I collagen from calf skin was purchased from MP Biomedicals (Irvine, CA, USA) for
rheometry. Versican was isolated from bovine liver. Recombinant human versican isoform V3 and
recombinant lumican protein (without GAGs) were from R&D Systems (Minneapolis, MN, USA).
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Aggrecan (A1960), decorin (D8428), ChABC from Proteus vulgaris and recombinant human
ADAMTS-5 (cc1034) were purchased from Sigma (St. Louis, MO, USA). Sodium hyaluronate (1.5
MDa) was from Lifecore (Chaska, MN, USA). HBSS (without calcium and magnesium, no phenol)
were from Fisher Scientific (Waltham, MA, USA). Heparin (5000 USP unit/mL) was from Medline
Industries (Westampton, NJ, USA). Tissue-Teck O.C.T. Compound was from Sakura Finetek
(Torrance, CA, USA). VECTASHIELD PLUS antifade mounting medium with DAPI was from
Vector Laboratories (Burlingame, CA, USA). Blyscan GAG assay was purchased from Biocolor
(Carrickfergus, County Antrim, UK).

Anti-versican (β-GAG domain, Ab1033) was from Millipore Sigma (Burlington, MA, USA) and antiversican ab19345 (against the neoepitope generated by ADAMTS-5 cleavage) was from Abcam
(Cambridge, UK). Cy™3 AffiniPure Donkey Anti-Mouse IgG (H+L) (715-165-151) and Cy™3
AffiniPure Donkey Anti-Rabbit IgG (H+L) (711-165-152) were from Jackson ImmunoResearch
(West Grove, PA, USA).

5.2.2 Collagen gel rheology
Type I collagen from MP Biomedicals was reconstituted at 5 mg/mL in 0.02 N acetic acid and
stored at 4°C, then diluted to a final concentration of 2.5 mg/mL in 1x PBS at pH=7.4. Briefly,
1000 µL collagen solution (5 mg/mL) was gently mixed with 200 µL 10× PBS, 20 µL 1 N NaOH,
and 780 µL diH2O. All collagen solutions were kept on ice before rheology measurements. For
some experiments, versican, the V3 isoform, aggrecan, or decorin was added to the collagen
solution to a final concentration of 0.167 mg/mL (Col:PG weight ratio = 15:1, a physiological ratio).
For other experiments, HA (1.5 MDa) was added to the collagen solution to a final concentration
of 0.1 mg/mL, or HA and V3 were added to the collagen solution together to a final concentration
of 0.1 mg/mL (for HA) and 0.167 mg/mL (for V3). A shear rheometer (Kinexus, Malvern) with
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rSpace software was used to evaluate the rheological (mechanical) properties. The temperature
was set to 37°C for polymerization and a 20 mm plate was used. 314 µL collagen solution was
added between plates (gap=1 mm). Both shear storage and loss moduli (G’ and G”) were
measured during gelation by applying an oscillatory shear strain of 2% at a frequency of 10
rad/sec (1.592 Hz). When the shear modulus reached equilibrium indicating full gelation, the
freshly formed collagen gel was tested under a strain sweep, during which the shear strain was
increased from 1% to 100% at a frequency of 1 rad/s (0.159 Hz). Some freshly formed gels were
tested for plasticity using creep and recovery measurements: 5 Pa shear stress was applied for
300 s during the creep phase and the gel was recovered for 300 s during a recovery phase. For
measuring G’ under compression, the gap was set to 0.9 mm to reach 10% compression. G’
measured under 10% compression was normalized to the uncompressed G’ for comparing
compression softening behavior. Both the G’ and G” during gelation were plotted against time.
The G’ values after full gelation for each condition were compared using one-way ANOVA in
ImageJ. The shear strain during creep and recovery was plotted against time. For strain sweep,
G’ values were plotted against the shear strain on a logarithmic scale and compared among all
conditions using two-way ANOVA.

5.2.3 Animal Studies
All animal studies followed the Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. The animal protocol (#804031) was approved by the Institutional Animal Care
and Use Committee of the University of Pennsylvania. 300-350 g Sprague-Dawley rats (Charles
River Laboratories, Malvern, PA) were housed in pairs strictly following the specifications of the
protocol.

103

5.2.4 Liver perfusion
Rats were anesthetized with pentobarbital by intraperitoneal injection (1 mL per 500 g). The
abdomen was opened, 5 mL 1000 USP unit/mL heparin was injected, and the portal vein was
catheterized (BD Insyte™ 18GA 1.16IN 1.3×30 mm catheter) and flushed with warm HBSS
(without Ca2+, at 37°C). The inferior vena cava was then transected. To enzymatically digest
versican into versikine, livers were perfused with 5 µg/200 mL ADAMTS-5 for 1h. To digest CS,
livers were perfused with 5 U ChABC for 1h. For control groups, livers were perfused with HBSS
for 1h. After starting the perfusion, the inferior vena cava was pressed with a cotton tipped
applicator to cause tissue swelling and push buffer through the entire liver. After perfusion, livers
were harvested, and the largest lobule was used for rheology testing. Other lobules were fixed in
two different ways. Some samples were fixed with 4% paraformaldehyde overnight and stored in
70% ethanol for processing. The Molecular Pathology and Imaging Core (MPIC) processed these
by paraffin embedding and sectioning. Other samples were frozen in OCT: liver tissues were
embedded with OCT compound in cassettes placed in a liquid nitrogen chamber and stored at 80°C. Frozen tissues were also sectioned by MPIC.

5.2.5 Liver Rheology
Liver tissues were kept in HBSS on ice and rheology studies were performed within 2h of tissue
harvest. A 20 mm punch was used to prepare liver samples and samples were kept hydrated
throughout testing. A shear rheometer (Kinexus, Malvern) with rSpace software was used to
quantify the rheological (mechanical) properties. The plate-tissue adhesive contact point was set
as the normal force reaching 10 g (equals to 0.1 N for a 20 mm plate). The rheological testing
sequence was done in the following order: (1) dynamic time sweep; (2) creep and recovery; (3)
dynamic strain sweep. During the time sweep test, G’, G” and normal force were measured under
2% strain with an oscillation frequency of 1 rad/s (0.159 Hz) for 120s. This measurement was
then taken under increasing uniaxial compression at 10, 15, 20 and 25% (returning to 0% in the
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end) by setting the gap. Young’s modulus was calculated by normal forces and gap changes. G’
and Young’s modulus were plotted against time. To study plastic deformation, shear creep and
recovery was assessed by applying 5 or 15 Pa shear stress for 300s with 300s of recovery. The
shear strain data were plotted against time, and the creep deformation (strain after creep), plastic
deformation (strain after recovery) and plasticity (plastic deformation/creep deformation) were
compared among all conditions. The strain sweep test was set up by increasing strain amplitude
from 1% to 50% (by logarithmic progression) with an oscillation frequency of 10 rad/s (1.59 Hz).
G’ was plotted against increasing shear strain.

5.2.6 Immunostaining
All paraffin-embedded sections were deparaffinized by washing with xylene (3 times, 2 min each),
washing with 100% ethanol (2 times, 2 min each), and then washing with 95%, 95%, 80%, and
70% ethanol and diH2O (1 min each). Slides were incubated with 10 mM citric acid buffer (pH = 6)
using a pressure cooker and rinsed with gently running water. For frozen sections, slides were
warmed to RT, incubated with 10% neutral buffered formalin for 4 min and rinsed with gently
running water for 5 min. Both kinds of sections were blocked with protein blocking agent (Thermo
Scientific Starting Block T20 Blocking Buffer, Fisher #PI-37539) for 1h and rinsed with PBS.
Frozen slides were then incubated with anti-versican β-GAG antibody (ab1033) and paraffin
slides were incubated with anti-versikine antibody (ab19345) (diluted 1:200 in PBT (0.2% Triton
X-100, 0.1% BSA in PBS)) at 4°C overnight. After washing with PBS 3 times (5 min each), all
slides were then incubated with secondary antibody (1:600 in PBT) in dark for 1 h and washed
with PBS. Each slide was mounted with mounting media with DAPI and a coverslip, and then
sealed with nail polish. Stained slides were stored in dark at 4°C up to 2 weeks before confocal
microscopy.
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5.2.7 Sulfated glycosaminoglycan quantification
The Blyscan sulfated GAG assay was used to quantify sulfated GAGs in enzyme-perfused liver
tissue; the protocol was adapted from the general protocol from Biocolor. Briefly, approximately
20 µg frozen liver tissue was digested with 4 M guanidine hydrochloride buffer and homogenized
using a Bullet Blender. The tissue buffer was shaken overnight at 4°C. After centrifugation, 100
µL of the supernatant was mixed with 1 mL Blyscan dye reagent. GAG standards were prepared
to 10, 20, 30, 40 and 50 µg/mL and were mixed with 1 mL dye reagent. After shaking at RT for 30
min, tubes were spun at 12,000 rpm for 10 min. The supernatant was removed, and the pellet
was dissolved with 0.5 mL dissociation reagent. After another centrifugation at 12,000 rpm for 5
min, 150 µL of the supernatant was added to a 96-well plate and the absorbance was read at 656
nm.

5.2.8 Statistical analysis
All results were analyzed by GraphPad Prism 7 (San Diego, CA, USA) using an unpaired t test,
one-way or two-way ANOVA. P values were determined by Tukey’s multiple comparison test, in
which *P<0.05 was considered to be statistically significant.

5.3 RESULTS
5.3.1 Versican accelerates collagen gelation on a rheometer in contrast to other
matrix PGs
In chapter 3, I reported that versican upregulated collagen fibrillogenesis as determined by the in
vitro turbidity assay. Here, I used shear rheology to record the changes in G’ and G” during
collagen gelation at 37°C while on the rheometer. The kinetic curves measured by rheometry
(Figure 5.1A-E) were not the typical sigmoidal shape observed in the turbidity assay. To compare
the gelation quantitatively, I recorded the time when G reached equilibrium and found that the
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addition of versican or the V3 isoform significantly accelerated collagen gelation (Figure 5.1F).
Because the isolated full-length versican is contaminated with small amounts of aggrecan and
decorin (Figure 2.2), I also tested them as controls. The addition of aggrecan and decorin had no
impact on gelation time (Figure 5.1F).
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Figure 5.1 Versican and its V3 isoform accelerate collagen gelation on a shear rheometer. (A-E)
Representative kinetic curves for collagen gelation measured by shear rheometry: (A) collagen
(Col; 2.5 mg/mL) alone, (B) collagen-versican (Ver; 0.167 mg/mL), (C) collagen-V3 isoform (V3;
0.167 mg/mL), (D) collagen-aggrecan (Agg; 0.167 mg/mL) and (E) collagen-decorin (Dec; 0.167
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mg/mL). (F) The gelation time was considered to be the time when G reached equilibrium. N=17
for Col, N=12 for Col-Ver, N=11 for Col-V3, N=15 for Col-Agg and N=11 for Col-Dec. Data
represent mean ± SD. *P<0.05, **P<0.01, ***P˂0.001 and ****P<0.0001.

5.3.2 The effect of versican on the viscoelasticity of collagen gels differs from
other matrix PGs
The mechanics of collagenous matrices can be regulated by structural factors of collagen fibrous
network such as fiber size and crosslinking density (Valero et al. 2018)(Lin and Gu 2015). I
observed by SEM that collagen matrices co-gelled with different matrix PGs had distinct network
organization (Figure 3.5). Here, I used a shear rheometer to study viscoelasticity and non-linear
rheological behaviors of collagen matrices and compared the effects of different PGs. Both G’
and G” were measured during gelation. When G reached equilibrium for each gel condition, G’,
G” and tan δ (which is G”/G’, representing the viscosity to elasticity ratio of collagen gels) were
compared for the different conditions. I found that the addition of versican or the V3 isoform
significantly decreased G’, while aggrecan, which belongs to hyalectan family and is structurally
similar to versican, had no influence on collagen gel stiffness (G’). Decorin, a SLRP, also showed
no impact on G’ (Figure 5.2A). Additionally, the presence of versican decreased G” significantly;
V3 also led to a decreased G” although it was not significantly different from collagen (Figure
5.2B). Aggrecan and decorin had no influence on viscosity (G”) (Figure 5.2B). Interestingly, the
inclusion of the V3 isoform significantly increased tan δ suggesting an increased energy
dissipation potential for Col-V3 co-gels (Figure 5.2C).
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Figure 5.2 Versican and its V3 isoform have distinct effects on the viscoelasticity of collagen gels.
(A) G’, (B) G”, and (C) tan δ (which is G”/G’) of Col (2.5 mg/mL), Col-Ver (Ver; 0.167 mg/mL),
Col-V3 (V3; 0.167 mg/mL), Col-Agg (Agg; 0.167 mg/mL) and Col-Dec (Dec; 0.167 mg/mL). N=17
for Col, N=12 for Col-Ver, N=11 for Col-V3, N=15 for Col-Agg and N=11 for Col-Dec. Data
represent mean ± SD. **P<0.01, ***P˂0.001 and ****P<0.0001.

5.3.3 Versican modulates non-linear rheological behaviors of collagen gels
differently than other matrix PGs
It is known that networks formed by biopolymers (including collagen), which are semiflexible
filaments, show complex non-linear behaviors such as compression softening and strain stiffening
(Van Oosten et al. 2016). To study the compression behavior in collagen gels and co-gels, the
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gap was set to 0.9 mm to reach 10% compression after full gelation. Normalizing G’ at 10%
compression to its G’ at equilibrium and quantification of the softening rate (the slope of Figure
5.3A) were used to compare the compression softening behavior of the different gels. All types of
collagen gels showed compression softening behaviors (Figure 5.3A, B). Only the presence of
aggrecan significantly attenuated compression softening (Figure 5.3B blue). After calculating the
slopes in Figure 5.3A (shown as absolute values in Figure 5.3C), I found that there was no
difference on the rate of G’ decay after compression between any conditions. By applying
increasing shear strain to the gel, I observed that the inclusion of versican eliminated the strain
stiffening behavior (Figure 5.3D red and Table 5.1) and the addition of the V3 isoform led to
markedly blunted strain stiffening behavior (Figure 5.3D orange and Table 5.1). Collagen cogelled with aggrecan or decorin strain stiffened, but slightly less than for the plain collagen gel
(Figure 5.3D purple and blue). The strain at which the plain collagen gel failed was significantly
higher than for collagen co-gelled with V3, aggrecan and decorin (the failure strain is 8% for ColV3, 15.85% for Col-Agg and Col-Dec, but 19.95% for plain collagen). Given that I observed
previously that the plastic re-organization of a collagen network could be generated by cell
contractile force (Figure 4.7), here I used a creep and recovery test to study the plastic
deformation of collagen networks by applying external shear stress. I observed that there was
plasticity (plastic deformation) for all different types of collagen gels and found that there was no
significant difference among these gels (Figure 5.3E).
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Figure 5.3 Matrix PGs show different regulation of non-linear mechanical behaviors of collagen
gels. (A) G’ was measured at equilibrium and under 10% compression. (B) G’ at 10%
compression was normalized to G’ at equilibrium. (C) The slopes of curves in (A) were calculated
and are shown as absolute values. (D) G’ was measured under increasing shear strain from 1%
to 100%. (E) Plasticity was measured by a creep and recovery test. Collagen gels were deformed
at 5 Pa for 5 min and recovered for another 5 min. Col (2.5 mg/mL), Col-Ver (Ver; 0.167 mg/mL),
Col-V3 (V3; 0.167 mg/mL), Col-Agg (Agg; 0.167 mg/mL) and Col-Dec (Dec; 0.167 mg/mL).
Freshly gelled samples were used separately for compression, strain sweep or creep and
recovery testing. For 10% compression testing, N=3 for Col, N=3 for Col-Ver, N=4 for Col-V3,
N=4 for Col-Agg and N=3 for Col-Dec; for strain sweep, N=3 for Col, N=3 for Col-Ver, N=3 for
Col-V3, N=4 for Col-Agg and N=3 for Col-Dec; for creep and recovery, N=5 for Col, N=4 for ColVer, N=3 for Col-V3, N=4 for Col-Agg and N=4 for Col-Dec. Data represent mean ± SD. *P<0.05,
**P<0.01, ***P˂0.001 and ****P<0.0001.
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Table 5.1 Significant differences in G’ of strain sweep testing (Figure 5.3D) when different PGs
were added to collagen gels. Different collagen gel conditions were compared using two-way
ANOVA. *P<0.05, **P<0.01, ***P˂0.001 and ****P<0.0001.
Condition #1

Condition #2

Shear strain (%)

Significance

Col

Col-Ver

7.9433

**

Col

Col-Ver

10

****

Col

Col-Ver

12.5893

****

Col

Col-Ver

15.8489

****

Col

Col-Ver

19.9625

****

Col

Col-Ver

25.1189

****

Col

Col-V3

1

*

Col

Col-V3

10

*

Col

Col-V3

12.5893

****

Col

Col-V3

15.8489

****

Col

Col-V3

19.9625

****

Col

Col-V3

25.1189

****

Col

Col-Agg

15.8489

**

Col

Col-Agg

19.9625

****

Col

Col-Agg

25.1189

****

Col

Col-Dec

19.9625

****

Col

Col-Dec

25.1189

****

Col-Ver

Col-V3

7.9433

*

Col-Ver

Col-Agg

7.9433

*

Col-Ver

Col-Agg

10

****

Col-Ver

Col-Agg

12.5893

****

Col-Ver

Col-Agg

15.8489

****
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Col-Ver

Col-Agg

19.9625

****

Col-Ver

Col-Agg

25.1189

*

Col-Ver

Col-Dec

7.9433

**

Col-Ver

Col-Dec

10

****

Col-Ver

Col-Dec

12.5893

****

Col-Ver

Col-Dec

15.8489

****

Col-V3

Col-Dec

10

**

Col-V3

Col-Dec

12.5893

****

Col-V3

Col-Dec

15.8489

****

Col-V3

Col-Agg

12.5893

****

Col-V3

Col-Agg

15.8489

****

Col-V3

Col-Agg

19.9625

**

Col-Agg

Col-Dec

15.8489

**

5.3.4 Versican and its chondroitin sulfate side chains regulate liver tissue
mechanics
My in vitro data strongly support the conclusion that versican plays an important role in
modulating the mechanics of collagenous tissues. To investigate the effects of versican and its
CS side chains in tissue mechanics, I used a shear rheometer to measure the stiffness (G’) and
non-linear rheological behaviors of liver tissue (as an in vivo model) perfused with ADAMTS-5 (for
versican cleavage at GAG domains) or ChABC (for CS removal). Neither enzymatic perfusion
had any impact on the stiffness (G’) in the un-compressed state but both attenuated the
compression stiffening of G’, resulting in a significant G’ decrease under 25% compression after
CS removal (Figure 5.4A). I also calculated the Young’s modulus from the gap changes and
normal forces, and the results indicated that perfusion with either enzyme significantly
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downregulated the compression stiffening of Young’s modulus, showing with a significant
decreased Young’s modulus at 22.5% compression (Figure 5.4B). In addition to compression
stiffening, native collagenous tissues also undergo another non-linear behavior, strain softening.
As shown in Figure 5.4C, normal liver strain softened, and this was not significantly affected by
perfusion with either ADAMTS-5 or ChABC.

Figure 5.4 Versican and its CS side chains alter compression stiffening of liver tissues. (A)
Compression stiffening behavior was studied by measuring G’ under 10%, 15%, 20% an 25%
compression via changing the gap of the rheometer. (B) Young’s modulus at 5%, 12.5%, 17.5%
and 22.5% compression. (C) G’ measured by strain sweep with an increasing strain from 1% to
50%. N=3 for HBSS, N=4 for ADAMTS-5 and ChABC, the compression and strain sweep
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experiments were done on the same liver sample. Data represent mean ± SD, *P<0.05,
***P<0.001 and ****P<0.0001.

To confirm the cleavage of versican by ADAMTS-5, I immunostained perfused tissue with antiversican βGAG antibody (this versican antibody targets aa. 1360-1439, covering the cleavage
site, and therefore only stains intact versican) and anti-DPEAAE (which recognizes the
neoepitope exposed after cleavage). Liver tissue is highly cellular and ECM proteins, including
collagen and PGs, are mainly located at the portal tract and vessel area. As shown in Figure
5.5A-C, intact versican was found in both HBSS and ChABC perfused samples but not in
ADAMTS-5 perfused samples. Meanwhile, DPEAAE staining was observed in ADAMTS-5
perfused samples (Figure 5.5E); the control group showed no positive staining for this neoepitope
(Figure 5.5D). To test the effectiveness of the enzymatic perfusions, sulfated GAGs from
perfused liver tissues were quantified and showed a significant decrease after both ADAMTS-5
and ChABC perfusions (Figure 5.5F).
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Figure 5.5 The enzymatic perfusions of liver tissues effectively alter versican and GAG content.
(A-C) Representative confocal images of veriscan β-GAG-stained tissue in HBSS-, ADAMTS-5and ChABC-perfused livers (the lumen of the portal tract or vessel was labeled with L). (D, E)
Representative confocal images of neoepitope-DPEAAE-stained tissue in HBSS- and ADAMTS5-perfused livers. (F) Quantification of sulfated GAGs in perfused liver tissues (N=6 for HBSS,
N=8 for ADAMTS-5 and N=7 for ChABC). Data represent mean ± SD, **P<0.01 and ***P<0.001.

5.3.5 HA explains the distinct alterations of versican on the G’ of collagenous
matrices versus tissues
I observed that there was a decrease in G’ for collagen gels manipulated with versican or its V3
isoform (Figure 5.2A), while in native tissue, the cleavage of versican did not lead to statisticallysignificant softening (Figure 5.6A). There is a large amount of HA in native ECM that can interact
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with both collagen and versican to alter the structure and mechanics of collagen fibrous network,
and I hypothesized that HA stiffens collagen network via upregulating swelling. I therefore
investigated the G’ of collagen-HA and collagen-HA-V3 co-gels in vitro. The inclusion of HA into
plain collagen gels increased G’ significantly while the addition of HA into collagen-V3 co-gels
prevented the decrease in G’ observed with the addition of V3 (Figure 5.2A), resulting in gels with
the same G’ as collagen alone (Figure 5.6B). Thus, the stiffening of the collagen network by HA
could balance the softening caused by versican.

Figure 5.6 The presence of HA increases the stiffness of collagenous matrices. (A) G’ measured
under no compression for enzymatically-perfused liver tissues. (B) G’ measured for Col (1.5
mg/mL) gels, Col-HA (1.5 MDa; 0.1 mg/mL) and Col-HA-V3 (HA 1.5 MDa, 0.1 mg/mL and V3,
0.167 mg/mL) co-gels. For G’ measurements of liver tissue, N=3 for HBSS, N=4 each for
ADAMTS-5 and ChABC; for G’ measurements of collagen gels, N=13 for Col, N=12 for Col0.1HA and N=10 for Col-0.1HA-V3. Data represent mean ± SD, *P<0.05.
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5.3.6 Versican and its chondroitin sulfate GAGs participate in the plasticity of liver
tissues
To investigate the plasticity of collagenous tissues, enzymatically-perfused livers were studied by
creep and recovery using a shear rheometer. First, I induced small tissue deformations by
applying 5 Pa shear stress and let it recovery. The creep deformation was the strain measured
after creep, the plastic deformation was the remaining strain measured after recovery and the
plasticity was defined as plastic deformation divided by creep deformation. The cleavage of
versican or the removal of CS residues decreased the plasticity significantly (Figure 5.7A, D).
Versican and CS had no impact on the shear deformation after the 5 Pa creep phase (Figure
5.7B) but both enzymatic perfusions resulted in a significant decrease in the plastic deformation
after the recovery phase (Figure 5.7C). Under these creep conditions, the tissue deformation was
only about 2%. Second, I used a 15 Pa shear stress to assess the role of versican and its GAGs
in plasticity under larger tissue deformations. In this trial, plasticity was also observed in liver
tissues regardless of the nature of the enzymatic perfusion (Figure 5.7E), with the tissue
deformation reaching up to about 18% (Figure 5.7F) and returning to about 7% after recovery
(Figure 5.7G). Under large deformations, neither ADAMTS-5 nor ChABC perfusions had any
impact on the plasticity of liver tissue or on any other part of the creep and recovery process
compared to control groups (Figure 5.7E-H).
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Figure 5.7 Versican and its CS side chains contribute to tissue plasticity at small deformations.
(A-D) A 5 Pa shear stress was applied to ADAMTS-5- and ChABC-perfused livers during a creep
and recovery test: (A) the shear strain curves generated by creep and recovery; (B) the creep
deformation after a 5 min creep phase; (C) the plastic deformation after a 5 min recovery phase;
(D) plasticity as calculated by dividing plastic deformation by creep deformation. (E-H) A 15 Pa
shear stress was applied to ADAMTS-5- and ChABC-perfused livers during creep and recovery:
(E) the shear strain curves generated by creep and recovery; (F) the creep deformation after a 5
min creep phase; (G) the plastic deformation after a 5 min recovery phase; (H) plasticity as
calculated by dividing plastic deformation by creep deformation. For 5 Pa creep testing, N=4 for
HBSS and ADAMTS-5, and N=5 for ChABC; For 15 Pa creep testing, N=3 for HBSS, N=4 each
for ADAMTS-5 and ChABC; experiments with the two different shear stresses for creep were
carried out on different samples. Data represent mean ± SD, *P<0.05 and **P<0.01.

5.4 DISCUSION
The mechanics of collagenous tissues are defined by the organization of collagen fibrous
networks and are essential for maintaining normal cell and tissue functions. Abnormal mechanics
have been observed for almost all collagen-related fibroproliferative diseases. Matrix PGs, which
are key regulators of collagen fibrillogenesis and fibrous network organization, can play important
roles in regulating the mechanics of collagen networks. Understanding the role of versican in
collagen gel and tissue mechanics is particularly important because versican is universally
distributed in various tissues; it has different effects on fibrillogenesis and fiber organization than
other PGs; and its deposition is upregulated in various collagen-related diseases. I report in this
chapter that the additions of versican and V3 to collagen matrices result in decreased stiffness
and attenuate strain stiffening. Versican and its GAGs also contribute to tissue mechanics by
maintaining tissue compression stiffening and participating in tissue plasticity at lower
deformations.
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In addition to the turbidity assay discussed previously in this thesis, rheometry can be used as a
technique for studying collagen gelation in vitro. When a collagen solution is placed between the
plates on the shear rheometer, both G’ and G” can be tracked during collagen gelation
(fibrillogenesis) at 37°C generating both the mechanics and kinetics of fibrillogenesis. This
approach has been used with confocal reflectance microscopy to study the effect of HA on
collagen fibrillogenesis as well as structural and mechanical alterations during gelation (Y. Yang
and Kaufman 2009). I found consistently using both techniques that versican and V3 accelerate
collagen gelation. Additionally, rheology data illustrate that aggrecan and decorin have no
influence on collagen gelation while they both show inhibitive effects using the in vitro turbidity
assay. Potential explanations for this difference are that: (1) rheometery and the turbidity assay
measure different things: the rheometer measures the changes in G while the turbidity assay
measures the changes in light scattering properties of collagen fibrils, neither of which is a direct
measure of fibrillogenesis; (2) the rheometer applies 2% shear strain to the collagen gel while the
effect of shear strain on gelation is unknown. The kinetic curves generated by rheometry only
represent the gain in G during collagen gelation, while there is not a defined correlation between
G and fibrillogenesis including fibril size, quantity and the structure of fibrous network. Thus,
these kinetic curves are not sigmoidal and do not contain the lag and rapid growth phases which
represent the nucleation and lateral growth in the kinetic curves generated by the turbidity assay
(Silver and Birk 1983)(Zhu and Kaufman 2014).

I have previously reported and discussed the differential interactions between collagen and
different PGs, which result in altered fibrillogenesis and fibrous network organization (Figure 3.2
and 3.5). In this chapter, I have also observed that different PGs have distinct effects on collagen
gel mechanics, which further supports the conclusion there is a correlation between collagen
structure and mechanics. Thus, understanding the relationship between matrix PGs and collagen
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mechanics may be important to understanding the mechanisms of fibroproliferative disorders.
Interestingly, in my shear rheometry studies, versican and the V3 isoform are unique among the
PGs tested in their effect on viscoelasticity. SEM data suggest that the presence of versican in a
collagen network can significantly increase fiber size and decrease network connections. It has
been previously published that the G’ of collagen gels is upregulated with increasing crosslinks
(Valero et al. 2018)(Lin and Gu 2015); it is thus not surprising that the G’ of collagen/versican gels
is significantly lower in the context of a loosely connected network with thicker fibers and fewer
connections. In addition, the inclusion of V3 into collagen matrices significantly decreased tan δ
suggesting that V3 increases energy dissipation in the collagen network. Unlike versican,
aggrecan and decorin have no impact on viscoelasticity in the assays reported in this chapter. It
has been published that the inclusion of decorin into collagen gels increases stiffness as
measured by a tensile test (Reese, Underwood, and Weiss 2013), and there are complicated
dose- and location-dependent effects of decorin on the tensile stiffness of tendons (Dourte et al.
2012)(Robinson et al. 2005). The effects of aggrecan on tissue stiffness are controversial: in an in
vitro engineered chondrocyte/collagen scaffold, local increases in stiffness are correlated with
local increases of aggrecan, as shown by a combination of histological staining and confocal
elastography (Middendorf et al. 2020); but an in vivo study yielded the opposite result that the
loss of aggrecan triggers ECM stiffening in cartilage (Alberton et al. 2019). However, there are no
published studies of rheological data of collagen/PGs co-gels that would allow me to compare
and discuss my results directly.

Non-linear rheological behaviors, including strain stiffening, compression softening and plasticity,
are typical mechanical features for semiflexible biopolymer network including collagen fibrous
networks (Van Oosten et al. 2016).The mechanism of these non-linear mechanical behaviors and
the relationship between physical and structural parameters and strain-dependent rheology is not
fully understood and requires further investigation. After applying a strain sweep to collagen gels,
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I observed strain softening (to a small degree) at low strains, strain stiffening at intermediate
strains and failure/collapse (or gel slipping) at higher strains. One explanation for the mechanism
underlying this observation is that strain softening at low strains is triggered by the slippage of
physical crosslinks and strain stiffening at intermediate strains is caused by stretch-induced fiber
alignment and stiffening (Kurniawan, Wong, and Rajagopalan 2012). Compression softening was
also found in all of the collagen and collagen/PG gels. Among them, only the inclusion of
aggrecan significantly attenuated compression softening, likely because it is modified by about
100 negatively charged GAG side chains, which is ten times the number for versican and
hundred times that of decorin. These negative GAG side chains can attract water, increase
swelling and cause resistance to compression as its native physiological function in cartilage
tissues (Roughley and Mort 2014).

Plasticity, which is the permanent deformation and reorganization of the collagen network caused
by cellular contractile forces or externally-applied mechanical forces, is another important
mechanical behavior of collagen networks. Importantly, there is also a reciprocal crosstalk
between the plasticity of collagen fibrous networks and cell behaviors: cell-generated forces
cause irreversible alterations in collagen networks (Ban et al. 2018) and plasticity can modulate
cell functions such as migration (Wisdom et al. 2018). After doing creep and recovery testing, I
found that there was no significant difference in collagen gel plasticity among the different
collagen co-gels, which is constant with my previous observation from the collagen plug assay
(Figure 4.7) that there is no difference in cell-mediated plastic deformation in collagen/versican
co-gels compared to plain collagen. Potential explanations are that: (1) interactions between
collagen and PGs are not significantly altered during stress-induced collagen re-organization and
(2) the effects of newly-formed or damaged collagen/PG interactions on the network organization
are limited, in contrast to the re-arrangement of collagen fibers/bundles in a larger scale.
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To further investigate the role of versican in native tissue mechanics, I used ADAMTS-5 perfusion
in liver tissue to induce the cleavage of versican. CS is predominantly deposited in prenatal liver
tissue and then largely converted into CSPGs in postnatal liver tissue, and it is particularly
versican V1 isoform that is highly expressed in liver (Gressner and Vasel 1985)(Cattaruzza et al.
2002). Thus, versican, especially its V1 isoform, is the major cleavage target for ADAMTS-5 and
ChABC. A well-studied cleavage site is in the βGAG domain (Glu441-Ala442 for the V1 isoform)
(Sandy et al. 2001) and produces two versican fragments, G1-DPEAAE and a G3-containing
fragment. My data support that there are G1-DPEAAE fragments remaining in liver tissue after
perfusion (Figure 5.5E), and I hypothesize that this is G1-binds HA and, because of the size of
HA, is retained. However, there are no antibodies available for staining the cleaved G3 fragment
(βGAG-G3), making it difficult to determine whether or not it remains in the tissue after perfusion.
A published study on aggrecan degradation by ADAMTS-5 strongly supports that HA,
hyaladherins (G1 and link proteins) and the G3 fragment can be released from native tissue
(Durigova et al. 2008)(Chockalingam et al. 2004). However, I have found significant differences in
the behaviors of versican and aggrecan; the binding of collagen to the versican G3 domain
(shown in Chapter 2) may protect the G3 fragment from removal. Given that I observed a
significant loss of tissue GAGs after ADAMTS-5 perfusion, it is likely that a significant part of the
versican GAG domain been cleaved and flushed out. There is also evidence that there are
multiple ADAMTS-5 cleavage sites on versican core protein in addition to the canonical site,
including Glu405-Gln406 on αGAG for V2 (Westling et al. 2004) and other cleavage sites on G1,
βGAG and G3 of V1 (Martin et al. 2021), which makes it possible that small GAG domains are
released from the core protein (and are potentially easily flushed from the tissue during perfusion).
In another trial, I degraded and removed versican CS side chains via ChABC perfusion, which my
control experiments showed also effectively removed GAGs (even better than ADAMTS-5). For
tissue subject to either enzymatic perfusion, there were significant changes in tissue mechanics,
namely the downregulation of compression stiffening behaviors as observed in both G’ and
Young’s modulus values. Unlike collagen network which shows compression softening, the
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opposing compression stiffening behavior observed in native tissue is due to the inclusion of inert
particles such as cells (van Oosten et al. 2019). In ECM, collagen fibers are crosslinked and form
the stress-bearing network and the volume-conserving cells are embedded. Increased fraction of
closely packed cells can suppress the compression derived relaxation of nonlinear biopolymer
network and contribute to tissue stiffening (van Oosten et al. 2019). The attenuation of
compression stiffening observed here is mainly due to the natural physiological functions of highly
negatively charged GAGs in ECM that they can attract water, cause swelling, increase osmotic
pressure and resist compression. This finding aligns well with previously published work done by
our lab indicating that liver perfusions with α-amylase, an enzyme that digests α-linked
polysaccharides including GAGs, also eliminated compression stiffening (Perepelyuk et al. 2016).

Interestingly, the inclusion of versican into collagen gels decreases G’ but the cleavage of
versican has no effect on G’ in the non-compressed state. One potential explanation is that the
compositional, structural, and mechanical features of native tissues are remarkedly different from
collagen matrices. For example, liver tissue is highly cellular, filled with cells which are normally
regarded as incompressible particles. The deposition of ECM proteins, including collagen, HA
and versican, is significantly increased during hepatic fibrosis (Bukong et al. 2016). The presence
of HA, an important binding partner of both collagen and versican, in the ECM can also modulate
the mechanics of collagenous matrices and tissues. For example, the G’ for Col-HA-V3 co-gels is
comparable to that of plain collagen gels while Col-HA co-gels are significantly stiffer (Figure 5.6).
Thus, double perfusions targeting both versican and HA may cause a significant tissue softening.
Another reason is that ADAMTS-mediated versican cleavage cannot remove the entire versican
from ECM as the G1-DPEAAE fragment has been found remaining in perfused tissue and may
still play a specific role in regulating tissue mechanics at least in part since it binds to HA.
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Native ECM, which collagen provides the fundamental structure for, also shows a typical
mechanical plasticity. After applying and removing external shear stress, tissue plasticity is
reflected in the fact that the shear deformation cannot fully recover to its initial state. Although the
mechanism underlying ECM plasticity is not fully understood, published works studying the
plasticity of collagen networks via cell contractile force and shear stress support that the
permanent reorganizations of collagen fibrils via crosslinking, fibrils sliding and fusion into large
bundles are responsible for plasticity (Kim et al. 2017)(Nam et al. 2016). Versican, as a regulator
of collagen fibrillogenesis and organization, alters tissue plasticity. Interestingly, I have observed
that the cleavage of the versican core protein or the degradation of its CS side chains only
downregulates plasticity under small shear deformations (1-2%) but not large deformations (1525%). This hypothetically indicates that versican-modulated collagen reorganization is more
effective at a lower magnitude of stress-induced deformation, whereas versican/collagen
interactions contribute to irreversible fibril reorganization via maintaining new crosslinking and
fibril bundles formation. For higher order plastic deformation, the dramatic alterations of the
collagen network via large scale fiber sliding, realignment and merging may obscure the relatively
minor structural alterations from the interactions between versican and collagen fibrils.

In sum, versican plays an important role in modulating the mechanics of collagen networks. In
contrast to other matrix PGs, versican and V3 soften collagen matrices and attenuate strain
stiffening behaviors in vitro. Given the distinct mechanical effects of different PGs, understanding
the time-dependent expression of different PGs quantitatively will shed light on ECM stiffening
and its potential reversal during fibrogenesis. Moving forward to native tissues, versican and its
CS side chains contribute to compression stiffening likely mainly because of the natural features
of negatively-charged GAGs which attract water and increase osmotic pressure. Although the role
of versican and its cleaved fragments in tissue mechanics is not fully understood, this work still
strongly supports the potential of versican as a therapeutical target in collagen-related
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fibroproliferative disorders for which there are dramatic alterations, especially tissue stiffening, in
mechanics.
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CHAPTER 6 CONCLUSIONS AND FUTURE DIRECTIONS

6.1 CONCLUSIONS
The compositional, structural, and mechanical complexities of the ECM are important for
maintaining normal cell and tissue functions during development and homeostasis. Collagen
forms the most fundamental network in the ECM, providing cell and tissue structure and
supporting and enabling biochemical and biomechanical cues. Collagen fibrous networks are
highly regulated by numerous factors including cells (Hall et al. 2016), externally applied
mechanical force (Vader et al. 2009) and other ECM components including PGs (D. Chen et al.
2020). Matrix PGs, especially the SLRP subfamily (Kalamajski and Oldberg 2010), have been
well studied as collagen binding partners (Kalamajski and Oldberg 2007)(Hedbom and Heinegard
1993) and key regulators of both in vitro and in vivo collagen fibrillogenesis (Reese, Underwood,
and Weiss 2013)(Robinson et al. 2005). The hyalectan family of large matrix PGs, however, in
particular versican, have been underestimated as important modulators of collagen behaviors in
spite of their important roles (and increased expression) in collagen-related diseases (Bukong et
al. 2016)(Lohmander et al. 1999). Unlike versican, the hyalectan aggrecan has been studied as a
collagen binding protein because of its abundant accumulation in cartilage (Hedlund et al. 1999).
Given versican’s wide distribution in human tissues and altered deposition and degradation
during fibrogenesis (Bukong et al. 2016)(Venkatesan et al. 2000), there is a particular need to
investigate the effects of versican in regulating multiple collagen behaviors. In this work, I have
studied the interaction between collagen and versican both in vitro and in vivo and have identified
their binding sites. The role of versican in regulating collagen behaviors at multiple scales
(different levels) has been investigated via different approaches covering collagen fibrillogenesis,
fibrous network organization, cell-mediated collagen functions and mechanics.
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Understanding the mechanism of the collagen/versican interaction is an essential start for
evaluating the role of versican in modulating collagen behaviors. This work has confirmed that
there is a direct interaction between versican and collagen in vitro and a colocalization of versican
and collagen fibers in vivo. The versican/collagen binding sites have for the first time been
identified as the versican C-terminal G3 domain and collagen sequences within Toolkit 4, 8, 11
and 18 peptides. Comparing the binding capacities for isolated versican, recombinant V3 isoform
and recombinant G1 and G3 domains with a solid phase assay makes it possible to overcome the
problem that native isolated versican is contaminated with some decorin and aggrecan, and
enabled me to localize the binding site at the C-terminus (G3). Given the impurity of my isolated
versican, the actual collagen binding with full length versican might show some differences which
could be due to the physical repulsion caused by negatively charged GAGs; the core protein level
interaction should remain consistent as my data showed that the positive bindings aligned well for
isolated versican, V3 and G3. Evaluating the impact of pH and ionic strength illustrates the
importance of charged residues, such as positive tracts including 3182-KYFAHRR-3188, 3306KTFGKMKPR-3324, 3360-RTYSMKYFK-3368 and 3386-RWSRR-3390 and negative tracts
including 3122-DQCELDFDE-3130 and 3163-EQDTETCD-3170 on the G3 domain, in mediating
collagen/versican binding. The recent development of the Collagen Toolkit provided me with an
approach to easily test various peptides that cover the entire amino acid sequence of type II
collagen (which is similar in sequence to type I collagen) and this finding indicates that: the
binding sites are likely located at the D1-period and the most commonly observed R-GHydrophobic-O motif (O represents hydroxyproline) is crucial for collagen/versican binding.
Additionally, the colocalization of versican and collagen fibers using the in vivo IEM assay further
supports the direct interaction between collagen and versican and the quantitative findings align
well with the previous observation from our lab that versican is a potential collagen regulator
during bile duct development (Khandekar et al. 2020).
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I used collagen gels, specifically the gelation process and fibrous network structure, as an in vitro
model to investigate: (1) collagen gelation, whereby the kinetic curves generated by the in vitro
turbidity assay provide information partially representing fibrillogenesis; (2) fiber organization, to
the extent that the relative structural features of networks persist after dehydration during SEM. In
this work, versican demonstrated the unique (amongst the PGs studied) functions of upregulating
collagen gelation (fibrillogenesis) and promoting the formation of a looser meshwork with larger
fiber bundles and smaller pores. The behavior of versican in these assays is distinct from that of
other matrix PGs including the structurally-similar hyalectan PG aggrecan. Further investigation
into fibroblast-mediated collagen fibrillogenesis demonstrated again the unique role of versican in
modulating cell derived collagen deposition and organization. The FDM assay also demonstrated
an unusual role for versican in fibrillogenesis, as compared to other PGs, via promoting the
deposition of collagen-rich matrix with increased fiber alignment mediated by fibroblasts. The
collagen plug assay showed how versican, but not the other PGs tested, upregulates long-range
force transmission-guided collagen compaction and realignment. The microfabricated engineered
microtissue gauges, made it possible to evaluate the impact of ECM proteins on collagenous
tissue contraction using less material than required for traditional collagen gel contraction assays.
Studying higher level tissue organization, as modeled by the engineered microtissue gauges,
showed that contraction of collagenous microtissues is also increased due to versican-mediated
regulation of collagen reorganization, but does not occur with other PGs.

Tissue mechanics are dependent on the organization of collagen fibrous networks (Ban et al.
2019). Versican, as a regulator of collagen fiber organization, plays an important and potentially
unique role in modulating tissue mechanics. I focused on shear modulus and non-linear
rheological behaviors in this work, studying collagenous matrices in vitro and in tissues,
specifically liver. Of the matrix PGs studied (including aggrecan and decorin, only the addition of
versican (or its V3 isoform) into collagen gels decreased the G’ and attenuated the strain
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stiffening behaviors. I believe these changed behaviors are due to decreased network
connections, which I observed (by SEM) in collagen/versican co-gels. To study the impact of
versican on tissue mechanics, I used enzymatic perfusions targeted at versican and GAGs to
make it possible to assess the participation of versican and its CS side chains in tissue
mechanics without using complicated animal models (such as versican conditional null mice). The
loss of cleaved versican fragments and CS side chains eliminated compression stiffening, and the
strain softening behaviors of treated tissues were numerically lower although not statistically
different from controls. Importantly, the data suggest that versican and its CS chains also play a
role in maintaining tissue plasticity under small deformation (about 2%) via the versican/collagen
interaction and an additional undefined CS/collagen interaction.

Overall, this thesis demonstrates the direct binding between collagen and versican, highlights the
unique roles of versican in upregulating collagen fibrillogenesis, condensation, alignment, and
contraction in contrast to other PGs, and indicates the specific contribution of versican into
collagen and tissue mechanics. The distinct regulations of different matrix PGs on collagen
structure and mechanics shed light on the importance of evaluating the time-dependent
deposition of different PGs quantitatively, which will yield a better understanding of the structural
and mechanical complexity of ECM and tissue. Versican, which binds HA via its N-terminal G1
and collagen via its C-terminal G3, could function as a linker between collagen fibers and long HA
chains in ECM modulating the organization of this complex fibrous network (Figure 6.1A, B).
Unlike SLRPs, which binding collagen monomers and affect fibril formation, versican is likely to
participate in higher-level fiber organization given its large molecular weight and formation of
HA/versican bio-aggregates. In addition, aggrecan can bind HA via its G1 domain and collagen
via its KS domain, which maintains a fixed and relatively close distance between collagen fibers
and HA chains (Figure 6.1A). However, the core protein of different versican isoforms can range
from 74 kDa to 372 kDa, which might result in dramatically altered distances between collagen
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fibers and HA chains in the fibrous network (Figure 6.1A). Negatively-charged CS side chains and
HA are likely to preferentially occupy void space (attracting water) and the presence of different
isoforms with distinct GAG domains might alter the space filling ability. Thus, different versican
isoforms, as distinct linkers (spacers) between collagen and HA, can likely modulate
collagen/versican/HA networks differently due to their various length and charge densities. These
linkers can further modulate mechanics by regulating network structure including fiber
arrangement and hydrated pore space and altering the osmotic pressure from GAG-induced
swelling. Although collagen and HA can interact with each other, highly negatively charged
versican and HA/versican aggregates could hypothetically inhibit their direct interaction.
Therefore, versican, as a linker within a collagen/HA network, almost certainly has an important
role in tissue structure and mechanics. For example, I report here that versican-induced cellmediated collagen realignment is pH sensitive (Figure 4.5G). Decreasing pH, with increasing H+,
could neutralize negatively-charged CS to downregulate the charge-mediated physical repulsion
between fibers. Meanwhile, the cleavage of versican by ADAMTS-5 could break the link between
collagen fibers and HA chains, weakening the network and suppressing tissue stiffening under
compression. Given the finding that versican upregulates collagen compaction, alignment and
fiber fusion into bundles, it could have a crucial physiological function during fibrogenesis as a
cause of the highly condensed and aligned collagen fibers that I observed by SEM and in the
collagen plug assay. By decreasing versican expression and increasing its degradation, it might
be possible to downregulate collagen deposition, fibrous network condensation and tissue
stiffness, which could make it possible to reverse fibrogenesis and fibrosis. Thus, versican, as a
unique regulator of collagen behaviors, needs to be further investigated as a modulator for
embryonic development, homeostasis, and tissue remodeling and as a therapeutic target for
collagen-related fibroproliferative disorders including fibrosis, metastasis and inflammation.
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Figure 6.1 Schematic of the interaction between collagen and large PGs and the
collagen/versican/HA network. (A) The collagen binding sites on different versican isoforms and
aggrecan. (B) Versican could function as a linker between collagen fibers and HA chains in
fibrous network. The diameter of collagen fibril/fiber is about 200 nm and the size of isolated
versican is 203.4 nm (measured by dynamic light scattering, data not shown here). (Illustrations
were created with BioRender.com).

6.2 FUTURE DIRECTIONS
6.2.1 Define the collagen/versican interaction in more detail
In this work, I started using isolated versican and the recombinant V3 isoform (G1 and G3
domains only) to investigate versican/collagen interactions. Binding has been confirmed in both
cases and thus I have used recombinant V3, which contains the collagen binding site of versican,
to identify the binding sites. Given the similar binding results from isolated versican, V3 and G3,
my findings strongly support that G3 is the major collagen binding domain of versican. Notably,
however, the collagen binding capacity of the GAG binding domains of versican have not been
well studied here. To overcome this limitation, there are several approaches that could be used in
future experiments. The first is based on the isolation and purification of different versican
isoforms from native tissue. Although versican is generally expressed in most tissues, there is a
differential deposition of different isoforms. For example, V1 is the most common isoform in liver
(Cattaruzza et al. 2002) while V2 is the major isoform found in bovine brain (Schmalfeldt et al.
1998). Selecting a source tissue with higher expression of certain isoforms combined with longterm ultracentrifugation or size-exclusion chromatography would make it possible to isolate and
purify single isoforms according to their abundance and molecular weight. Gene-edited fibroblasts
with overexpression of selected versican isoforms could also achieve the production of pure
isoforms derived from cell lysate, although versican is a large gene and proper GAG modification
could be difficult to achieve (Sheng et al. 2005). Another approach would be to synthesize
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recombinant versican fragments and even versican mimetic peptides (as for the synthesis of the
Collagen Toolkit) for studying the binding in more detail. Comparing the binding affinity of different
versican isoforms and recombinant versican peptides will shed light on the role of the GAG
domain, if it has one, in versican/collagen interactions and may uncover other potential collagen
binding sites on versican and generate distinct collagen binding models for specific isoforms.
GAGs themselves, as collagen regulators, can also mediate collagen/versican interactions via the
negative charges and resulting physical repulsion and electrostatic interactions. For example, CS
can accelerate in vitro fibrillogenesis and alter fibrous networks by increasing void space which is
further correlated with decreased gel stiffness (Stuart and Panitch 2008). In addition, my work
indicates that the collagen/versican interaction is pH and ionic strength dependent, highlighting
the importance of highly charged motifs in this interaction. Given that the G3 domain of versican
contains the collagen binding site, evaluating the binding capacity of recombinant highly charged
motifs (such as positive tracts including 3182-KYFAHRR-3188, 3306-KTFGKMKPR-3324, 3360RTYSMKYFK-3368 and 3386-RWSRR-3390 and negative tracts including 3122-DQCELDFDE3130 and 3163-EQDTETCD-3170, shown in Figure 2.7) will enable better development of a
collagen/versican binding model. The 3D structure/conformation of versican, including the V0-V3
isoforms and the G3 domain, remains unknown and should be solved using X-ray crystallography
(Y. Shi 2014) and cryo-EM (Danev, Yanagisawa, and Kikkawa 2019). This requires a pure
versican sample but could be beneficial to understanding the structural interactions between
collagen and versican (including different isoforms).

6.2.2 Understand the distinct effects of different versican isoforms in altering
collagen behaviors
Given the evidence that distinct versican isoforms have diverse or even opposing effects on cell
functions (Ricciardelli et al. 2009) and that CS can play a role in collagen fibrillogenesis (Stuart
and Panitch 2008)(Moorehead, Prudnikova, and Marcolongo 2019), the V0-V3 isoforms may
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have distinct effects on collagen behaviors including fibrillogenesis, fiber organization and
mechanics. The investigations described in 6.2.1 would provide more information, especially on
the interaction between collagen and versican isoforms, and would provide important information
about the importance and feasibility of studying specific isoform-mediated collagen behaviors.
After obtaining versican isoforms (as in 6.2.1), the in vitro turbidity assay, FDM and engineered
microtissue assays used in this thesis could also be carried out to evaluate the influence of
specific isoforms in altering collagen gelation, fibroblast-mediated collagen fibril deposition and
organization as well as their role in collagenous tissue contraction. If enough of each versican
isoform could be isolated from native tissues or cell lysates, a collagen plug assay and
collagen/isoform co-gel rheometry could be carried out and would provide a better understanding
of isoform-dependent cell-mediated collagen reorganization and collagen network mechanics.
Given the fact that there is a differential versican isoform expression during embryonic
development (Snyder et al. 2015)(Landolt et al. 1995) and a tissue specific isoform deposition
(Cattaruzza et al. 2002), investigating the isoform-dependent regulation of collagen functions will
help to explain the mechanism underlying the spatially and temporally variant expression of
different versican isoforms. Thus, certain versican isoforms may be crucial for maintaining the
normal functions of certain tissues and the same isoform-dependent pattern could also be taken
into consideration when studying versican-related disorders.

6.2.3 Investigate the role of versican in collagen behaviors when forming
HA/versican aggregates
Versican, regardless of its different isoforms, has an N-terminal G1 domain that binds HA to form
a large bottlebrush like bio-aggregate which can be stabilized by Link proteins (S. Shi et al. 2004).
These HA/CSPG aggregates are important structural components of many tissues including
articular cartilage and blood vessels. In this thesis, I have learned that there are specific effects of
versican, even without binding HA to form bio-aggregates, on the regulation of in vitro collagen
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gel stiffness; the presence of HA in collagen/versican co-gels balances the softening from
versican via HA-induced network stiffening (Figure 5.6). The mechanical differences suggest that
HA/versican aggregates may have specific structural effects on collagen fibrous networks since
versican is a linker that binds HA via its G1 domain and collagen via its G3 domain. The presence
of HA/versican bio-aggregates could control the distance between collagen fibers and HA chains
and fill the void space between fibers, which can further alter the organization of collagen fibrous
network. Given the distinct molecular weights and GAG quantities of versican isoforms, HA
aggregates bound with different isoforms might have distinct effects on fibrous networks that
could also change the mechanics in different ways. To validate this hypothesis, in vitro collagen
gels could be manipulated with HA and versican (various isoforms generated from 6.2.1)
aggregates and their roles in collagen gelation (fibrillogenesis), fibrous network structure and
tissue contraction could be evaluated using the turbidity assay, FDM, SEM and engineered
microtissue assays. The amount of isolated isoforms would determine the feasibility of studying
the impact of HA/versican aggregates on cell-mediated collagen compaction and realignment
using the collagen plug assay; this is also true for using shear rheometry to assess the isoformdependent effects of these aggregates in the viscoelasticity of collagen gels given the fact that
both assays require significant amount of gel solution (1 mL for 3 technical repeats).

6.2.4 Investigate the role of versican in tissue structure and mechanics using
mouse models
In this work, in vitro assays including SEM (on collagen gels), FDM and collagen plug assays
have been carried out to study the structure of fibrous networks and cell-mediated collagen
reorganization, although the structural regulation of the collagen/versican interaction in vivo has
not been investigated in detail here. Mouse models with altered versican expression could
provide diverse tissue samples to study the role of versican in collagen organization in vivo.
There are three published mouse models available to achieve this goal: versican-deficient mice
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(Kang et al. 2017), versican knockin mice (versican overexpression) (Islam et al. 2020), and
ADAMTS-4 and -5 knockout mice (versican proteolysis is protected) (Demircan et al. 2014).
Collagen fibrous networks in liver samples (or other tissues) could be imaged by SHG and
versican and HA stained with anti-versican antibodies and HA binding protein (HABP). The
organization of the collagen fibrous network in versican-deficient and -overexpressed samples
should be compared by analyzing SHG images using CT-FIRE for fiber size, length and
orientation quantification. Given the evidence that versican regulates hepatic fibrosis (Bukong et
al. 2016), the carbon tetrachloride (CCl4) method of inducing liver fibrosis could be applied to
these mouse models, which have different levels of versican expression, and used to evaluate
the effect of versican on collagen network alterations during fibrogenesis as well as recovery. As
versican causes upregulation of collagen compaction, alignment and contraction, I predict that
increased deposition of versican will worsen fibrosis by condensing and realigning collagen fibers
with increased fiber entanglement into bundles.

Livers perfused with ADAMTS-5 and studied with shear rheometry have been used in this work to
explore the mechanical functions of versican in native tissues. However, incomplete knowledge of
versican proteolysis and the localization of some proteolytic products after prefusion make it
difficult to interpret the relationship between versican (as well as its cleaved fragments) and tissue
mechanics. Importantly, a recent publication using quantitative proteomics has discovered
additional 21 cleavage sites for ADAMTS-1, -4 and -5 degradation (with 9 novel sites for
ADAMTS-5) (Martin et al. 2021). Thus, I cannot fully understand the relationship between
versican and tissue mechanics based on my findings. In the future, mouse models with versican
deficiency or overexpression will shed light on the contribution of versican in modulating tissue
mechanics. The relationship can be quantitatively established by evaluating versican content in
different mouse models and measuring tissue viscoelasticity as well as non-linear rheological
behaviors. Using the CCl4 liver fibrosis model in these mouse models would help to understand
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the role of versican in mediating tissue stiffening during fibroproliferative processes.
Nanoindentation on un-aligned and aligned collagen areas with an analysis of versican deposition
in corresponding areas could also be used to study the regulation of versican on collagen
bridging in vivo and its effect on local ECM stiffening within the highly aligned collagen bundles.

6.2.5 Understand the role of different matrix PGs expression in collagen
behaviors
It has been confirmed many times via diverse approaches in this work that distinct matrix PGs,
even belonging to the same subfamily and having structural similarities, have different effects on
collagen structural and mechanical behaviors. Differential expression and deposition of matrix
PGs have been observed in multiple physiological settings including embryonic development and
fibrosis. During tendon development, both lumican and fibromodulin mediate fibrillogenesis at the
early stage but only fibromodulin plays a dominant role in maturation with an upregulated ratio of
fibromodulin to lumican (Ezura et al. 2000). For collagen assembly in cornea, lumican deficiency
as well as lumican/biglycan double deficiency leads to corneal opacity with irregular collagen
organization and abnormal fiber size while biglycan deficiency has no impact (S. Chen et al.
2014). When studying bile duct development, our group has also found that different matrix PGs
have a distinct time course of deposition: lumican deposition decreases over time while decorin
remains constant (Khandekar et al. 2020). As for fibrotic disorders, taking liver as an example,
lumican and aggrecan show a time-dependent expression but fibromodulin does not (Krull and
Gressner 1992). Although both lumican and versican expression has been found to increase
during liver fibrosis, lumican deficiency cannot inhibit fibrogenesis while versican deficiency
results in decreased fibrogenesis and reduced proliferation (Bukong et al. 2016)(Krishnan et al.
2012). Thus, there is a particular interest in quantitatively investigating the spatial and temporal
deposition of different matrix PGs by carrying out western blots on tissue samples harvested at
various time points during development or fibrogenesis. After knowing the dynamics of matrix PG
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content during a physiological process, the most predominant PG at a crucial time, such as
during initiation of fibril assembly into fibers or the development of bridging fibrosis, will be
regarded as a regulatory target for future therapeutic research. This quantitative information will
also help with understanding the correlation between structure and mechanics of collagen fibrous
networks. This thesis has already provided quantitative data on the structure of collagen/PG
networks including fiber diameter and length, network connection and pore size. A future
collaboration with a computational modeling group which has expertise in theoretical
mechanobiology would help build the model to explain the correlation between PG-related
structural features and collagen mechanics by using inputs including PG content and structural
information and outputs such as G’ or even complicated strain stiffening behaviors.
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